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Abstract 
 
Microglia are active sensors in the brain that rapidly engage adequate functional 
activity states in response to injury to restore homeostasis. During the neonatal period, 
the brain is more vulnerable to several injury conditions such as the one induced by 
hyperbilirubinemia, a common situation observed in the newborn, where excessive levels 
of unconjugated bilirubin (UCB) can reach and damage the brain. Although UCB-induced 
neuronal and astrocytic toxicity have already been approached, the role of microglia in 
this condition remains unclear. Thus, this thesis intended to investigate microglial 
reactivity to UCB and to characterize the intervention of other brain cells in the 
modulation of their response.  
Isolated microglial cells showed to acquire a phagocytic phenotype upon UCB 
exposure that preceded the release of pro-inflammatory cytokines. This release showed 
to involve activation of upstream signalling pathways such as mitogen-activated protein 
kinases (MAPKs) and nuclear factor-κB (NF-κB). We next investigated whether and how 
the microenvironment influenced microglial response to UCB. Our findings revealed that 
soluble factors released by UCB-stimulated astrocytes refrained microglial activation 
while neuron-microglia interaction, evaluated using conditioned media and mixed culture 
models, signalled microglial clearance functions but also enhanced its inflammatory 
potential, ultimately leading to microglia demise. Finally, we evaluated microglial 
neuroprotective or neurotoxic effects in a cell-to-cell concerted action in response to 
UCB. Microglia revealed to participate in glutamate homeostasis, and to induce the 
release of this neurotransmitter and of nitric oxide (NO) in UCB-treated organotypic-
cultured hippocampal slices, molecules that showed to be key players in UCB-induced 
neurotoxicity. Moreover, our results point to interleukin (IL)-10 and glycoursodeoxycholic 
acid (GUDCA) as promising therapies in neonatal hyperbilirubinemia.  
In conclusion, microglia displays a dual activation profile in response to UCB 
stimulation which is tailored by the influence of neighbouring cells. Collectively, these 
data contribute for the understanding of microglia’s role in hyperbilirubinemia and 
reinforce their remarkable functional plasticity. 
 
Keywords: Astrocytes; Hyperbilirubinemia; Inflammation; Intracellular signalling; 
Microglia; Neurons; Neuron-glia dynamics; Phagocytosis. 
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Resumo 
 
As células da micróglia são sensores activos de dano no cérebro e rapidamente 
adquirem estados funcionais de activação adequados à restauração da homeostase. 
Durante o período neonatal o cérebro está mais vulnerável a certas lesões tais como as 
induzidas pela hiperbilirrubinémia, uma condição comum no recém-nascido, na qual 
níveis excessivos de bilirrubina não conjugada (BNC) podem atingir e lesar o cérebro. A 
toxicidade desencadeada pela BNC em neurónios e astrócitos já foi alvo de estudos 
prévios, no entanto o papel da micróglia nesta condição ainda não está completamente 
esclarecido. Assim, foi objectivo desta tese investigar a reactividade da micróglia à BNC 
e caracterizar a intervenção das restantes células do cérebro na modulação da sua 
resposta. 
As células de micróglia isoladas reagem à exposição à BNC pela aquisição de 
um fenótipo fagocítico que precede a libertação de citocinas pró-inflamatórias. Esta 
libertação parece envolver a activação a montante de vias de sinalização tais como as 
cinases proteicas activadas por mitogénios (mitogen-activated protein kinases, MAPKs) 
e o factor nuclear-κB (nuclear factor-κB, NF-κB). Em seguida investigámos a influência 
do micro-ambiente celular na resposta da micróglia desencadeada pela BNC. 
Verificámos então que astrócitos expostos à BNC libertam factores solúveis que contêm 
a activação da micróglia. Por outro lado, a interacção entre neurónios e micróglia, 
avaliada através do modelo dos meios condicionados e do das culturas mistas, parece 
sinalizar a micróglia a empreender funções de eliminação de restos celulares, ao 
mesmo tempo que aumenta o potencial inflamatório desta célula levando, em última 
análise, à degeneração celular. Por fim, estudámos os efeitos neuroprotectores ou 
neurotóxicos da micróglia face à BNC num modelo onde as interacções celulares são 
preservadas. Os resultados obtidos em culturas organotípicas de fatias de hipocampo 
revelam a participação das células da micróglia na homeostase do glutamato para além 
de libertarem este neurotransmissor em conjunto com o óxido nítrico (nitric oxide, NO). 
Os dados obtidos demonstram ainda que o glutamato e o NO são peças chave na 
neurotoxicidade provocada pela BNC. Por fim, a interleucina-10 e o ácido 
glicoursodesoxicólico (AGUDC) salientam-se como promissores agentes terapêuticos na 
hiperbilirrubinémia neonatal.  
Em conclusão, a micróglia apresenta um duplo perfil de activação em resposta à 
BNC que é modulaado pela influência das células adjacentes. Em conjunto, estes dados 
contribuem para uma melhor clarificação do papel da micróglia na hiperbilirrubinémia e 
corroboram a sua notável plasticidade funcional. 
Resumo 
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1. The brain – an integrated network of interactive neurons and glia 
Neurons are the functioning unit of the central nervous system (CNS) and are 
responsible for information processing. Glia make up 90% of the cells in the human 
brain, and although their name derives from the greek word “glue”, research in the past 
20 years has proven that these cells not only provide physical support to neurons but 
make important contributions in the formation and operation of the neural circuitry and 
play a key role in the brain’s immune functions (Fig.I.1) (Allen and Barres, 2009; Miller, 
2005).  
 
 
 
Fig. I.1. The brain as an integrated network. Glial cells (i.e. astrocytes, microglia and 
oligodendrocytes) are intimately related to neurons and blood vessels, contributing for 
their support and participating in various key brain functions. Adapted from Allen and 
Barres (2009). 
 
The major difference between glia and neurons is that the latter ones fire action 
potentials that underlie sensation, movement and thought, while glial cells lack this 
capacity. Nevertheless, emerging research suggests that glial cells participate in 
information processing and interact with synapses (Wake et al., 2009). In fact, the 
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acknowledgement of neuron-glia crosstalk during synaptic transmission has 
progressively challenged the classical view of the brain as a network of neuronal 
contacts but rather as an integrated circuit of interactive neurons and glia (Bezzi and 
Volterra, 2001). Hence glia is emerging as critical participants in every aspect of brain 
development, function, and disease (Barres, 2008). 
 
1.1. Neurons 
Neurons are highly specialized nerve cells responsible for communicating 
information in both chemical and electrical forms throughout the body (Bloom, 2003). 
Their structure comprises a cell body, or soma, from which an elaborate arborisation tree 
emerges. Neuronal processes give neurons the regionalization of their functions, their 
polarity and capacity to connect to other neurons, to sensory cells and to effector cells 
(Hammond, 2001). Information is received and processed through the dendritic 
branches, whose major structural components are the actin and microtubule 
cytoskeleton together with microtubule-associated proteins (MAPs), responsible for 
stabilization (Chen and Ghosh, 2005). The neuronal axon is a long cytoplasmic process 
that culminates in a highly specialized structure, the pre-synaptic terminal, which, 
together with the post-synaptic terminal of the adjacent neuron forms the synapse 
(Bloom, 2003). The high molecular weight MAP-2 protein is more common in dendrites 
than in axons and for this reason, MAP-2A and MAP-2B antibodies coupled to 
fluorescent molecules are useful tools for labelling dendrites, allowing morphometric 
analysis in cell cultures (Hammond, 2001).  
Electrical signalling in the nervous system involves the movement of ions across 
the neuronal plasma membrane through specific transmembrane proteins called ion 
channels. These ionic currents evoke transient changes of membrane potential (action 
potentials) which fire neuronal communication (Hammond, 2001). In the synapse, 
neurotransmitters are released and establish communication between adjacent neurons 
or between neurons and effector or sensory cells (Bloom, 2003). Several molecules 
serve as neurotransmitters, such as acetylcholine, amino acids like glutamate, γ-
aminobutyric acid (GABA) and glycine and neuropeptides and their release at the pre-
synaptic terminal is induced by calcium-regulated vesicle exocytosis. Neurotransmitters 
released into the synaptic cleft bind their specific receptors in the post-synaptic terminal 
of the adjacent neuron and propagate action potential (Hammond, 2001).  
Glutamate is the major excitatory neurotransmitter in the CNS and activates two 
main types of post-synaptic receptors: ionotropic glutamate receptors that are ligand-
gated ion channels and are divided into N-methyl-D-aspartate (NMDA), α-amino-3-
hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) and kainate receptors, and 
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metabotropic glutamate receptors (mGluRs) that are receptors coupled to guanosine 
triphosphate (GTP)-binding proteins. Glutamate’s concentration in the synaptic cleft must 
be kept low as high or sustained glutamate receptor activation may induce neuronal 
death via intracellular calcium and/or sodium deregulation, a mechanism called 
excitotoxicity (Gras et al., 2006).  
 
1.2. Oligodendrocytes 
 Oligodendrocytes are the myelinating cells of the CNS and constitute about 5 to 
10 % of the total glial population. Their processes enwrap neuron axons and form 
myelin, an insulating lipid-rich membrane sheath that speeds the conduction of electrical 
impulses. Therefore, saltatory propagation of action potentials occurs at the nodes of 
Ranvier between oligodendrocyte myelin sheaths (Bradl and Lassmann, 2010). 
Oligodendrocytes are vulnerable to cytotoxicity induced by dysfunctional astrocytes 
(Sharma et al., 2010) or activated microglia as oligodendroglial cell death can be initiated 
by increased levels of cytokines and reactive oxygen species (ROS) (Sherwin and Fern, 
2005). Demyelination due to damage to oligodendrocytes leads to various diseases from 
neurodevelopment to neurodegeneration such as periventricular leukomalacia (Volpe, 
2009) and multiple sclerosis (MS) (Allen and Barres, 2009), respectively. Moreover, the 
existence of direct chemical synapses between pyramidal neurons and oligodendrocyte 
precursor cells (OPCs) in the mammalian hippocampus has been demonstrated, 
underscoring the active role of glial cells in information processing (Bergles et al., 2000). 
 
1.3. Astrocytes 
Astrocytes comprise about 85% of the glial population and are star-shaped cells. 
They exert structural functions, are required for neuronal survival, neurite formation and 
angiogenesis and maintain CNS homeostasis by regulating pH, ionic concentrations and 
osmolarity (Montgomery, 1994). Astrocytes also provide metabolic support to neurons by 
fueling their activity with energy and substrates and remove excess neurotransmitter 
molecules from the extracellular space (Tsacopoulos and Magistretti, 1996). These cells 
take part in the neurovascular unit of the blood-brain barrier (BBB) since their end-feet 
ensheathe endothelial cells in micro-vessels (Cardoso et al., 2010). By signalling blood 
vessels to expand or narrow, astrocytes regulate local blood flow to provide oxygen and 
nutrients to neurons in need. Moreover, astrocytes were shown to induce tight junctions 
in endothelial cells, thus participating actively in the establishment of the CNS 
boundaries (Yamagata et al., 1997). More recently, bidirectional communication between 
neurons and astrocytes was demonstrated. This fact altered the long-lasting paradigm of 
the bipartite synapse, established between a pre- and a post-synaptic neuronal element, 
Chapter I 
 
 
6 
leading to the novel concept of the tripartite synapse, where astrocytic participation in the 
regulation of synaptic activity (Araque et al., 1999; Perea et al., 2009) and plasticity 
(Barker and Ullian, 2010) is acknowledged. Moreover, astrocytes can communicate to 
each other through the generation of calcium waves (Cornell-Bell et al., 1990) and to 
neurons by the activation of calcium-based signalling cascades triggered by 
neurotransmitters released by neurons which feedback the production of neuroactive 
substances (Araque et al., 1999). Furthermore, Alvarez-Maubecin et al. (2000) 
demonstrated gap-junctional electrical coupling between neurons and astrocytes and 
also that selective changes in the membrane potential of glia modulate neuronal 
excitability. 
Considering these interesting concepts, a new role has been established for glial 
cells, particularly astrocytes, in the so-called neuron-exclusive functions such as 
information processing. 
 
1.4. Microglia 
 Microglia are small glial cells that reside within the CNS parenchyma and 
constitute about 10 to 20 % of the total glial cell population (Chew et al., 2006; Vilhardt, 
2005). They are ubiquitously distributed in the brain, being present in both grey and 
white matter and exhibiting a higher density within the hippocampus, basal ganglia and 
substantia nigra (Walter and Neumann, 2009).  
 Microglial cells share many properties of macrophages as they belong to the 
mononuclear phagocyte lineage (Vilhardt, 2005). The notion that microglial cells are the 
resident immune cells of the CNS has altered the concept of the brain as an 
immunologically privileged organ supported by the existence of the BBB. Although 
microglial immunocompetent functions are not on the same scale as that of peripheral 
leucocytes, it is well established that they act as the brain’s innate immune system 
(Aloisi, 2001; Streit, 2002). 
 
1.4.1. Heterogeneity of microglial phenotypes 
 The traditional classification of microglial subtypes described a resting and an 
activated state. In the resting state microglia would display a ramified morphology, with 
small bipolar or rod-shaped cell bodies bearing multiple branching processes (Chew et 
al., 2006; Kim and de Vellis, 2005), while in the activated state, microglia would undergo 
morphological changes acquiring an amoeboid appearance, up-regulate several cell 
surface markers and produce a plethora of bioactive substances (Ladeby et al., 2005). 
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However, emerging research has updated the concept of microglial activation redefining 
it as a shift in activity states rather than an activation process in itself (Fig. I.2).  
 
 
 
Fig. I.2. Microglial activation is a shift between activity states. Microglia in its 
“resting” state plays a very important role in surveying the brain parenchyma (1) and can 
be prompted into an activated state (2) due to the presence of activating signals (such as 
inflammatory mediators and neurotransmitters) or the absence of constitutive calming 
signals, such as chemokines or neurotrophins that trigger a transition to an alerted state. 
During the activation process, microglia commit to distinct response phenotypes which 
can be altered throughout the pathological process (3, 4 and 4.1) by the influence of 
other nerve and immune cells (illustrated as feedback signals). At the end of this 
process, microglia can either return to a resting state (1), be eliminated (5) or step into a 
post-activated state (6), in which the cells acquire a kind of “memory” (indicated in the 
figure by a floppy disk icon). Adapted from Hanisch (2008). 
 
Therefore, microglial activation should no longer be considered an all-or-none 
event but an adaptive response to microenvironmental changes. (Hanisch and 
Kettenmann, 2007). Indeed, Kreutzberg (1996) had already dubbed microglia as a 
sensor of pathology.  
The discoveries made by Nimmerjahn et al. (2005) and Davalos et al. (2005) 
demonstrated that resting microglia showed highly motile extension and retraction of 
processes which enabled them to constantly scan the neural parenchyma. These novel 
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findings, that we will further explore below, produced a dramatic change in the concept of 
resting microglia since this phenotype could no longer be considered dormant or inactive 
but rather a surveying state with an important role in the normal and healthy brain 
(Hanisch and Kettenmann, 2007; Raivich, 2005). Hence, microglia function as local 
sentinels that can detect microdamages in the brain and rapidly repair such minute 
insults without even being noticed. However, stronger or more prolonged insults may 
trigger more drastic changes in microglial functional phenotype (Hanisch and 
Kettenmann, 2007). Some authors now define activated microglia as a cell working to 
restore CNS parenchymal homeostasis, in accordance with the new concept of 
microglial activation phenotypes (Streit and Xue, 2009). The traditional classification of 
microglial subtypes based on morphological criteria is no longer suitable, being replaced 
by the definition of functional activation states (Schwartz et al., 2006). Furthermore, 
microglia do not constitute a single and uniform cell population but comprise a family of 
different cell phenotypes with ultimate beneficial or destructive outcomes, being 
microglial responses tailored in regional and insult-specific manners (Carson et al., 
2007).  
 
1.5. Extracellular matrix 
The extracellular matrix (ECM) accounts for about 20% of the adult brain volume 
and is composed of collagen, proteoglycans, hyaluronan, fibronectin, elastins, laminins, 
vitronectin, thrombospondins, tenascins, among other proteins and carbohydrates 
(Zimmermann and Dours-Zimmermann, 2008). Mounting evidence demonstrates that 
ECM is not merely mechanical scaffolding for nervous cells. ECM components are 
involved in neural migration, proliferation, axon growth and guidance, or synapse 
formation, processes that are essential during brain development. Furthermore, several 
cell matrix receptors, like integrins, and cadherins have been shown to affect long-term 
potentiation (LTP), revealing the implication of ECM in synaptic plasticity, as reviewed in 
Pavlov et al. (2004). Interactions with ECM can also regulate immune cell action in both 
a positive and negative fashion. For instance, ECM breakdown, from either microbe 
colonization or resulting from the action of matrix metalloproteinases (MMPs) released 
during inflammation, can produce fragments of specific ECM proteins that may act as 
pro-inflammatory agents. In contrast, ECM proteins can also contribute to the down-
regulation of inflammation since decorin and biglycan were reported to inhibit the 
classical pathway of complement activation (Morwood and Nicholson, 2006). Moreover, 
the interaction of microglial receptors with ECM components such as cell adhesion 
molecules contributes to microglial chemotaxis (Hristova et al., 2010; Raivich, 2005). 
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2. Role of microglia in different brain development stages 
The function of microglia depends on the age of the cell or organism (Walter and 
Neumann, 2009). Therefore, we will next address the involvement of microglia in 
different development stages of the brain (Fig. I.3).  
 
Fig. I.3. Microglia along brain development. Summary of the role of microglia in 
different brain development stages, from embryonic period to the aging brain.  
 
2.1. Embryonic period 
The origin of microglia has been a very contentious issue over the years. 
However current view concerning microglial ontogenesis comprises a mesodermal origin 
for microglia corroborating the original observations made by Pio del Rio-Hortega that 
“microglia arise from polyblasts or embryonic cells of the meninges” (Cuadros and 
Navascues, 1998). In fact, microglia are descendants of mesodermal fetal macrophages 
which appear early in development and derive from primitive macrophages of the yolk 
sac. The entry of fetal macrophages into the neuroepithelium and invasion through the 
CNS occurs later in embryonic development, at about mid-gestation or earlier in rodents, 
and late during the first trimester in humans (Alliot et al., 1999; Chan et al., 2007; Streit, 
2001). Additionally, it is now accepted that microglial cells can be acutely derived from 
blood-borne monocytes in the adult upon certain pathologic conditions (Graeber and 
Streit, 2009; Kaur et al., 2001). 
After their entry in the CNS, microglial precursors proliferate and spread through 
the CNS by tangential and radial migration. Finally, mesodermal precursors originate 
resident microglia that display an amoeboid-globoid appearance, with an enlarged cell 
body and retracted processes (Chew et al., 2006; Cuadros and Navascues, 1998). 
Microglia play an active role in CNS development and remodelling since they phagocyte 
dead cells, cellular debris and aberrant axons (Kim and de Vellis, 2005; Streit, 2001). 
Later in development microglia also participate in neuritogenesis, axonal growth and 
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guidance, as well as on the subsequent synaptogenesis and even in vasculogenesis. 
The production of trophic factors by microglia also contributes for the development, 
proliferation and growth of neurons and glia (Cuadros and Navascues, 1998; Nakajima 
and Kohsaka, 2004). 
 
2.2. Neonatal period  
In the neonatal period microglial cells transform into a more ramified morphology 
constituting the resident immune cell population and presenting a slow turnover rate 
(Cuadros and Navascues, 1998). An interesting study suggests that resident microglia, 
in contrast to immune cells in other tissues, are not terminally differentiated along the 
myeloid lineage. This immature state of microglial cells could explain their graded 
response to activation as well as their enormous plasticity and capacity to assume 
different phenotypes upon brain injury (Santambrogio et al., 2001).  
Birth is not a deadline for the end of brain maturity since several key processes 
such as synaptogenesis and gliogenesis take place postnatally rendering the brain highly 
vulnerable to injury during the neonatal period. (Rice and Barone, 2000).  
Interestingly, microglia has been implicated in neonatal pathologic conditions 
such as hypoxic-ischemic (Vexler and Yenari, 2009) or excitotoxic brain injury 
(Dommergues et al., 2003). In these cases, activated microglial cells rapidly accumulate 
in the injured neonatal brain displaying up-regulation of cell surface markers such as 
major histocompatibility complex I and II (MHC I and II) or complement receptors and 
producing inflammatory mediators (Doverhag et al., 2010) and ROS. The inflammatory 
response, in conjunction with excitotoxic and oxidative responses, is the major 
contributor to ischemic injury in the immature brain (Vexler and Yenari, 2009).  
 
2.3. Microglia in the aging brain 
An additional phenotype has recently been added to the concept of microglial 
functional plasticity: a dystrophic or senescent phenotype (Streit et al., 2004). The 
prevalence of degenerating microglia increases dramatically in Alzheimer’s disease 
(AD), co-localizing with neurofibrillary degeneration (Graeber and Streit, 2009). 
Moreover, fragmentation of cytoplasm (cytorrhexis) has been pointed to be indicative of 
widespread microglial degeneration in amyotrophic lateral sclerosis (ALS) models 
(Fendrick et al., 2007) and beading and clusters of fragmented twigs have also been 
demonstrated in the aged brain (Hasegawa-Ishii et al., 2010). Such degenerative 
changes may underlie a loss of microglial functionality and support, leading to 
pathological outcomes like neurodegenerative changes and synapse loss (Streit and 
Xue, 2009). This concept contributes for the growing notion that microglial activities are 
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essentially beneficial, becoming destructive only when they escape from the strict control 
imposed on them (Schwartz et al., 2006). 
 
3. Functional roles of microglia – activation and overactivation 
The definition of microglia’s function in the adult brain is not simple since it 
encompasses the ability to respond to environmental changes and toxic insults (Fig. I.4).  
 
 
 
Fig. I.4. Functional activation states of microglia. Resident microglia can become 
activated to adopt one of many diverse phenotypes depending on several circumstantial 
variables and these reactive phenotypes may be alternated along disease progression. 
Adapted from Perry et al. (2010). 
 
 
Perhaps the most comprehensive term is “pathology sensor” coined by 
Kreutzberg (1996). In fact, microglia assume an activated state and exhibit 
immunological functions in response to danger signals. Nevertheless, several evidences 
have demonstrated that overactivation might lead to microglial cell death, possibly as a 
safety mechanism to prevent further deleterious effects (Liu et al., 2001; Polazzi and 
Contestabile, 2006). In the following sections we will approach the several functions 
performed by microglia in the healthy and injured brain. 
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3.1. Surveillance functions and role in synaptic plasticity 
As stated above, resident and “so-called resting” microglia are not functionally 
silent cells. In vivo two-photon microscopy demonstrated that microglial processes are 
remarkably motile presenting high velocities of extension and retraction interspersed with 
brief static periods. By continuously sampling the environment with their highly motile 
protrusions, microglia exert an important surveillance function and completely scan the 
brain parenchyma every few hours (Nimmerjahn et al., 2005). Interestingly, adenosine 
triphosphate (ATP) released from damaged tissue regulates microglial branch dynamics 
in the intact brain and mediates a rapid microglial response towards injury (Davalos et 
al., 2005). 
Recently microglia have been shown to directly interact with synapses by 
establishing intimate but transient connections with pre-synaptic and post-synaptic 
elements. The frequency of these connections in the healthy brain corresponded with the 
static periods observed by Nimmerjahn et al. (2005), while this connectivity increased 
significantly during ischemic lesion (Wake et al., 2009) or after excitotoxic brain injury 
(Hasegawa et al., 2007). Such observations led to the assumption that microglia monitor 
the synapse functional status making brief contacts with the healthy ones and prolonged 
contacts with the injured or pathological synapses. Additionally, pre-synaptic buttons 
disappear after prolonged contact with microglia in ischemic conditions, suggesting that 
microglia might produce synaptic stripping in a similar fashion as the one observed after 
facial nerve axotomy (Wake et al., 2009). In this latter case, microglia become activated 
and promote the detachment of afferent synaptic terminals from the surface of 
motoneurons in an attempt to remove the excitatory input and limit further deleterious 
outcomes (Kreutzberg, 1996; Moran and Graeber, 2004). These findings underscore 
microglia’s function as sensors of the integrity of the CNS circuitry and may render them 
a novel epithet as the CNS electrician (Graeber and Streit, 2009). 
 Moreover, mounting evidence of microglial interaction with synaptic elements 
contributes for the concept that microglial cells also participate in synaptic plasticity, a 
process connoted as a hallmark of neurons (Ben Achour and Pascual, 2010). Synaptic 
plasticity is the basis of learning and memory and consists in a modification of synaptic 
strength (Ben Achour and Pascual, 2010). Evidence of communication between 
microglia, astrocytes and neurons relies on the expression of matching sets of 
transmitters and receptors. Indeed, microglia express a variety of neurotransmitter 
receptors such as AMPA, mGluRs, GABA receptor, as well as purinergic, cholinergic, 
adrenergic, cannabinoid, dopaminergic and opioid receptors. Activation of those 
receptors may trigger the release of several neuroactive substances like glutamate, ATP, 
nitric oxide (NO), cytokines and chemokines (Pocock and Kettenmann, 2007).  
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 The high density of purinergic P2X7 receptors in microglia mediates microglial 
participation in the synapse and incited the emergence of quadpartite synapse concept 
(Fig. I.5) (Bennett, 2007).  
 
Fig. I.5. Microglia are vital members of the “quadpartite synapse”, which also 
includes pre-synaptic and post-synaptic neurons, and astrocytes. Input to the pre-
synaptic terminal induces glutamate (Glu) release which binds to α-amino-3-hydroxyl-5-
methyl-4-isoxazole-propionate (AMPA) and N-methyl-D-aspartate (NMDA) receptors on 
the post-synaptic neuron and also to AMPA receptors on the astrocytes end-feet, leading 
to the release of adenosine triphosphate (ATP) from the astrocyte. This acts as a 
chemoattractant driving microglia into intimate contact with synapses. ATP binds to 
P2X7 receptors on the pre-synaptic terminal, potentiating glutamate release from the 
terminal and acts on P2X7 receptors on microglia, leading to the release of tumour 
necrosis factor (TNF)-α which increases the effectiveness of the AMPA receptors on 
both the neuron and astrocytes. Adapted from Bennett et al. (2009). 
 
ATP released from astrocyte processes at the synapse acts as a chemoattractant 
on microglia driving them into intimate contact with synapses. Once microglia processes 
are interlaced at the synapse they can themselves release ATP due to nerve terminal-
derived glutamate. ATP may also act on synaptic microglia P2X7 receptors to evoke the 
release of cytokines such as tumour necrosis factor-α (TNF-α), which can then increase 
AMPA receptors in the post-synaptic membrane processes. Thus the P2X7 receptor 
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mediates mechanisms that give rise to significant changes in the efficacy of synapses 
(Bennett et al., 2009). 
 
3.2. Role of microglia in innate and adaptive responses 
Microglia constitute the first line of defence against invading microorganisms 
(Town et al., 2005) and are intricately implicated in the initiation and propagation of the 
inflammatory response (Chew et al., 2006). Activation of microglia can result in different 
functional phenotypes entailing several characteristic features such as up-regulation of 
cell surface markers, production of pro-inflammatory mediators and phagocytosis 
(Hanisch and Kettenmann, 2007). Some authors refer to microglial activation as a 
continuum where the innate or phagocytic response is at one end and the adaptive 
response (comprising antigen presentation functions) is at the other (Town et al., 2005). 
Therefore, the duration and type of stimulation received by microglia will determine the 
activation features displayed by these cells reinforcing their remarkable plasticity in 
response to injury (Town et al., 2005). 
 
3.2.1. Phagocytosis  
Phagocytosis is defined as the process by which large particles (>0,5 µm) are 
recognized, internalized and digested by phagocytic cells involving actin-dependent 
mechanisms. This process is critical for the removal of infectious agents or senescent 
cells and is performed by immune cells of the body such as macrophages and microglia. 
Interaction of specific receptors expressed by phagocytic cells with ligands in the surface 
of the particle is the first step for particle internalization, followed by actin polymerization 
at the site of ingestion and internalization culminating in the formation of a 
phagolysosome. Recognition mechanisms can be cell-mediated by cellular receptors like 
integrins or mannose and scavenger receptors or humoral by the opsonisation of the 
invading pathogen by antibodies or complement proteins which are then recognized by 
specific receptors (Aderem and Underhill, 1999). 
Activation of microglial phagocytic receptors can be associated with the 
production of inflammatory products, as occurs in the case of Toll-like receptors (TLRs) 
or Fc- receptors’ interaction with microbes (Neumann et al., 2009). On the other hand, 
phagocytosis may occur in the absence of inflammation by the engagement of several 
receptors such as complement, scavenger, phosphatidylserine (Neumann et al., 2009) or 
purinergic (Koizumi et al., 2007) receptors as well as triggering receptor expressed on 
myeloid cells-2 (TREM-2) (Takahashi et al., 2005). In fact, removal of apoptotic cells by 
phagocytosis is described as a rather silent process which is essential during brain 
development as well as in some pathologic conditions. Studies in hippocampal slices 
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show that microglia rapidly respond to neuronal death leading to phagocytic clearance 
(Petersen and Dailey, 2004). Several putative “eat-me” signals have been established for 
apoptotic cells such as phosphatidylserine externalization, interaction with vitronectin 
receptors and changes in the pattern of glycosilation of surface proteins allowing 
microglial recognition of apoptotic cells by lectin receptors (Ravichandran, 2003; Witting 
et al., 2000). 
As described previously, the phagocytic role of microglia in CNS development 
and remodelling is widely established as these cells promote a clearance of dead or 
dying cells and debris. In addition, microglial phagocytic activity is not limited to clearing 
the corpses but it is also implicated in promoting axon pruning and cell death (Mallat et 
al., 2005) as demonstrated by the studies of Marin-Teva et al. (2004) demonstrating that 
microglia provoke the death of developing Purkinje cells by producing high levels of 
superoxide. A putative hypothesis for the recognition of these Purkinje cells as prey for 
phagocytic microglia involves the activation of caspase-3 which can lead to the 
production of chemotactic agents like lysophosphatidylcholine (Lauber et al., 2003). A 
role for microglia in the removal of unwanted synapses tagged by complement has also 
been demonstrated (Stevens et al., 2007).  
In the context of brain pathology, phagocytosis performed by microglia also plays 
an essential role in the clearance of tissue debris and, therefore, in the generation of a 
pro-regenerative environment (Neumann et al., 2009). In fact, microglia is able to 
phagocyte myelin debris upon a demyelinating insult (Glezer et al., 2007; Takahashi et 
al., 2007) and amyloid-β (Aβ) from senile plaques (Kakimura et al., 2002), thus triggering 
repair. Nonetheless, an inadequate regenerative response may prevail if insufficient 
clearance by microglia occurs (leading to pathology) or when microglial phagocytic 
properties decline with aging (Zhao et al., 2006). 
 
3.2.2. Production of mediators in neuroprotection and neurodegeneration 
Activated microglia release a plethora of soluble factors, which may be pro-
inflammatory and cytotoxic or, in contrast, exert neuroprotective or neurotrophic 
functions (Block and Hong, 2005; Kim and de Vellis, 2005).  
In fact, microglia are recognized producers of neurotrophic molecules such as 
neurotrophins (NT), nerve growth factor (NGF), brain-derived neurotrophic factor 
(BDNF), basic fibroblast growth factor, hepatocyte growth factor, glial cell-line derived 
neurotrophic factor (GDNF), plasminogen, platelet-derived growth factor, among several 
others (Nakajima et al., 2001a; Nakajima and Kohsaka, 2004). This panoply of 
molecules have been reported to exert important roles in the development of the CNS 
given their implication in the survival, maturation and differentiation of neurons, 
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astrocytes and oligodendrocytes as well as their involvement in neurite outgrowth and 
synapse homeostasis (Kim and de Vellis, 2005; Nakajima and Kohsaka, 2004). 
Furthermore, upon exposure to toxic insults, microglia also proved to secrete molecules 
with a neuroprotective potential. For instance, lipopolysaccharide (LPS) stimulation of 
microglia led to increased production of BDNF, NT-4/5 and NGF suggesting the 
participation of these cells in neuronal regeneration (Miwa et al., 1997; Nakajima et al., 
2001a). After middle cerebral artery occlusion (MCAO), microglia secretes increased 
amounts of insulin-like growth factor-1 that can promote neural precursors proliferation, 
survival and differentiation, thus rendering microglia a pro-neurogenic role upon stroke 
(Thored et al., 2009). In addition, glutamate may signal microglia to release neurotrophic 
factors like BDNF, GDNF and NGF as an attempt to rescue neurons from excitotoxic 
damage (Liang et al., 2010).  
Microglia can also play additional neuroprotective actions as glutamate 
scavengers by the expression of glutamate transporter-1 (GLT-1) (Nakajima et al., 
2001b). Moreover, GLT-1 expression by microglia is up-regulated upon motoneuron 
injury in axotomized rat facial nucleus (Lopez-Redondo et al., 2000) or in response to 
TNF-α production (Persson et al., 2005). Glutamine synthetase, the enzyme responsible 
for converting glutamate into the less toxic glutamine, is also expressed in activated 
microglia (Chretien et al., 2002; Rimaniol et al., 2000). Furthermore, the concept of 
protective autoimmunity, developed by Schwartz et al. (2003) illustrates an interaction 
between activated microglia and the adaptive immune system (namely T-cells) which 
ultimately contributes for the orchestration of glutamate homeostasis (Schwartz et al., 
2003). 
On the other hand, activation of microglia is also associated with the release of a 
myriad of potentially cytotoxic substances such as ROS, proteases, pro-inflammatory 
cytokines, chemokines, glutamate, among others (Aloisi, 2001; Kim and de Vellis, 2005). 
In fact, microglia is one of the principal sources of cytokines in the brain, such as IL-1β, 
TNF-α and IL-6 (Hanisch, 2002). Cytokines are low molecular weight proteins which 
participate in a wide range of biological responses such as development and modulation 
of inflammation (Acarin et al., 2001; Gebicke-Haerter, 2001). Interleukin (IL)-1β and TNF-
α are two important cytokines with pleiotropic functions (Fig. I.6). Both cytokines are 
implicated in CNS inflammation given their ability to induce the expression of adhesion 
molecules and chemokines leading to BBB breakdown and facilitating leukocyte 
recruitment into the CNS (Allan and Rothwell, 2003; Hanisch, 2002; Lee and Benveniste, 
1999).  
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Fig. I.6. Overview of the signaling pathways following cytokine receptor activation. 
Tumour necrosis factor (TNF)-α interacts with its specific receptor TNFR-1 initiating 
intracellular cascades through the recruitment of TNFR-associated factor (TRAF) 2. This 
event may lead to TNF-α-induced phosphorylation of members of the mitogen-activated 
protein kinases (MAPKs) family such as MAPK kinase kinases (MEKKs) and 
subsequently of the MAPKs [namely p38, extracellular signal regulated kinases 1 and 2 
(ERK1/2) and c-Jun N-terminal kinases 1 and 2 (JNK1/2)]. MAPKs activation may then 
induce the activation of transcription factors (TF) such as nuclear factor-kB (NF-kB). 
Stimulation of the NF-kB pathway may be initiated by the phosphorylation of the inhibitor 
of NF-κB (IκB) kinase complex (IKK) which is crucial for the degradation of IκB allowing 
NF-κB to translocate into the nucleus and promote gene transcription. Additionally, 
Interleukin (IL)-1 may also trigger NF-κB and MAPKs activation by the engagement of its 
membrane receptor IL-1R and consequent recruitment of myeloid differentiation factor 
88 (MyD88). This latter adaptor protein associates with IL-1R-associated kinase 4 (IRAK 
4) and subsequently activates TRAF6. These pathways may consequently result in 
modification of the inflammatory response and even cell death. 
 
IL-1β has been broadly implicated in acute neuronal injuries such as the ones 
resulting from ischemic or excitotoxic challenges (Hagberg et al., 1996). In fact, studies 
where the action of IL-1β was inhibited culminated in marked reduction of the extent of 
cell death elicited by ischemic, traumatic or excitotoxic brain injury (Allan and Rothwell, 
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2003). TNF-α was reported to promote neuronal (Venters et al., 2000) and 
oligodendroglial cell death and is also involved in demyelination (Akassoglou et al., 
1998). Nevertheless, the neuroprotective or neurotoxic outcomes induced by TNF-α 
seem to depend on the existence of two distinguishable signalling pathways mediated 
through the TNF receptor (TNFR) 1 and 2 (Arnett et al., 2001). Indeed, a recent report 
demonstrates that microglia up-regulates TNFR2 expression in response to an 
inflammatory stimulus and that this event leads to the induction of anti-inflammatory 
pathways (Veroni et al., 2010). In addition, IL-6 can have both anti- and pro-inflammatory 
actions since it can significantly reduce ischemic brain damage after MCAO (Loddick et 
al., 1998) or, in contrast, contribute to the pathophysiology of many diseases (Gadient 
and Otten, 1997). Microglial cells express surface receptors for this multitude of 
cytokines, thus propagating the inflammatory response (Aloisi, 2001). Among the 
upstream signalling pathways involved in the production of cytokines by microglia are 
mitogen-activated protein kinases (MAPKs), responsible for the phosphorylation of 
several transcription factors such as nuclear factor-κB (NF-κB) or activator protein-1 (AP-
1) (Koj, 1996; Roux and Blenis, 2004). The nuclear translocation of these factors may 
culminate in the production of the above described cytokines as well as chemokines, 
complement factors and others (Nakajima et al., 2006).  
A correlation between Notch-1 and NF-κB was recently confirmed in LPS-
stimulated microglia demonstrating that Notch signalling may amplify the pro-
inflammatory response of microglia by enhancing NF-κB signalling (Cao et al., 2010). 
The signal transducers and activators of transcription (STAT) pathway might also be 
activated in microglia upon ischemic lesion and lead to enhanced production of 
inflammatory products (Justicia et al., 2000; Planas et al., 1997).  
 
Cytokine release can also raise the production of other inflammatory mediators 
such as NO (Chao et al., 1995). Microglial cells are reported to generate a burst of NO in 
response to injury, which may lead to neuronal dysfunction and cell death (Bal-Price and 
Brown, 2001; Cassina et al., 2002; Kawase et al., 1996; Sunico et al., 2010). 
Interestingly, oxidative stress may lead to excessive glutamate production in microglia, 
culminating in excitotoxic brain damage (Barger et al., 2007; Golde et al., 2002). The 
release of glutamate in microglia is conveyed by the Xc antiporter, an heterodimeric 
protein complex which exchanges extracellular cystine for intracellular glutamate (Barger 
and Basile, 2001; Domercq et al., 2007). Glutamate is an excitatory neurotransmitter but 
when present in the synaptic space above a certain threshold will lead to excitotoxicity, 
that is, to the excessive activation of its receptors (namely NMDA, AMPA or kainate 
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receptors) with subsequent increase in intracellular calcium influx that culminates in 
neuronal death (Johnston, 2005). 
The extensive list of bioactive substances released by microglia in response to 
brain injury encompasses molecules with chemoattractant properties such as 
chemokines and MMPs (involved in the degradation of ECM components facilitating 
leukocyte recruitment); molecules implicated in the initiation and propagation of 
inflammation like prostanoids produced by cyclooxigenase-2 (COX-2) and complement 
factors; substances involved in endoplasmic reticulum stress such as cathepsins; anti-
inflammatory cytokines like IL-10 and transforming growth factor (TGF)-β; and others 
(Aloisi, 2001; Kim and de Vellis, 2005; Nakajima and Kohsaka, 2004). 
The inflammatory response engaged by microglia has also been implied in the 
inhibition of neurogenesis (Ekdahl et al., 2003; Monje et al., 2003) adding on the notion 
that inflammation equals toxicity. Nevertheless, inflammation is a normal response of the 
organism to infection, injury and trauma and some authors envisage this response as 
primarily beneficial (Amor et al., 2010; Harry and Kraft, 2008) and as an internal 
mechanism for repair (Schwartz et al., 2003). Yet, deregulation of the inflammatory 
response and chronic immune activation can lead to deleterious effects and ultimately 
cell death (Graeber and Streit, 2009; Harry and Kraft, 2008). It is, therefore, important to 
recognize the beneficial aspects of the immune response and harness them, in order to 
contribute to damage resolution instead of aggravating injury. 
 
4. Microglial reactivity and modulation by cell interplay  
 
4.1. Models for the evaluation of microglial reactivity  
Activation of microglia comprises the up-regulation of several surface markers, 
which in the “resting” or “surveying” state are expressed at low or moderate levels (Aloisi, 
2001; Guillemin and Brew, 2004). Some of these markers have been used to identify 
microglia in tissue sections and cell cultures (Fig. I.7) but, the existence of a single 
specific molecular marker for microglia is still unknown (Graeber and Streit, 2009). This 
is explained by the fact that microglia share several antigens with macrophages, 
endothelial cells, lymphocytes, among other cells (Guillemin and Brew, 2004). Therefore, 
the known microglia markers are cell-specific in the sense that they do not label other 
glial cells or neurons (Graeber and Streit, 2009). Some of the most commonly used 
surface markers are lectins (carbohydrate binding proteins) such as wheat germ 
agglutinin, mistletoe lectin, Ricinus communis agglutinin-1, Griffonia simplicifolia B4 
isolectin and Lycopersicon esculentum (tomato) lectin, which present an increased 
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affinity for microglial cell but also bind neurons and myelin nodes and membranes 
(Acarin et al., 1994). Other very commonly used markers are β2-integrins (CD11a, 
CD11b and CD11c); the ligand for CD11a is intercellular adhesion molecule-1 whereas 
the ligands for CD11b and CD11c are complement proteins (Kim and de Vellis, 2005). 
CD11b is also commonly known as complement rerceptor-3 (CR3), and the antibodies 
aimed at its recognition are orexin (OX) 42 or macrophage receptor 1 (Mac 1) depending 
on the rat or mouse origin of the protein, respectively. Additional antibodies have been 
proposed for the detection of activated microglia such as ED-1, also called CD-68, which 
is expressed on the membranes of cytoplasmic granules such as phagolysosomes and 
has been shown to correlate with phagocytic activity (Damoiseaux et al., 1994); or OX-6 
that recognizes MHC class II antigens (Guillemin and Brew, 2004). One of the most 
versatile immunocytochemical marker for microglia is ionized calcium-binding adaptor 
molecule 1 (Iba1), an EF-hand protein which is up-regulated in activated microglia (Imai 
et al., 1996). 
 
 
Fig. I.7. Surface markers used for microglial labelling. Rat primary cortical microglia 
are labelled with ionized calcium-binding adaptor molecule 1 (Iba1) (A) or with orexin 
(OX) 42, an antibody raised against rat complement receptor 3 (B). Scale bar represents 
20 µm. 
 
However, the expression of these surface markers depends on the activation 
state of microglial cells, as demonstrated by Cristovão and colleagues (2010), and its 
presence is not always constant in all activation processes. For instance, activated 
microglia accumulated in the facial nucleus after axotomy do not express ED-1 (Graeber 
et al., 1998), and MHC class II can be also found in ramified microglia besides being 
present in the activated state (Streit et al., 2004). These observations further corroborate 
the functional plasticity exhibited by microglia. Additionally, different behaviors have been 
A B
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reported for microglial cells when applying in vitro or in vivo models which may be 
attributable to the fact that these cells are always activated to same extent when in 
culture somewhat limiting the ability to study microglial actual functions (Farber and 
Kettenmann, 2005) and also to the lack of interaction with neighboring cells, a 
determinant factor for the modulation of microglial reactivity (Hanisch and Kettenmann, 
2007). The abundance of surface receptors expressed by microglia as well as the 
panoply of soluble factors produced by these cells certainly vouches for its ability to 
interact with other cells. The most striking example is the capacity of microglia to function 
as an antigen presenting cell. Microglia bind the processed antigens to MHC complex on 
its surface and engage interaction with T-cells. Optimal T-cell-microglia adhesion and 
reciprocal activation are achieved through additional interactions between adhesion and 
co-stimulatory molecules i.e. lymphocyte function-associated antigen 1, B7-1 and B7-2 
molecules (CD80 and CD86), CD40 and their specific counterparts in the surface of T-
cells (Aloisi, 2001; van Kooten and Banchereau, 2000). 
Therefore, when evaluating microglial response towards toxic or external stimulus 
several experimental approaches can be used in order to explore the cross-talk between 
microglia and nerve or immune cells (Fig. I.8). The conditioned medium model is used in 
this thesis and aims at the evaluation of the influence of soluble factors on cell reactivity. 
In fact, soluble factors released by either neurons or glial cells have proven to 
reciprocally influence the development and reactivity of these cells (Gomes et al., 2001). 
Mixed culture models, also applied in this thesis, rely on cell-to-cell interactions, such as 
ligand-receptor interaction and phagocytosis. Finally, organotypic slice cultures (OSCs) 
are heralded as the most approximate model to the in vivo conditions. In this model the 
three dimensional architecture of the brain is maintained, recapitulating the cellular 
contacts existent between neurons and glial cells. OSC are thick sections (250 – 400 
µm) usually obtained from the early post-natal period by the roller tube method (in which 
the cultured tissue is maintained attached to a coverslip rotating in the incubator) or by 
the interface method developed by Stoppini et al. (1991), where explanted tissues are 
layered onto a semiporous membrane and kept at an air – liquid interface (Lossi et al., 
2009).  
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Fig. I.8. Schematic representation of experimental models and respective main 
applications used for the evaluation of microglial reactivity. 
 
 
4.2. Reciprocal reactivity modulation by interplay of microglia with neighboring 
cells  
Neurons have been mainly regarded as the victims of overactivated microglia, 
nevertheless, compelling evidence demonstrates the existence of reciprocal signalling 
between neurons and microglia (Biber et al., 2007). Some authors have listed several 
signals by which microglial function seems to be controlled and divided them in “off” or 
“on” signals. “Off” signals are constitutively found in the healthy brain and its absence 
may trigger microglial activation (Biber et al., 2007). The classical example of an “off” 
signal is CD200, a member of the immunoglobulin (Ig) superfamily constitutively 
expressed at the neuronal membrane, which is able to bind to its receptor CD200R, at 
the surface of microglia, leading to the inhibition of microglial inflammatory functions 
(Hoek et al., 2000). Among the “off” signals are also chemokines such as CX3CL1 or 
fractalkine that exert a similar microglial inhibition (Mizuno et al., 2003; Zujovic et al., 
2000). Therefore, “off” signals can be envisaged as a way of neurons to maintain 
microglia in a “resting” state in the healthy brain. “On” signals, by the other hand, are 
described as substances produced by endangered or injured neurons and may lead to 
microglial activation. Some of the “on” signals described are purines like ATP (Koizumi et 
al., 2007), chemokines like CCL21 (Zhao et al., 2007) and MMPs (Kim et al., 2005), 
CM
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which may induce microglial chemotaxis towards the injury site and enhance its 
phagocytic activity. Whether the outcome resulting from neuron-microglia signalling is 
either beneficial or detrimental is the question many researchers try to answer employing 
different study models.  
 Using the conditioned medium model (Polazzi and Contestabile, 2006) found that 
soluble factors released by healthy neurons lead to an overactivation of LPS-stimulated 
microglia culminating in the apoptotic elimination of microglia, probably as a safety 
mechanism. Reciprocally, activated microglia release factors such as NO that cause 
neuronal cell death and neurite destruction (Munch et al., 2003). In addition, the severity 
of neuronal injury appears to modulate the production of neurotrophic or neurotoxic 
molecules by microglia (Lai and Todd, 2008). In fact, some studies have reported an 
increased production of neurotrophins by microglia upon exposure to neuronal 
conditioned medium (Nakajima et al., 2007). However, not only soluble factors but also 
cellular interaction has to be accounted for when studying microglial response to 
activating factors. In fact, if unstimulated microglia promotes neuronal survival by the 
production of soluble factors, when in contact with neurons (in a mixed culture system) 
and upon LPS stimulation, they lead to neuronal death, a situation that failed to occur 
when conditioned media from LPS-stimulated microglia was applied to neurons (Zhang 
and Fedoroff, 1996). Similarly, a proximity dependent mechanism, probably mediated by 
NO, seems to govern microglial-induced neuronal death (Gibbons and Dragunow, 2006). 
In contrast, there are also examples of neuron-microglia mixed cultures where neurons 
seem to reduce microglial responsiveness to LPS (Chang et al., 2001). Microglia in 
OSCs have demonstrated to migrate specifically towards sites of excitotoxic injury 
(Heppner et al., 1998) and to participate in neuronal death in both excitotoxicity 
(Bernardino et al., 2008; Dehghani et al., 2004) and hypoxia-ischemia models (Leonardo 
et al., 2009) owing to the production of pro-inflammatory cytokines, NO and MMPs. 
However, the neurotoxic or neuroprotective effects of microglia upon excitotoxic injury 
may also depend on the concentration of inflammatory cytokines produced and on the 
signalling pathways engaged (Bernardino et al., 2005).  
 Regarding microglial interplay with astrocytes, the latter cells produce substances 
like colony stimulating factors (CSFs) which act as mitogens promoting microglial 
proliferation (Suzumura et al., 1990). Moreover, microglia are able to sense astrocytic 
calcium waves responding to it by the activation of purinergic receptors (Farber and 
Kettenmann, 2005). Upon brain injury, nucleotides, chemokines and adhesion molecules 
rapidly activated at the astrocytes’ surface act as chemoatractants driving microglia 
towards the lesion site (Davalos et al., 2005; Raivich, 2005). 
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Conversely, astrocytes have been reported to down-regulate microglial ROS 
production, probably as a mechanism of preventing excessive brain inflammation (Min et 
al., 2006). The same was verified by Eskes et al. (2003) in an astrocyte-microglia mixed 
culture where TNF-α release was decreased after exposure to a neurotoxicant. In 
accordance, astrocytes were shown to counteract microglial glutamate-induced neuronal 
death in a model using both conditioned media and mixed cultures (Liang et al., 2008). In 
contrast, in a study employing OSCs, astrocytes react to excitotoxicity by the production 
of the chemokines CXCL10 which interact with its specific microglial receptor culminating 
in neuronal death (van Weering et al., 2010). Another study regarding the role of IL-18 in 
neuropathic pain demonstrated that this cytokine mediates astrocyte-microglia 
interaction and further enhances pain (Miyoshi et al., 2008). 
Microglia has been long implicated in demyelinating diseases given its ability to 
phagocyte myelin and to produce potential harmful factors such as TNF-α, which may 
lead to oligodendroglial death (Selmaj and Raine, 1988a; Selmaj and Raine, 1988b). A 
recent report showed that conditioned medium from LPS-activated microglia attenuated 
primary OPC proliferation without inducing cell death (Taylor et al., 2010). In contrast, 
microglial activation was shown to enhance OPC recruitment and to promote debris 
removal, rendering the brain tissue more responsive to myelin repair (Glezer et al., 
2007). 
 In summary, interplay between CNS cells may have a strong and diverse 
influence on the cascade of microglial responses and, in exchange, microglial activation 
may also interfere with the reactivity of the remaining nerve cells leading to beneficial or 
detrimental outcomes depending on the environmental circumstances.  
 
5. Involvement of microglia in the progression of neurological diseases 
Microglial activation is the consequence of virtually all conditions associated with 
neuronal injury. Therefore, the involvement of microglia in several neurological diseases 
is notorious. In fact, the presence of activated microglia in regions of brain injury led to 
the assumption that these cells where accountable for pathological effects (Harry and 
Kraft, 2008). Nevertheless, emerging research as abovementioned proved the essential 
roles of microglia in the brain’s normal functions as well as their neuroprotective effects 
in some pathologic conditions.  
 
5.1. Acute and chronic neurological diseases 
Among the most common acute neurological diseases are CNS infections by 
different strains of bacteria, viruses or parasites (Rock et al., 2004). Innate immune cells 
such as microglia interact with invading pathogens by pattern recognition receptors that 
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bind to structures designated as pathogen-associated molecular patterns (PAMPs) 
(Janeway, 2001). Among the pattern recognition receptors are TLRs, CD14 receptor, 
mannose receptors and CR3 and their interaction with PAMPs leads to the expression of 
MHC class II and co-stimulatory molecules thus facilitating antigen presentation 
(Janeway, 2001; Town et al., 2005). In fact, some authors stated that microglial role in 
the defence of CNS against invading microorganisms relies mainly on their ability to “call 
in the troops”, meaning systemic lymphocytes, monocytes and neutrophils (Rock et al., 
2004). Moreover, upon activation due to pathogen recognition, phagocytosis is engaged. 
Phagocytic engulfment of the pathogen is often followed by a “respiratory burst” involving 
the production of ROS (Block and Hong, 2005) aiming at eliminating the pathogen. 
Microglia also participate in the opsonization of pathogens aiding in their recognition and 
elimination (Hadas et al., 2010).  
In acute CNS injury like entorhinal cortex injury (Rappert et al., 2004) or facial 
nerve axotomy (Graeber et al., 1998) microglia rapidly migrates towards the lesion and 
proceeds with the removal of injured neurons, thus exerting a pro-regenerative function. 
In hypoxic-ischemic brain injury, a leading cause of mortality and morbidity, microglia 
and macrophages accumulate at the lesion site (McRae et al., 1995) and may cause 
injury through the production of pro-inflammatory mediators (Doverhag et al., 2010; 
Hagberg et al., 1996) and consequent neuronal death (Dean et al., 2010). Yet, 
contrasting data suggest that inhibition of microglial activation worsens hypoxic-ischemic 
brain injury in a neonatal mouse model (Tsuji et al., 2004). In addition, ablation of 
microglial cells results in significant increase in infarct size after MCAO in the adult stage 
(Lalancette-Hebert et al., 2007). In this context microglia have also been demonstrated 
to produce neurotrophic factors in response to stroke in the adult (Thored et al., 2009), 
and therefore to promote recovery. 
 
Compelling evidences have demonstrated that microglial activation is one of the 
hallmarks of chronic neurodegenerative diseases such as AD, Parkinson’s disease (PD), 
MS, ALS, human immunodeficiency virus (HIV) – associated dementia, among others 
(Gebicke-Haerter, 2001), displaying both causative and exacerbating roles. The role of 
microglia in neurodegenerative diseases is supported by the prevalence of progressive 
neuronal loss and pathological levels of cytotoxic products like ROS and pro-
inflammatory cytokines, to the production of which microglia may be accounted for (Lull 
and Block, 2010).  
AD is a neurodegenerative disease characterized by the presence of insoluble 
plaques containing Aβ and intraneuronal neurofibrillary tangles in the cortical region of 
the brain (Lull and Block, 2010). The presence of MHC class II positive microglia was 
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reported in clusters formed around Aβ containing plaques in postmortem AD tissue 
(McGeer et al., 1988; McGeer et al., 1987). Aβ recruits and activates microglia leading to 
the release of NO (Ii et al., 1996), TNF-α (Dheen et al., 2005) and superoxide (Qin et al., 
2002), which may ultimately culminate in neuronal damage. Moreover, chemokine 
receptors such as CX3CR1, which are critical for microglia – neuron communication 
seem to be required for neuron loss in a mouse model of AD (Fuhrmann et al., 2010). 
Although these evidences point to microglia as neurotoxic and disease aggravating in 
AD, microglia was also reported to phagocyte Aβ (Das et al., 2003; Koenigsknecht-
Talboo and Landreth, 2005), thus playing a neuroprotective role. The clearance of 
perivascular Aβ deposits by microglia seems to be mediated by the chemokine CCR2 (El 
Khoury et al., 2007). In fact, immunization of animals with Aβ peptide proved to provide 
protection against AD progression since it prompted microglial clearance of Aβ (Schenk 
et al., 1999). However, clinical trials in humans were arrested due to the emergence of 
meningoencephalitis symptoms (Senior, 2002). A contrasting theory defends that 
microglia do not cause bystander damage but instead become senescent and 
dysfunctional with normal aging, becoming disabled and deprived of their normal neuron-
supporting functions. Consistently, signs of microglial degeneration were found in AD 
tissue, where microglia presented structural abnormalities and cell death (Streit, 2002).  
PD is characterized by the degeneration of dopaminergic neurons in the 
substantia nigra of the brain (Kim and Joh, 2006). Activated microglia was observed in 
the striatum of postmortem PD brains (McGeer et al., 1988) and was associated with 
neuronal damage due to the production of oxidative stress (Dexter et al., 1994) and 
inflammatory mediators (Mogi et al., 1994). In addition, minocycline, a known blocker of 
microglia activation, prevents loss of dopaminergic neurons (Wu et al., 2002), further 
reinforcing the implication of inflammation and microglia in PD progression. However, 
minocycline has also direct anti-apoptotic effects which may modulate microglial 
response since this depends on the severity of cell death or injury (Kraft et al., 2009). In 
fact, microglia may be neuroprotective in the early stages of disease but become 
neurotoxic upon dopaminergic neuron degeneration (Sawada et al., 2006).  
MS is the most prevalent inflammation-mediated demyelinating disease in which 
the myelin sheath is damaged by an autoimmune response with a clear inflammatory 
component (Block and Hong, 2005). Increased microglial activity was demonstrated 
around MS lesions (Banati et al., 2000). Microglia may contribute for the disease 
progression by the production of inflammatory cytokines and ROS (Murphy et al., 2010), 
and also by their antigen-presentation function which sparks the autoimmune response 
targeting myelin (Mack et al., 2003). Nevertheless, phagocytic clearance of debris has 
been proven favorable for myelin repair (Glezer et al., 2007). In fact, a beneficial role has 
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been described for the microglial phagocytic TREM-2 receptor in an experimental 
autoimmune encephalomyelitis (EAE) model (Piccio et al., 2007). 
ALS is a very incapacitating neurodegenerative disorder characterized by the 
degeneration of motor neurons (Henkel et al., 2009). Studies using a transgenic animal 
model of ALS demonstrated the presence of structural abnormalities like cytorrhexis in 
microglial cells (Fendrick et al., 2007), thus reinforcing the concept that microglial 
dysfunction may underlie the onset or progression of chronic diseases. 
HIV-associated dementia is a neurological syndrome that develops in the later 
stages of HIV infection (Block and Hong, 2005). Microglia share some surface receptors 
like CD4 and chemokine receptors with peripheral lymphocytes, which enables them to 
harbor HIV and consequently act as viral replication sites (Garden, 2002). Indeed, 
microglia are activated by HIV proteins such as Tat (D'Aversa et al., 2004) and gp120 
(Kong et al., 1996) leading to the production of ROS, cytokines, chemokines and NO 
(Brabers and Nottet, 2006) which ultimately lead to neuronal death. Some authors claim 
even that persistent infection with HIV may disable or deplete microglia leading the way 
for opportunist CNS infections and dementia (Streit, 2002).  
 
5.2. Neonatal hyperbilirubinemia 
Hyperbilirubinemia is a frequent condition in the neonatal period, defined by an 
increase in serum bilirubin above 5 to 7 mg/dl and occurring in up to 60% of full term 
newborns and 80% of preterm infants (Porter and Dennis, 2002; Stevenson et al., 2001). 
Generally designated as neonatal jaundice, it is characterized by a yellowish 
discoloration of the skin and mucous membranes (Cohen et al., 2010; Porter and 
Dennis, 2002). Unconjugated bilirubin (UCB) is formed by the catabolism of heme 
(Gourley, 1997; Stevenson et al., 2001) and may reach excessive levels in newborn and 
preterm infants due to its overproduction and to the limited ability to excrete this 
molecule as a result of the of enzymatic machinery immaturity in these infants (Dennery 
et al., 2001). In most cases, unconjugated hyperbilirubinemia occurs in a transient and 
non-injurious manner and is called “physiologic jaundice” (Ostrow et al., 2002). When 
UCB exceeds physiological concentrations, multifocal deposition of UCB may take place 
in selected regions of the brain originating bilirubin encephalopathy (Gourley, 1997; 
Ostrow et al., 2004). However, the serum bilirubin levels associated to the term 
“physiologic jaundice” are under scrutiny since they may not accurately define a 
harmless hyperbilirubinemia condition (Maisels, 2006). In fact, some studies have 
reported a protective effect of UCB against oxidative stress injury, when present in low 
levels (Dore and Snyder, 1999; Dore et al., 1999). Contrastingly, the same UCB levels 
may reveal safe in normal newborn infants while become potentially hazardous in 
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premature infants (Stevenson et al., 2001; Watchko and Maisels, 2003) or even in term 
neonates displaying additional pathologies, such as sepsis (Hansen et al., 1993; Kaplan 
and Hammerman, 2005) or hypoxia-ischemia (Ahdab-Barmada and Moossy, 1984; 
Falcão et al., 2007b), which may pose as risk factors for bilirubin encephalopathy. For 
instance, data from magnetic resonance imaging (MRI) showed that severe cerebral 
palsy occurred for relatively low serum bilirubin levels in preterm infants but only at high 
levels in full terms (Gkoltsiou et al., 2008). Regarding prematurity as a risk factor for 
bilirubin toxicity, data from in vitro (Falcão et al., 2005; Falcão et al., 2006) and in vivo 
studies (Conlee and Shapiro, 1997; Keino and Kashiwamata, 1989) point to the 
existence of windows of developmental susceptibility of the CNS to bilirubin toxicity 
(Shapiro, 2010).  
The term acute bilirubin encephalopathy is used to describe the sharp 
manifestations of bilirubin toxicity seen in the first weeks after birth (American Academy 
of Pediatrics, 2004). Such manifestations, that might be reversible, progress from 
lethargy and decreased feeding to hypotonia and hypertonia, high-pitched cry, 
impairment of upward gaze, fever and seizures (Shapiro, 2003). Recommended 
therapeutic approaches for acute bilirubin encephalopathy are phototerapy and in the 
more severe cases exchange transfusion (American Academy of Pediatrics, 2004).  
The classic form of chronic bilirubin encephalopathy is called kernicterus, 
originally a pathological term referring to the yellow staining (-icterus) of the deep nuclei 
of the brain (kern-, relating to the basal ganglia) (Shapiro, 2010). This condition is 
characterized by chronic and permanent sequelae like athetoid cerebral palsy, deafness 
or hearing loss, impairment of upward gaze and dental enamel hypoplasia, or even 
death. Brain regions more prone to neuropathological lesions produced by 
hyperbilirubinemia are the globus pallidus and subthalamic nucleus, auditory and 
oculomotor brainstem nuclei, cerebellum and hippocampus (Shapiro, 2003; Shapiro, 
2005). The increasing prevalence of bilirubin encephalopathy (Ebbesen, 2000; Hansen, 
2000) due to earlier hospital discharge and to the implementation of less aggressive 
clinical approaches in the management of neonatal jaundice (Maisels and Newman, 
1998) has reawakened interest in understanding the pathophysiology of this condition. 
Moreover, the incidence of severe jaundice is at near epidemic proportions among some 
developing countries (Gordon et al., 2005; Katar, 2007; Owa and Ogunlesi, 2009). 
There is evidence that even moderate levels of unconjugated bilirubin can 
produce subtle encephalopathy, referred to as bilirubin-induced neurological dysfunction 
(BIND) (Shapiro, 2003; Shapiro, 2005). BIND is associated with cognitive disturbances, 
mild neurological abnormalities (Hyman et al., 1969; Odell et al., 1970; Rubin et al., 
1979), isolated hearing loss (Bergman et al., 1985; Salamy et al., 1989) and auditory 
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neuropathy (Rance et al., 1999; Simmons and Beauchaine, 2000). Recent data have 
demonstrated a high incidence of acute auditory neuropathy spectrum disorder among 
neonates with severe jaundice (Saluja et al., 2010). Nonetheless, auditory dysfunction 
may occur in children with or without other signs of classical kernicterus given the high 
sensitivity of the auditory system to bilirubin toxicity (Shapiro and Nakamura, 2001). The 
cellular mechanism underlying bilirubin-induced hearing dysfunction seems to involve 
protein kinases A and C – mediated GABA/glycinergic synaptic transmission in postnatal 
rat ventral cochlear nucleus neurons (Li et al., 2010). In addition, hyperbilirubinemia has 
been shown to cause degeneration of excitatory synaptic terminals in the auditory 
brainstem and this is associated with activation of neuronal nitric oxide synthase (nNOS) 
(Haustein et al., 2010). 
Regarding cognitive disturbances and neurological abnormalities, moderate 
hyperbilirubinemia has been associated with minor neurologic dysfunction throughout the 
first year of life (Soorani-Lunsing et al., 2001). Additional studies have demonstrated that 
neonatal hyperbilirubinemia can have an impact on learning and memory later in infancy 
(Zhang et al., 2003) as well as affect long-term cognitive ability (Seidman et al., 1991). 
An interesting association has also been made between hyperbilirubinemia and 
increased vulnerability for later development of mental disorders (Dalman and Cullberg, 
1999). In fact, neonatal jaundice has been considered a perinatal risk factor for autism 
spectrum disorders and sensory processing disorder given its higher prevalence in 
children suffering from these disorders (May-Benson et al., 2009). An association 
between hyperbilirubinemia and developmental delay, attention-deficit disorder, and 
autism was also observed (Jangaard et al., 2008). Similarly, schizophrenic patients 
showed a significantly higher incidence of hyperbilirubinemia relative to patients suffering 
from other psychiatric disorders, and the psychiatric symptom score was significantly 
higher in schizophrenic patients with hyperbilirubinemia than in patients without 
hyperbilirubinemia (Miyaoka et al., 2000). Another study using Gunn rats, the animal 
model for bilirubin encephalopathy, demonstrated that these animals displayed 
stereotypical behaviors, considered as positive symptoms of schizophrenia, as well as 
more aggressive behaviors (Hayashida et al., 2009). These findings further strengthen 
the neurodevelopmental hypothesis which proposes that a proportion of schizophrenia is 
the result of an early brain insult, either pre or perinatal, which affects brain development 
leading to abnormalities expressed in the mature brain (Gupta and Kulhara, 2010). In 
fact, UCB has been proven to cause impairment of neurotransmitter release in synaptic 
vesicle membranes (Roseth et al., 1998), alteration of long-term synaptic plasticity 
(Chang et al., 2009) and decreased synaptic activity in hippocampal slices (Hansen, 
1994). In addition, UCB leads to neurite outgrowth impairment in immature cortical 
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neurons (Falcão et al., 2007c) and also interferes with axonal growth cone area and 
spine formation (Fernandes et al., 2009). These findings further confirm that UCB’s 
effects in the developing brain may lead to decreased synaptic connectivity, which may 
underlie the emergence of neurodegenerative diseases.  
 
5.2.1. Molecular mechanisms of bilirubin-induced CNS injury 
Bilirubin-induced neurotoxicity is initiated at the level of the membrane. Indeed, 
UCB interacts with whole nerve cell and mitochondrial membranes disrupting its redox 
status and increasing oxidative damage (Rodrigues et al., 2002b). Rough endoplasmic 
reticulum abnormalities were also observed in astrocytes exposed to UCB (Silva et al., 
2001a). UCB-induced membrane permeabilization leads to mitochondrial swelling and 
release of cytochrome c (Rodrigues et al., 2000b), which is followed by caspase-3 
processing, poly-ADP ribose polymerase (PARP) cleavage and Bax translocation, 
resulting in apoptotic cell death (Rodrigues et al., 2002a). Studies have also showed the 
involvement of caspase-8 in cell death provoked by UCB (Seubert et al., 2002). 
Susceptibility to UCB-induced damage differs with age and cellular type. Younger cells 
are more susceptible to UCB-induced injury (Falcão et al., 2005; Falcão et al., 2006; 
Rodrigues et al., 2002c; Silva et al., 2002) and to this may account the reduced 
expression of multidrug resistance associated protein 1 (Mrp1) in immature cells (Falcão 
et al., 2007a), an efflux pump involved in UCB export. Moreover, neurons are more 
vulnerable to death mechanisms than astrocytes (Falcão et al., 2006; Silva et al., 2002), 
in which an inflammatory response is triggered by UCB (Fernandes et al., 2004). 
Neurons are also more exposed than astrocytes to oxidative injury by UCB, for which 
accounts the lower glutathione stores in neuronal cells (Brito et al., 2008b) (Fig. I.9). 
In addition, UCB causes a bioenergetic and oxidative crisis in immature neurons, 
inhibiting cytochrome c oxidase activity and increasing glycolitic activity as well as ROS 
production (Vaz et al., 2010). Interestingly, a recent report demonstrated that oxidative 
damage by UCB may be mediated by overstimulation of glutamate receptors (Brito et al., 
2010).  
Glutamate and NMDA receptors are particularly important in the pathogenesis of 
neonatal neuronal injury (Johnston, 2005). In fact, UCB inhibits glutamate uptake by 
astrocytes (Silva et al., 1999) prolonging glutamate’s presence in the synaptic cleft, 
which may engender NMDA receptors overstimulation and excitotoxicity in both in vitro 
(Grojean et al., 2000; Grojean et al., 2001) and in vivo studies (Hoffman et al., 1996; 
McDonald et al., 1998).  
Astrocytes and microglia react to UCB through the increased production of pro-
inflammatory cytokines and glutamate (Fernandes et al., 2006; Fernandes et al., 2004; 
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Gordo et al., 2006). Upstream signalling pathways involved in astrocytic cytokine 
production elicited by UCB are MAPKs and NF-κB, which also contribute to the observed 
cell death (Fernandes et al., 2007a; Fernandes et al., 2006). In addition, activation of p38 
MAPK is involved in bilirubin-induced granule cerebellar neuronal death (Lin et al., 
2003). Moreover, decreased viability and apoptotic and/or necrotic cell death is also 
observed in oligodendrocytes (Genc et al., 2003) and microglial cells exposed to UCB 
(Gordo et al., 2006). 
 
 
 
 
Fig. I.9. Major findings regarding the molecular mechanisms involved in 
unconjugated bilirubin (UCB)-induced toxicity. UCB triggers several toxicity-related 
molecular mechanisms in neurons, astrocytes and microglia. Moreover, the intensity of 
the observed deleterious effects depends on cell type and also on maturation stage, 
given that both immature neurons and astrocytes are more vulnerable to UCB-induced 
toxicity. (DIV – days in vitro). 
 
Concerning potential therapeutical strategies to prevent UCB-induced injury, 
glycoursodeoxycholic acid (GUDCA) and IL-10 have already been assayed with positive 
results. Indeed, ursodeoxycholic acid (UDCA) and its conjugates have demonstrated 
neuroprotective effects by the stabilization of mitochondrial membranes (Sola et al., 
2002), inhibition of mitochondrial swelling (Rodrigues et al., 2000c), cytochrome c 
release (Rodrigues et al., 2000a) and, ultimately, by the decrease of apoptotic cell death 
(Silva et al., 2001b). UDCA oral administration induces a rapid and sustained decrease 
in plasma UCB concentrations in Gunn rats (Cuperus et al., 2009). Moreover, recent 
reports have described GUDCA to prevent UCB-induced alterations in protein oxidation, 
lipid peroxidation, impairment of glutathione homeostasis and neuron cell death (Brito et 
al., 2008a) as well as its ability to ameliorate UCB-induced mitochondrial respiratory 
chain dysfunction and to restore cellular antioxidant potential (Vaz et al., 2010). In 
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addition, both GUDCA and IL-10 can modulate astrocytic reactivity to UCB decreasing 
the elicited inflammatory properties and reducing cell death (Fernandes et al., 2007b). 
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6. Global aims of the thesis 
The main goal of the present work is to explore the role of microglia in 
hyperbilirubinemia by addressing microglial reactivity, characterizing the dynamics of 
neuron-glia interplay and identifying potential therapeutic strategies. 
 
As a first step we sought to investigate the cellular and molecular mechanisms of 
isolated microglial reactivity towards UCB by the evaluation of cell survival and by the 
assessment of the different phenotypes acquired by microglia when facing UCB. 
Therefore we intended to evaluate microglial phagocytic abilities and to characterize the 
inflammatory response engaged by these cells by studying the temporal profile of pro-
inflammatory cytokines’ secretion as well its underlying signalling pathways and by the 
analysis of indicators of the inflammatory response such as MMPs activation and COX-2 
up-regulation. 
Since microglia exhibited different activation stages in the presence of UCB, 
displaying both phagocytic and inflammatory phenotypes in a sequenced fashion along 
exposure time, we decided to study how neuron-glia interplay could modulate the effect 
of UCB. For this matter we used a conditioned media model to evaluate the influence of 
soluble factors released by UCB-stimulated astrocytes and neurons in microglial 
reactivity. We also assessed the influence of neuron-microglia cell-to-cell interactions in 
UCB-induced deleterious effects on immature neurons in a neuron-microglia mixed 
culture. 
Finally, we advanced one step further and sought to investigate the role of 
microglia in the modulation of UCB-induced neurotoxicity in organotypic-cultured 
hippocampal slices where selective ablation of microglia was performed. Furthermore, 
we aimed at unravelling the molecular mechanisms triggering UCB-induced neurotoxicity 
which may underlie the association of hyperbilirubinemia with mental disorders. 
Ultimately we evaluated the ability of GUDCA and IL-10 to prevent UCB’s deleterious 
effects in both neuronal cultures and organotypic-cultured hippocampal slices. 
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Abstract 
Microglia constitute the brain’s immunocompetent cells and are intricately 
implicated in numerous inflammatory processes included in neonatal brain injury. In 
addition, clearance of tissue debris by microglia is essential for tissue homeostasis and 
may have a neuroprotective outcome. Since unconjugated bilirubin (UCB) has been 
proven to induce astroglial immunological activation and neuronal cell death, we 
addressed the question of whether microglia acquires a reactive phenotype when 
challenged by UCB and intended to characterize this response. 
In the present study we report that microglia primary cultures stimulated by UCB 
react by the acquisition of a phagocytic phenotype that shifted into an inflammatory 
response characterized by the secretion of the pro-inflammatory cytokines tumour 
necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6, up-regulation of cyclooxygenase 
(COX)-2 and increased matrix metalloproteinase (MMP)-2 and -9 activities. Further 
investigation upon upstream signalling pathways revealed that UCB led to the activation 
of mitogen-activated protein kinases (MAPKs) and nuclear factor (NF)-κB at an early 
time point, suggesting that these pathways might underlie both the phagocytic and the 
inflammatory phenotypes engaged by microglia. 
Curiously, the phagocytic and inflammatory phenotypes in UCB-activated 
microglia seem to alternate along time, indicating that microglia reacts towards UCB 
insult firstly with a phagocytic response, in an attempt to constrain the lesion extent and 
comprising a neuroprotective measure. Upon prolonged UCB exposure periods, either a 
shift on global microglia reaction occurred or there could be two distinct sub-populations 
of microglial cells, one directed at eliminating the damaged cells by phagocytosis, and 
another that engaged a more delayed inflammatory response.  
In conclusion, microglial cells are relevant partners to consider during bilirubin 
encephalopathy and the modulation of its activation might be a promising therapeutic 
target. 
 
 
Keywords: Microglial activation; Cyclooxygenase-2; Hyperbilirubinemia; Inflammatory 
signalling pathways; Matrix metalloproteinases; Mitogen activated protein kinases; 
Nuclear factor-κB; Phagocytic activity. 
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1. Introduction 
Hyperbilirubinemia is a common condition in the neonatal period and results from 
a limited ability of the newborns to excrete an over produced bilirubin (Dennery et al., 
2001; Watson, 2009). Physiological to pathological transition is driven by the multifocal 
deposition of unconjugated bilirubin (UCB) in selected regions of the brain leading to 
encephalopathy and kernicterus (Hansen, 2002; Porter and Dennis, 2002). This event is 
directly correlated with death, as well as with impairments of neural development and 
hearing (Oh et al., 2003). Additionally, moderate hyperbilirubinemia has been proven to 
be associated with a significant increase in minor neurologic dysfunction throughout the 
first year of life (Soorani-Lunsing et al., 2001) and has also been related to the outcome 
of mental disorders such as schizophrenia (Miyaoka et al., 2000). 
The cytotoxic effects of UCB in the central nervous system (CNS) have been 
broadly studied and comprise several features such as: perturbation of nerve cell and 
mitochondria membranes (Rodrigues et al., 2002b; Rodrigues et al., 2002c); inhibition of 
glutamate uptake prolonging its presence in the synaptic cleft (Silva et al., 1999; Silva et 
al., 2002); N-methyl-D-aspartic acid (NMDA)-mediated excitotoxicity (Brito et al., 2010; 
Grojean et al., 2000; Grojean et al., 2001; McDonald et al., 1998); and increase in 
intracellular calcium (Brito et al., 2004). All these events may culminate in cell death by 
both necrosis and apoptosis (Rodrigues et al., 2002a; Silva et al., 2001) being neurons 
more susceptible to death mechanisms than astrocytes (Falcão et al., 2006; Silva et al., 
2002). Some of the injurious effects of UCB on astrocytes are an elevated glutamate 
secretion and the activation of inflammatory pathways that lead to cytokine release 
(Falcão et al., 2006; Fernandes et al., 2006; Fernandes et al., 2004). Furthermore, our 
group was the first to demonstrate that UCB activates and damages microglial cells 
(Gordo et al., 2006). Indeed microglia showed to be the most reactive brain cells when 
compared to astrocytes and neurons, as they evidence increased UCB-induced cell 
death, release of glutamate and cytokine production (Brites et al., 2009).  
Microglial cells reside within the CNS parenchyma (Streit, 2002) and engage 
several important roles in the developing brain (Cuadros and Navascues, 1998; Kim and 
de Vellis, 2005) as well as in pathological conditions (Block and Hong, 2005; Nakajima 
and Kohsaka, 2004). In response to injury, microglia turn into an activated state and 
display a complexity of phenotypic alterations that illustrate what is called “reactive 
microglia”. This activation entails several features such as: dramatic morphologic 
changes by the acquisition of an amoeboid phenotype (Kreutzberg, 1996); up-regulation 
of intracellular enzymes and cell surface markers, release of pro-inflammatory mediators, 
oxygen radicals and proteases (Kim and de Vellis, 2005), antigen presentation (Aloisi, 
2001) and phagocytosis (Chew et al., 2006).  
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Moreover, the implication of microglia to neonatal pathologic conditions has been 
acknowledged (McRae et al., 1995; Vexler and Yenari, 2009), since the production of 
inflammatory mediators by these cells is a major contributor to hypoxic- ischemic injury in 
the neonatal brain (Doverhag et al., 2010).  
Microglial activation must not be viewed as an “on/off” process, but rather as a 
shift between activity states, altering between a surveying and an effector status. In fact, 
microglia’s activation process is an adaptive one but, depending on the circumstances in 
which it occurs, may have neuroprotective or neurotoxic outcomes (Hanisch and 
Kettenmann, 2007). Indeed, microglial involvement in various neurodegenerative 
disorders is notorious, namely in Parkinson’s disease (Tansey et al., 2008), Alzheimer’s 
disease (Kim and Joh, 2006), multiple sclerosis (Jack et al., 2005; Muzio et al., 2007), 
and human immunodeficiency virus (HIV)-associated dementia (Gonzalez-Scarano and 
Baltuch, 1999), mostly owing to its inflammatory character. Yet, microglial phagocytic 
role in numerous neurodegenerative diseases as well as in acute brain injury is essential 
for tissue debris removal and contributes for a pro-regenerative environment (Neumann 
et al., 2009). Moreover, phagocytic clearance of debris may be considered a protective 
measure as it constitutes an attempt to restrain further detrimental inflammatory 
responses (Napoli and Neumann, 2009). 
In this study we characterize the microglial response to UCB stimulation by 
evaluating both its phagocytic properties and the inflammatory mechanisms engaged 
upon activation. We observed, for the first time, that UCB induces an increase in the 
phagocytic properties of microglia, followed by a shift into a rather inflammatory 
response with prolonged exposure time. Moreover, this inflammatory response triggered 
by UCB follows different temporal profiles of interleukin (IL)-1β, tumour necrosis factor 
(TNF)-α and IL-6 secretion. Remarkably, an increase in TNF-α and IL-1β release is 
observed prior to the secretion of IL-6. Our findings also point to mitogen-activated 
protein kinases (MAPKs) and nuclear factor (NF)-κB as probable signalling pathways 
involved in microglial reactivity to UCB as they might be entailed either in inflammation 
(Hanisch et al., 2001) or phagocytosis (Sun et al., 2008; Tanaka et al., 2009). In fact, we 
demonstrate that MAPKs phosphorylation is an essential step for NF-κB nuclear 
translocation. Furthermore, our results reveal the induction of cyclooxygenase (COX)-2 
expression and matrix metalloproteinase (MMP)-2 and -9 activity in a later phase of 
microglial response to UCB, implicating these events in the overall deleterious and 
inflammatory response. We provide evidence that UCB-induced cytokine secretion may 
participate in MMP activation and hypothesize that these events might be reciprocally 
regulated, further contributing to the complex network of microglia activation process. 
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Taken together, these results strongly imply a multiple response of microglia to UCB, 
suggesting that those cells are relevant partners to consider during bilirubin 
encephalopathy.  
 
2. Material and Methods 
 
2.1. Chemicals 
Dulbecco’s modified Eagle’s medium-Ham’s F12 medium (DMEM-Ham’s F-12), 
Opti-MEM medium, fetal bovine serum (FBS), L-glutamine, sodium pyruvate and non-
essential aminoacids (NEA) were purchased from Biochrom AG (Berlin, Germany). 
Antibiotic antimycotic solution (20X), human serum albumin (HSA; fraction V, fatty acid 
free), bovine serum albumin (BSA), Hoechst 33258 dye, biotinylated tomato lectin 
(Lycopersicon esculentum), avidin-fluorescein isothiocyanate (FITC), avidin-
tetramethylrhodamine isothiocyanate (TRITC), fluorescent latex beads 1μm (2.5%), 
mouse anti-β-actin, FITC-labelled goat anti-rabbit IgG, rabbit anti-glial fibrillary acidic 
protein (GFAP), TRITC-labelled goat anti-rabbit IgG, Coomassie Brilliant Blue R-250 and 
propidium iodide (PI) were from Sigma Chemical Co. (St. Louis, MO). UCB was also 
obtained from Sigma and purified according to the method of McDonagh and Assisi 
(1972). Trypsin/Ethylenediamine tetraacetic acid (EDTA) solution (0.25% trypsin, 1 mM 
EDTA in Hank’s balanced salt solution) and Alexa Fluor 594 chicken anti-goat IgG were 
purchased from Invitrogen Corporation (Carlsbad, CA).  
FuGENE HD Transfection Reagent was acquired from Roche Molecular 
Biochemicals (Mannheim, Germany); Dual Luciferase reporter assay system was from 
Promega (Madison, WI, USA); and caspase-3, -8 and -9 substrates, Ac-DEVD-pNA, Ac-
IETD-pNA and Ac-LEHD-pNA, respectively, were purchased from Calbiochem (San 
Diego, CA). Concentrated solutions (10 mM) of MAPK pathways inhibitors SB203580 
(p38 MAPK inhibitor; Calbiochem, La Jolla, CA, USA), and U0126 [Extracellular signal 
regulated kinase (ERK1/2)-upstream inhibitor; Promega, Madison, WI, USA], were 
prepared in dimethylsulfoxide. 
Recombinant rat IL-1β and DuoSet® ELISA kits were from R&D Systems, Inc. 
(Minneapolis, MN, USA). Nitrocellulose membrane, Hyperfilm ECL and Horseradish 
peroxidase-labelled goat anti-mouse IgG were obtained from Amersham Biosciences 
(Piscataway, NJ, USA). LumiGLO®, Cell lysis buffer®, rabbit anti-phosphorylated-p38 
(P-p38) and rabbit anti-phosphorylated-ERK 1/2 (P-ERK1/2) were from Cell Signalling 
(Beverly, MA, USA).  
Mouse anti-phosphorylated-c-Jun N-terminal kinase (P-JNK1/2), rabbit anti-p65 
NF-κB subunit and horseradish peroxidase-labelled goat anti-rabbit IgG were from Santa 
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Cruz Biotechnology (Santa Cruz, CA, USA). Goat anti-Ionized calcium-binding adaptor 
molecule 1 (Iba1) was from Abcam (Cambridge, UK).  
All other chemicals were of analytical grade and were purchased from Merck 
(Darmstadt, Germany). 
 
2.2. Primary culture of microglia 
Animal care followed the recommendations of European Convention for the 
Protection of Vertebrate Animals Used for Experimental and other Scientific Purposes 
(Council Directive 86/609/EEC) and National Law 1005/92 (rules for protection of 
experimental animals). All animal procedures were approved by the Institutional Animal 
Care and Use Committee. Every effort was made to minimize the number of animals 
used and their suffering. 
Mixed glial cultures were prepared from 1-to-2 day-old Wistar rats as previously 
described (McCarthy and de Vellis, 1980), with minor modifications (Gordo et al., 2006). 
Cells (4 x 105 cells/cm2) were plated on uncoated 12 or 6-well tissue culture plates 
(Corning Costar Corp., Cambridge, MA) in culture medium (DMEM-Ham’s F-12 medium 
supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, nonessential amino acids 
1X, 10% FBS, and 1% antibiotic-antimycotic solution) and maintained at 37ºC in a 
humidified atmosphere of 5% CO2.  
Microglia were isolated as previously described by Saura et al. (2003). Briefly, 
after 21 days in culture, microglia were obtained by mild trypsinization with a trypsin-
EDTA solution diluted 1:3 in DMEM-Ham’s F12 for 20–45 min. The trypsinization 
resulted in detachment of an upper layer of cells containing all the astrocytes, whereas 
the microglia remained attached to the bottom of the well. The medium containing 
detached cells was removed and replaced with initial mixed glial-conditioned medium. 
Twenty-four hours after trypsinization, the attached cells were subjected to the different 
treatments. The use of 21-days-in-vitro cells intents to achieve the maximal yield and 
purity of the cultures. In fact, astrocyte contamination was less than 2%, as assessed by 
immunocytochemical staining with a primary antibody against GFAP followed by a 
species-specific fluorescent-labelled secondary antibody. Microglia were counterstained 
with a biotinylated tomato lectin (Lycopersicon esculentum), using a 1:166 dilution in 1% 
Triton X-100® in phosphate-buffered saline (PBS) overnight at 4ºC followed by 1 h 
incubation at room temperature with avidin-TRITC in a 1:100 dilution in PBS and the 
nuclei immunostained with Hoechst dye 33258. Thus, the high purity level of microglia 
cultures excludes interference of contaminating astroglial cells. 
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2.3. Cell treatment 
Microglial cells were incubated in the absence (control) or in the presence of 50 
µM UCB plus 100 µM HSA, from 5 min to 48 h, at 37ºC. A UCB stock solution (10 mM) 
was prepared in 0.1 M NaOH immediately before use and the pH of the incubation 
medium was restored to 7.4 by addition of equal amounts of 0.1 M HCl. All the 
experiments with UCB were performed under light protection to avoid photodegradation. 
To study the role of MAPK pathways in microglial response to UCB, cells were 
pretreated for 20 min with 10 µM of the MAPK inhibitors prior to UCB stimulation: 
SB203580, a selective inhibitor of p38 MAPK and U0126, a selective inhibitor of the 
MAPK kinases (MEK)1/2, upstream kinases in the ERK1/2 pathway. 
The involvement of IL-1β in MMP activation was investigated by treating microglia 
with 2 ng/mL recombinant rat IL-1β or vehicle alone, in the presence of 100 µM HSA, for 
30 min and 1 h at 37ºC. The selected concentration of cytokine was based on the 
maximal levels obtained in our culture model upon UCB stimulation.  
 
2.4. Measurement of cytokine release 
Aliquots of the cell culture media were collected at the end of the incubations and, 
after removal of cellular debris by short centrifugation, placed in a 96-well microplate and 
assessed in triplicate for TNF-α, IL-1β and IL-6 with specific DuoSet® ELISA 
Development kits from R&D Systems, according to the manufacturer’s instructions. 
Results were expressed as pg/mL. 
 
2.5. Western blot assay 
Western blot assay was carried out as usual in our lab (Fernandes et al., 2006). 
Briefly, total protein was extracted from primary microglia using Cell lysis buffer®. Protein 
extracts were separated on a 10% sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE). Following electrophoretic transfer onto a nitrocellulose 
membrane and blocking with 5% milk solution, the blots were incubated with primary 
antibody overnight at 4ºC [anti-P-p38 MAPK (1:1000), anti-P-ERK1/2 (1:1000), anti-P-
JNK1/2 (1:200), rabbit anti-COX-2 (1:1000) or anti-β-actin (1:10000) in 5% (w/v) bovine 
serum albumin] and with horseradish peroxidase-labelled secondary antibody [anti-
mouse (1:5000) or anti-rabbit (1:5000)] for 1 h at room temperature. Protein bands were 
detected by LumiGLO® and visualized by autoradiography with Hyperfilm ECL. 
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2.6. Detection of NF-κB activation 
To assay the transcriptional activity of NF-κB, reporter gene analysis was applied. 
A reporter plasmid under control of NF-κB binding sites was provided by Dr. Guy 
Haegeman (Flanders Interuniversity Institute for Biotechnology and University of Gent, 
Belgium). NF-κB-dependent reporter plasmids, p(IL6κB)350hu.IL6P-luc+, contain three 
NF-κB binding sites in the promoter region, while NF-κB-independent plasmids, 
p50hu.IL6P-luc+, do not (Vanden Berghe et al., 1998). These reporter genes were 
introduced into microglial cells using FuGene HD Transfection Reagent. After 24 h of 
transfection, cells were treated with 50 µM UCB plus 100 µM HSA from 30 min to 4 h, at 
37ºC. Luciferase assays were carried out using a Dual Luciferase Reporter Assay 
System (Promega), according to the instructions in manufacturer’s manual. Firefly and 
renilla luciferase activities were measured using a luminometer (Berthold Technologies, 
Wildbad, Germany). Firefly luciferase activity value was normalized to renilla luciferase 
activity value from pSV-Sport-Rluc plasmid. Readings of promoter activities of NF-κB-
independent plasmids, p50hu.IL6P-luc+ and p1168hIL6m NF-κB-luc (plasmid presenting 
a mutation in NF-κB binding sites), were also performed. Results were presented as fold 
change of the relative luciferase activity compared to the respective control. 
For immunofluorescence detection of NF-κB nuclear translocation, cells were 
fixed for 20 min with freshly prepared 4% (w/v) paraformaldehyde in PBS and a standard 
immunocytochemical technique was performed using a polyclonal rabbit anti-p65 NF-κB 
subunit antibody (1:200) as the primary antibody and a FITC-labelled goat anti-rabbit 
antibody (1:160) as the secondary antibody. To identify the total number of cells, 
microglial nuclei were stained with Hoechst 33258 dye as previously described. 
Fluorescence was visualized using a Leica DFC490 camera adapted to an AxioSkope® 
microscope (Zeiss). Pairs of U.V. and green-fluorescence images of ten random 
microscopic fields (original magnification: 400X) were acquired per sample. NF-κB-
positive nuclei (identified by localization of the NF-κB p65 subunit staining exclusively at 
the nucleus) and total cells were counted (>500 cells per sample) to determine the 
percentage of NF-κB-positive nuclei. Results were expressed as fold change vs. 
respective control. 
 
2.7. Morphological Analysis 
For morphological analysis, cells were fixed as described above and a standard 
indirect immunocytochemical technique was carried out using a primary antibody raised 
against Iba-1 (goat, 1:500) and a secondary Alexa Fluor 594 chicken anti-goat antibody 
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(1:200). Fluorescent images were acquired using a Leica DFC490 camera attached to 
an AxioSkope® microscope (Zeiss). 
 
2.8. Assessment of microglial phagocytic properties 
After treatment with UCB, cells were incubated with 0.0025% (w/w) 1 μm 
fluorescent latex beads for 75 min at 37ºC and fixed with freshly prepared 4% (w/v) 
paraformaldehyde in PBS. Labelling with tomato lectin was performed followed by avidin-
TRITC and the nuclei counterstained with Hoechst 33258 dye. U.V., green and red-
fluorescence images of fifteen random microscopic fields (original magnification: 630X) 
were acquired per sample. The number of ingested beads per cell was counted in 
approximately 250 cells per sample.  
 
2.9. Gelatin zymography 
Aliquots of culture supernatant were analyzed by SDS-PAGE zymography in 
0.1% gelatine – 10% acrylamide gels under non-reducing conditions. After 
electrophoresis, gels were washed for 1 h with 2.5% Triton X-100 (in 50 mM Tris pH7.4; 
5 mM CaCl2; 1μM ZnCl2) to remove SDS and renature the MMP species in the gel. Then 
the gels were incubated in the developing buffer (50 mM Tris pH7.4; 5 mM CaCl2; 1μM 
ZnCl2) overnight to induce gelatine lysis. For enzyme activity analysis, the gels were 
stained with 0.5% Coomassie Brilliant Blue R-250 and destained in 30% ethanol/10% 
acetic acid/H2O. Gelatinase activity, detected as a white band on a blue background, 
was quantified by computerized image analysis and normalized with total cellular protein. 
 
2.10. Evaluation of microglial cell death 
Necrotic-like cell death was assessed by monitoring the cellular uptake of the 
fluorescent dye propidium iodide [PI; 3,8-diamino-5-(3-(diethylmethylamino)propyl)-6-
phenyl phenanthridinium diiodide]. PI readily enters and stains non-viable cells, but 
cannot cross the membrane of viable cells. This dye binds to double-stranded DNA and 
emits red fluorescence (630 nm; absorbance 493 nm). Unpermeabilized adherent cells 
cultured on coverslips were incubated with a 75 μM PI solution for 15 min in the absence 
of light. Subsequently, cells were fixed with freshly prepared 4% (w/v) paraformaldehyde 
in PBS and the nuclei immunostained with Hoechst 33258 dye.  
Red-fluorescence and U.V. images of ten random microscopic fields (original 
magnification: 400X) were acquired per sample and the percentage of PI positive cells 
was counted and expressed as fold vs. respective control.  
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Activities of caspase-3, -8 and -9 were measured by a commercial colorimetric 
method (Calbiochem, Darmstadt, Germany). Cells were harvested, washed with ice-cold 
PBS and lysed for 30 min on ice in the lysis buffer [50 mM HEPES (pH 7.4); 100 mM 
NaCl; 0.1% (w/v) CHAPS; 1 mM dithiothreitol (DTT); 0.1 mM EDTA]. The activities of 
caspase-3, -8 and -9 were determined in cell lysates by enzymatic cleavage of 
chromophore p-nitroanilide (pNA) from the substrate Ac-DEVD-pNA for caspase-3, Ac-
IETD-pNA for caspase-8 and Ac-LEHD-pNA for caspase-9, according to manufacturer’s 
instructions. The proteolytic reaction was carried out in protease assay buffer [50 mM 
HEPES (pH 7.4); 100 mM NaCl; 0.1% (w/v) CHAPS; 10 mM DTT; 0.1 mM EDTA; 10% 
(v/v) glicerol], containing 2 mM specific substrate. Following incubation of the reaction 
mixtures for 1 to 2 h at 37ºC, the formation of pNA was measured in a microplate reader 
(PR 2100, BioRad Laboratories, Inc.) at λ= 405 nm with a reference filter at 620 nm. 
Readings were normalized to total protein content determined using a protein assay kit 
(Bio-Rad, Hercules, CA, USA) according to the manufacturer’s specification, and 
expressed as fold change of respective control. 
 
2.11. Statistical analysis 
Results of, at least, three different experiments were expressed as mean ± 
S.E.M. Significant differences between two groups were determined by the two-tailed t-
test performed on the basis of equal and unequal variance as appropriate. Comparison 
of more than two groups was done by ANOVA using Instat 3.05 (GraphPad Software, 
San Diego, CA, USA) followed by multiple comparisons Bonferroni post-hoc correction. 
Statistical significance was considered for a p value less than 0.05. 
 
3. Results 
 
3.1. UCB triggers IL-1β, TNF-α and IL-6 secretion following different temporal 
profiles 
Supporting evidence reports reactive microglia as one of the main sources of pro-
inflammatory cytokines in the brain (Hanisch, 2002), which are known to exert 
deleterious effects in nerve cells (Rothwell, 1999). Previous results suggested that UCB 
is able to induce an inflammatory response by microglia (Gordo et al., 2006). Thus, we 
intended to further characterize those inflammatory events by the evaluation of the 
temporal secretion profile of IL-1β, TNF-α and IL-6. In Figure II.1 it can be observed that 
UCB stimulates cytokine release in a time-dependent manner but following different 
temporal profiles. In fact, TNF-α and IL-1β seem to be the first to be up-regulated, as an 
increase in those cytokine levels in culture supernatants can be observed as early as 2 h 
Chapter II 
 
 
58 
after the addition of 50 μM UCB. However, while peak values for TNF-α are reached at 4 
h of UCB exposure (changing from 365 pg/mL for control conditions to 520 pg/mL for 
UCB, p<0.05) and decline gradually along time of exposure (although an additional 
increase is noticed at 24 h), the maximum release of IL-1β was only achieved at 12 h, 
but in a much higher amount (ranging from 980 pg/mL for control conditions to 1700 
pg/mL for UCB, p<0.05). On the other hand, IL-6 secretion was only noticed from 2 h on, 
reaching peak levels at 8 h of UCB exposure (shifting from 1650 pg/mL for control 
conditions to 2050 pg/mL for UCB, p<0.01) and decreasing thereafter. These results 
seem to indicate that microglia responds to UCB stimulus with a rather inflammatory 
profile which is manifested for prolonged incubation periods. As earlier results on 
astrocytes demonstrated that UCB-induced cytokine secretion involves MAPK and NF-
κB activations (Fernandes et al., 2007; Fernandes et al., 2006) we sought to verify if the 
same inflammatory signalling pathways are maintained by microglia. 
 
 
 
Fig. II.1. UCB induces the release 
of TNF-α, IL-1β and IL-6 by 
microglia following different 
temporal profiles. Rat cortical 
microglial cells were treated with 50 
µM UCB in the presence of 100 µM 
HSA for the indicated time periods. 
TNF-α, IL-1β and IL-6 
concentrations in the media were 
determined by ELISA and expressed 
as mean ± SEM cytokine release 
from four independent experiments 
performed in triplicate, after 
deduction of cytokine values in 
control assays. *p<0.05 and 
**p<0.01 vs. respective control. 
 
 
3.2. p38 and ERK1/2 phosphorylation is elicited by UCB in microglia at an early 
time point 
MAPKs have been reported by several studies to be involved in the production of 
inflammatory mediators by microglia (Bhat et al., 1998; Lee et al., 2000; Waetzig et al., 
2005), but their involvement on UCB microglial stimulation is still not known. So, we 
assessed the phosphorylated (activated) forms of all three MAPKs (p38, ERK1/2 and 
JNK1/2) in total cell lysates of UCB-exposed microglia, by western blot, using specific 
antibodies. 
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As shown in Figure II.2, upon UCB stimulation, P-p38 and P-ERK1/2 expression 
were significantly up-regulated in a rapid but transient manner. A 1.4-fold induction 
(p<0.05 vs. control) was observed for P-p38 as early as 15 min after UCB exposure, and 
this activation was sustained until 30 min of incubation (1.3-fold, p<0.05 vs. control), 
fading afterwards. A second activation peak was observed after 2 h of exposure (1.4-
fold, p<0.05), declining to control levels at 6 h. In regard to P-ERK1/2, a 1.2-fold increase 
(p<0.05 vs. control) was observed at 15 min of exposure and, as for P-p38, a second 
peak was observed, but now smaller (1.12 -fold, p<0.05) and at 1 h of exposure, 
declining from this point on. A weaker increase in P-JNK1/2 is perceived at 15 and 30 
min of UCB exposure; however, this effect is not significantly different from the 
respective controls. 
 
Figure II.2. MAPKs activation is elicited by UCB in microglia. Rat cortical microglia 
were exposed to 50 µM UCB in the presence of 100 µM HSA for the indicated time 
periods. Total cell lysates were analysed by western blotting with antibodies specific for 
the phosphorylated forms of the three MAPKs, P-p38, P-ERK1/2 and P-JNK1/2. (A) 
Representative results of one experiment are shown. Similar results were obtained in 
three independent experiments. (B) The intensity of the bands was quantified by 
scanning densitometry, standardized with respect to β-actin protein expression and 
expressed as mean ± SEM fold change compared with control conditions. *p<0.05 vs. 
respective control. 
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Prolonging UCB incubation to longer periods did not modify the pattern of MAPK 
activation (data not shown). These results indicate that MAPK activation is a rather early 
event on microglial activation, seeming to involve two activation peaks. Next we found 
interesting to check if this activation could be followed by the engagement of NF-κB 
nuclear translocation.  
 
3.3. NF-κB signalling pathway is triggered in UCB-activated microglia 
NF-κB is described as a convergent point of signalling for microglial activation by 
cytokines and other stressors (Glezer et al., 2007) and its implication in the inflammatory 
response induced by UCB in astrocytes has already been established (Fernandes et al., 
2006). Hence, we examined the effect of UCB on NF-κB transactivation in microglial 
cells by gene reporter assay (Figure II.3A). The results indicated that UCB markedly 
induced NF-κB activation at 15 and 30 min of exposure (1.4-fold, p<0.01 for both time 
points). It should be stated that readings of the promoter activities of p50hu.IL6P-luc+ 
and p1168hIL6m NF-κB-luc plasmids (empty and mutated vectors, respectively) showed 
no change in the presence or absence of UCB (data not shown), thus validating the 
assay. 
 
To further confirm the activation of this signalling pathway we investigated NF-κB 
activation in microglia exposed to UCB at various time points by the immunochemical 
assessment of the cytoplasmic or nuclear localization of p65 NF-κB subunit. Interestingly 
we found NF-κB translocation into the nucleus to be significantly increased from 15 min 
to 2 h of exposure when compared to the respective controls (Figure II.3B-C), which is in 
line with our previous observations regarding NF-κB transcriptional activation. Maximum 
levels of nuclear NF-κB were observed at 30 min (2.2-fold, p<0.01), while from 4 h 
onwards NF-κB was mostly localized in the cellular cytoplasm. These results follow the 
ones from MAPK activation, suggesting that, as previously verified in astrocytes, both 
events are connected.  
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Fig. II.3. UCB activates NF-κB signalling pathway in microglia. Rat cortical microglia 
were exposed to 50 µM UCB in the presence of 100 µM HSA for the indicated time 
periods. (A) Microglial cells were transiently transfected with NF-κB-dependent luciferase 
plasmids and control plasmids. Relative luciferase activities were plotted as fold change 
of respective controls. To further confirm NF-κB activation, cells were fixed and 
immunostained with an antibody against p65 NF-κB subunit. (B) Representative results 
of one experiment are shown. Scale bar, 20 μm. (C) The percentage of NF-κB-positive 
nuclei was calculated and expressed as fold change vs. respective control. Results are 
mean ± SEM from three independent experiments performed in triplicate. *p<0.05 and 
**p<0.01 vs. respective control. 
 
3.4. UCB-induced NF-κB translocation depends on both ERK1/2 and p38 
 To assess whether MAPKs phosphorylation is an essential step for UCB-evoked 
NF-κB translocation, we investigated this event after exposure of microglia to UCB alone 
or in combination with the MAPK inhibitors SB203580 (p38 selective inhibitor) and 
UO126 [(MEK)1/2 selective inhibitor, upstream kinases in the ERK1/2 pathway]. The use 
of 30 min and 1 h incubation periods was based on previous results showing that 
maximal translocation of NF-κB to the nucleus in UCB-challenged microglia occurs 
between 30 min and 4 h.  
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 As expected, pre-incubation with SB203580 and U0126 completely abrogated 
UCB-stimulated NF-κB nuclear translocation after 30 min (p<0.01) and 1 h (p<0.05) of 
UCB stimulation (Figure II.4), thus providing proof of concept that p38 and ERK1/2 
phosphorylation are required for the engagement of NF-κB pathway upon UCB 
exposure. 
 
Fig. II.4. Phosphorylation of p38 and ERK1/2 is essential for UCB-evoked NF-κB 
activation. Rat cortical microglia were exposed for 30 min and 1 h to 50 µM UCB alone 
or in combination with 10 µM of the p38 inhibitor SB203580 or the ERK1/2 inhibitor 
U0126. Cells were fixed and immunostained with an antibody against p65 NF-κB 
subunit. (A) Representative results of one experiment are shown. Scale bar, 20 μm. (B) 
The percentage of NF-κB-positive nuclei was calculated and expressed as fold change 
vs. respective control. Results are mean ± SEM from three independent experiments 
performed in triplicate. **p<0.01 vs. respective control, §p<0.05 and §§p<0.01 vs. UCB 
alone. 
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So far our results have described the engagement of early inflammatory 
signalling pathways that culminate in the acquisition of an inflammatory phenotype 
characterized by the release of proinflammatory mediators. We next intended to 
characterize UCB-stimulated microglia at a morphological level, in order to verify the 
acquisition of this activated state. 
 
3.5. Microglia depict morphological changes upon UCB stimulation 
 Modification of microglial morphology is one of the hallmarks of its activation 
profile and has been widely used to categorize different activation states (Chew et al., 
2006; Kim and de Vellis, 2005; Lynch, 2009; Raivich et al., 1999). For that reason, we 
evaluated the morphology and reactivity of UCB-stimulated microglia by 
immunocytochemistry after 4 and 24 h incubation periods. Our results indicate that, after 
a short UCB exposure, microglia shifted from an elongated morphology to a large and 
amoeboid shape (Figure II.5). This phenotype is characteristic of activated or reactive 
microglia (Nakajima and Kohsaka, 2004). In contrast, for longer exposure periods, 
microglia display fragmented and condensed cytoplasm, a feature described by other 
authors (Fendrick et al., 2007; Hasegawa-Ishii et al., 2010) as cytorrhexis, indicative of 
microglia degeneration and senescence. 
 
 
Fig. II.5. UCB-stimulated microglia show 
reactive morphological changes. Rat cortical 
microglia were exposed to 50 µM UCB in the 
presence of 100 µM HSA for the indicated time 
periods. Cells were fixed and immunostained 
with an antibody against Iba1 reactivity marker. 
Representative results of one experiment are 
shown. Scale bar, 20 μm.  
 
 
Interestingly, the inflammatory phenotype previously described occurs after 
prolonged UCB incubation periods. However, activation features were also observed for 
shorter stimulations. For that matter, we sought to evaluate the phagocytic properties of 
UCB-challenged microglia and, more importantly, to verify whether this reactive 
phenotype occurred prior, simultaneously or after the inflammatory response triggered by 
UCB, in order to further characterize the chronologic events of UCB microglial activation. 
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3.6. UCB differently modulates microglial phagocytosis depending on exposure 
time 
Phagocytosis is one of the main features of microglial activation dumping cell 
debris prior to cell regeneration, and can be involved in the pathogenesis of several brain 
dysfunctions (Neumann et al., 2009). However, this microglial property was never 
investigated under UCB stimulation. As can be seen in Figure II.6, a sharp increase in 
the uptake of fluorescent latex beads by UCB-stimulated microglia occurs from 2 h on, 
reaching a maximum peak after 4 h of exposure, (~50%, p<0.05). This is a strong 
evidence that UCB is able to induce microglial phagocytic properties in a rather early 
time of exposure.  
 
 
 
 
 
 
Fig. II.6. Microglial phagocytosis 
is differently modulated by UCB. 
Rat cortical microglia were exposed 
to 50 µM UCB in the presence of 
100 µM HSA for the indicated time 
periods and incubated with 1 μm 
fluorescent latex beads as 
described in Methods.  (A) 
Representative results of one 
experiment are shown. Scale bar, 
20 μm. (B) Results are expressed 
as number of ingested beads per 
cell (± SEM) from three 
independent experiments. *p<0.05 
vs. respective control. 
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Unspecific entry of latex beads due to UCB-induced cell permeabilization was 
excluded by performing the phagocytosis assay in microglial cells incubated with UCB for 
4 h and simultaneously determining PI uptake. Dead cells did not appear to engulf 
particles (data not shown). Interestingly, prolonging UCB incubation for 8 and 12 h 
slightly reverts this phagocytic ability although it approached control values for 24 h of 
exposure. This may indicate that, after an initial phagocytic reaction, microglial cells 
shifted to the previously observed inflammatory response to UCB stimulus. To add on 
the characterization of microglial behaviour we advanced to the evaluation of other 
markers of its inflammatory response such as MMPs activity and COX-2 expression.  
 
3.7. Release of active MMPs is enhanced upon UCB stimulation of microglia 
 
MMPs are a family of proteases with many important roles in normal development 
although they may also participate in several neuronal diseases such as multiple 
sclerosis, ischemia and neuroinflammation given their ability to degrade the basal lamina 
surrounding the blood-brain barrier allowing infiltration of immune cells and, thus, 
aggravating inflammatory reactions in the CNS (Michaluk and Kaczmarek, 2007; 
Rosenberg, 2002). Since microglia have been reported to secrete active MMPs further 
contributing to neuronal injury (Kauppinen and Swanson, 2005; Woo et al., 2008), and 
given the fact that cytokines are reported to stimulate MMPs secretion and activity 
(Gottschall and Yu, 1995; Lin et al., 2009; Vincenti and Brinckerhoff, 2007), we intended 
to evaluate the levels of active MMPs secreted by these cells in response to UCB and to 
verify if this activation could be ascribed to UCB-induced IL-1β. 
 
Cell supernatants collected after UCB incubation were subjected to gelatin 
zymography for the assessment of MMP-2 and MMP-9 activity levels. As can be seen in 
Figure II.7 there is a slight but significant increase in the activity of MMP-2 and MMP-9 
(1.07-fold and 1.08-fold, p<0.05, respectively) after a prolonged exposure time (24 h) to 
UCB.  
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Fig. II.7. MMP-2 and MMP-9 
activities are enhanced upon UCB 
stimulation. Culture supernatants 
from rat cortical microglial cells were 
harvested after incubation with 50 µM 
UCB in the presence of 100 µM HSA 
or with 2 ng/mL IL-1β for the indicated 
time periods and subjected to 
zymography as described in Methods. 
(A) Representative gels of one 
experiment are reported. MMP-2 and 
MMP-9 were identified by their 
apparent molecular mass of 67 and 
92 kDa, respectively. (B) The intensity 
of the bands was quantified by 
scanning densitometry, standardized 
with respect to total protein content 
and expressed as mean ± SEM fold 
change compared with control 
conditions. *p<0.05 and **p<0.01 vs. 
respective control. 
 
 
 
Since this event occurs after the onset of cytokine secretion elicited by microglia, 
a possible regulation of this event by inflammatory mediators could be occurring. In fact, 
stimulation of microglia with 2 ng/mL of IL-1β (which correspond to maximal levels 
obtained in our culture model upon UCB stimulation) increases significantly MMP-2 and 
MMP-9 activity at both 12 (1.3-fold and 1.2-fold, p<0.05 and p<0.01, respectively) and 24 
h of exposure (1.2-fold and 1.3-fold, p<0.01, respectively). 
 
3.8. UCB-stimulated microglia evidence enhanced COX-2 expression 
COX-2 is the enzyme responsible for the production of prostanoids such as 
prostaglandin E2 (PGE2), which is known to be involved in the initiation and propagation 
of the immune response (de Oliveira et al., 2008). The expression of this enzyme can be 
induced by lipopolysaccharide (LPS) and cytokines (Levi et al., 1998) and has been 
proven to be elevated in Alzheimer’s disease (Yokota et al., 2003) and ischemia 
(Iadecola et al., 1999). As depicted in Figure II.8, a significant up-regulation of COX-2 
expression was only noticed after 12 and 24 h of UCB exposure (1.13-fold, p<0.01 and 
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1.18-fold, p<0.05, respectively), when compared to the respective controls, again 
suggesting a later response of microglia to UCB, in line with the previous results. 
Finally, we were interested in examining how UCB interaction affected microglial 
cell survival.  
 
 
Fig. II.8. COX-2 expression is up-regulated by UCB in microglia. Rat cortical 
microglia were exposed to 50 µM UCB in the presence of 100 µM HSA for the indicated 
time periods. Total cell lysates were analysed by western blotting. (A) Representative 
results of one experiment are shown. Similar results were obtained in three independent 
experiments. (B) The intensity of the bands was quantified by scanning densitometry, 
standardized with respect to β-actin protein and expressed as mean ± SEM fold change 
compared with control conditions. *p<0.05 vs. respective control. 
 
3.9. UCB reduces microglial viability leading to loss of membrane integrity and 
increased caspase activity 
To evaluate the necrotic-like cell death we used the uptake of the fluorescent dye 
PI as an indicator of membrane integrity and cell damage since this polar substance can 
only enter dead or dying cells. To address the possible involvement of the apoptotic 
pathways in microglial demise we determined the relative levels of caspases activity, 
since these proteases have been traditionally viewed as central regulators of apoptosis 
(Fink and Cookson, 2005). As depicted in Figure II.9, UCB stimulation only arouses 
increased PI uptake from 4 to 12 h of exposure, reaching maximum significance at 8 h. 
Accordingly, the activities of initiator caspases -8 and -9 were found to be significantly 
elevated in response to UCB from 2 to 12 h of exposure reaching maximum activity at 6 
h (Figure II.10) while effector caspase-3 was significantly increased at a relatively later 
time point (from 4 to 12 h of exposure). It is interesting to notice that cell death seems to 
occur on the onset of inflammatory response and when phagocytic activity declines, 
again suggesting a possible double response from microglia to UCB. 
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Fig. II.9. UCB induces microglial 
decreased viability and 
membrane disruption. Rat cortical 
microglia were exposed to 50 µM 
UCB in the presence of 100 µM 
HSA for the indicated time periods 
and incubated with 75 μM PI as 
described in Methods. The 
percentage of PI-positive cells was 
calculated and expressed as fold 
vs. respective control. Results are 
mean ± SEM from three 
independent experiments 
performed in triplicate *p<0.05 and 
**p<0.01 vs. respective control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. II.10. Microglial apoptotic cell 
death is elicited by UCB. Rat cortical 
microglia were exposed to 50 µM 
UCB in the presence of 100 µM HSA 
for the indicated time periods. The 
activities of caspases -3, -8 and -9 
were determined in cell lysates by 
enzymatic cleavage of chromophore 
p-nitroanilide (pNA) from specific 
substrates. Results are expressed as 
fold of respective control at each time 
point. Data are means ± SEM from at 
least three independent experiments. 
*p<0.05 and **p<0.01 vs. respective 
control. 
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4. Discussion 
In this paper we describe, for the first time, different activation stages of microglia 
in the presence of UCB, since these cells display both phagocytic and inflammatory 
phenotypes. Indeed, this study is original in depicting the increased phagocytic 
properties of microglia upon UCB stimulation. In addition, our group was also the first to 
implicate microglial cells in the inflammatory response elicited by UCB (Gordo et al., 
2006). Thus, in this study we further investigated the activation profile of microglia under 
UCB stimulation, by the evaluation of some of its characteristical features, and the 
signalling events involved in cell response. In fact, previous studies performed by our 
group have proven that UCB induces immunological responses in astrocytes by the 
activation of inflammatory pathways and secretion of glutamate (Fernandes et al., 2006; 
Fernandes et al., 2004), and also that UCB is neurotoxic (Falcão et al., 2007; Silva et al., 
2001). Accordingly, it is conceivable that increased microglia reactivity may further 
contribute to neuronal injury during hyperbilirubinemia. 
Microglia contribute to both innate and adaptive immune responses in the brain 
(Chew et al., 2006). As innate immune cells, they constitute the first line of defence 
against invading microorganisms. The hallmark indicators of such response are the 
production of pro-inflammatory cytokines, the up-regulation of cell surface antigens and 
phagocytosis (Town et al., 2005). In addition, phagocytosis of debris by microglia can be 
beneficial in several pathological conditions such as multiple sclerosis (Takahashi et al., 
2007) and Alzheimer’s disease (Simard et al., 2006) as it restricts lesion extension and 
facilitates tissue recovery.  
The fact that UCB may alter the function of various cells of the immune system 
(both in vivo and in vitro) seems to be firmly established and a wide range of 
immunosuppressive effects on peripheral immune cells are summarized by Vetvicka et 
al. (1991) such as alterations on antigen expression, chemotaxis, bactericidal activity, 
proliferative response of T lymphocytes, or antibody production. On the other hand, an 
increase in phagocytosis of both peripheral blood granulocytes and monocytes after 
UCB treatment was reported by Miler et al. (1985). Thus, a rather contradictory 
immunosuppressive – immunostimulant status seems to be observed upon UCB 
challenge that might be explained by dose or time-dependent effect (Vetvicka et al., 
1991).  
Our findings demonstrate that, in conditions that intend to mimic a mild 
hyperbilirubinemia, enhancing of microglial phagocytic properties by UCB is an early, but 
transient, event that seems to be lost with increased time of exposure. Thus, we may 
assume that phagocytosis is the first response towards UCB insult and may constitute a 
neuroprotective measure. 
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Various conditions have been shown to greatly modify microglial phagocytic 
activity, such as cytokines (Koenigsknecht-Talboo and Landreth, 2005), and LPS (Sun et 
al., 2008), among others. Interestingly, the study performed by von Zahn et al. (1997) 
reports an induction of nearly two-fold increase in the uptake of uncoated latex particles 
by TNF-α-stimulated microglia, substantiating this cytokine as an autocrine activator of 
microglial immune functions. Indeed, UCB-activated microglia are reportedly one of the 
main sources of TNF-α, even when compared to astrocytes (Brites et al., 2009). Similarly 
to what we already observed for astrocytes (Fernandes et al., 2006), our results point to 
TNF-α as the first cytokine to be released by microglia upon UCB challenge, and, 
remarkably, its temporal profile of secretion is rather paralleled by the observed 
phagocytic alterations. TNF-α secretion reaches a maximum level at 4 h of UCB 
exposure, when microglial phagocytic properties are significantly increased and a decline 
in UCB-induced TNF-α release is observed from this point on, coinciding with decreased 
phagocytosis elicited by UCB.  
Besides its role as microglial phagocytosis inducer, several experiments have 
also implicated TNF-α in demyelination (Akassoglou et al., 1998) and neuronal 
degeneration (Allan and Rothwell, 2003; Silva et al., 2006), and this cytokine, along with 
IL-1β, participates in astrogliosis (Hanisch, 2002). IL-1β is involved in fever induction and 
edema, stimulation of COX-2, release of nitric oxide (NO) and free radicals (Rothwell, 
1999), also participating in the recruitment of circulating leukocytes into the CNS due to 
its ability to up-regulate the expression of adhesion molecules and chemokine synthesis 
(Lee and Benveniste, 1999; Sedgwick et al., 2000). IL-6 can have both pro and anti-
inflammatory functions and is produced in the early phases of CNS insult (Raivich et al., 
1999). Our results clearly imply microglia as an important player in the inflammatory 
response instigated by UCB, since the observed early release of TNF-α, previously 
discussed, is followed by a later but intense secretion of IL-6 and an even stronger 
induction of IL-1β.  
Strikingly, UCB seems to induce a major release of pro-inflammatory cytokines in 
a time period in which phagocytosis is already absent. Recent reports have, in fact, 
substantiated the existence of a non-phlogistic (non-inflammatory) phagocytic response 
from microglia (Neumann et al., 2009), triggered by apoptotic stimuli and potentially 
mediated by phosphatidylserine receptors (PRs) and triggering receptor expressed on 
myeloid cells-2 (TREM2) (Hsieh et al., 2009; Takahashi et al., 2005). Additionally, IL-1β 
and PGE2 were shown to suppress microglial ability to phagocytise insoluble fibrillar β-
amyloid deposits, suggesting that a pro-inflammatory milieu inhibits this type of 
phagocytosis (Koenigsknecht-Talboo and Landreth, 2005).  
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Our findings also suggest a role for MMPs in UCB-induced microglia reactivity, 
since their activity is enhanced upon prolonged exposure periods to this molecule. MMP-
9 has been associated with glutamate dysfunction (Michaluk and Kaczmarek, 2007) and 
its release can be a cause of microglia-induced neuron death (Kauppinen and Swanson, 
2005). In addition, inhibition of gelatinases (MMP-2 and -9) showed efficacy in reducing 
neural injury and dampening neuroinflammation (Leonardo et al., 2008). Thus, these 
proteases seem to actively participate in inflammatory events and their activity is very 
tightly regulated (Sternlicht and Werb, 2001). Cytokines are firmly established inducers 
of MMP expression and secretion (Gottschall and Yu, 1995; Ito et al., 1996), and the 
induction of MMPs has been shown to be mediated by MAPKs, NF-κB and activator 
protein-1 signalling pathways (Lin et al., 2009; Shakibaei et al., 2007; Vincenti and 
Brinckerhoff, 2007; Woo et al., 2008). Interestingly, in our study model, MMPs enhanced 
activity occurs at a later time of exposure, when MAPKs and NF-κB activation as well as 
cytokine secretion have already taken place, suggesting that these events might be 
involved in the activation of MMPs induced by UCB. Moreover, active MMPs may also 
participate in the regulation of cytokine activity by promoting the secretion and activation 
of these molecules (Chauvet et al., 2001; Kim et al., 2005; Nuttall et al., 2007; Woo et al., 
2008) or, on the other hand, by negatively regulating their biological activities (Ito et al., 
1996). As stated above, MMPs increased activity in UCB-stimulated microglia takes 
place after the peak of cytokine secretion, suggesting a possible reciprocal regulation 
between pro-inflammatory cytokines and MMPs, since the latter molecules could be 
involved in the termination of the inflammatory response by means of the degradation of 
IL-1β. Our results further address this issue since IL-1β demonstrated to intensely 
elevate MMP-2 and -9 activation providing proof of concept that IL-1β secretion 
produced upon UCB stimulation, is at least in part, responsible for MMP activation. 
Discrepancy between the activation levels observed for UCB or IL-1β alone may be a 
result of UCB-multiple cytokine activation which results in a pleiotropic regulatory loop, 
absent in the second condition. 
COX-2 expression can also be induced in microglia by several inflammatory 
conditions. As can be seen in our results, UCB is able to induce up-regulation of COX-2 
in microglial cells in a profile very similar to the observed for IL-6 and IL-1β, thus 
contributing to the overall inflammatory environment described so far and again pointing 
to an inflammatory response secondary to phagocytosis. Therefore, our studies suggest 
a dual role for microglia upon UCB stimulation, shifting from a phagocytic and possibly 
neuroprotective phenotype towards an inflammatory and deleterious one. This is 
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consistent with our findings demonstrating that microglia portray altered morphological 
features after a prolonged UCB exposure, typical of an activated state. 
As previously observed for astrocytes (Fernandes et al., 2006; Fernandes et al., 
2004) we show here that UCB stimulation of microglial cells also involves the activation 
of MAPKs and NF-κB. MAPKs can be activated by a variety of different stimuli (Roux 
and Blenis, 2004), and the engagement of this signalling pathway can lead to the 
phosphorylation of several substrates, including transcription factors such as NF-κB, 
which may ultimately lead to the enhanced transcription of genes encoding for pro-
inflammatory cytokines (Koj, 1996). Activation of p38 and ERK1/2 are regarded as 
essential steps for cytokine induction since their involvement in TNF-α, IL-1β, IL-6, COX-
2 and inductible nitric oxide synthase (iNOS) expression in microglia has been widely 
established (Bhat et al., 1998; Hanisch et al., 2001; Lee et al., 2000). Intriguingly, 
MAPKs activation, particularly p38, seems to be also involved in the induction of 
microglia phagocytosis (Sun et al., 2008; Tanaka et al., 2009). 
In this regard our data indicate a rapid activation of p38 and ERK1/2 by UCB in 
microglial cells, which occurs prior to the production of inflammatory mediators 
previously reported. In fact, MAPKs activation by UCB in microglia is triggered at a much 
earlier stage than in astrocytes (Fernandes et al., 2006), reinforcing the greater 
responsiveness of these glial cells during hyperbilirubinemia but also suggesting that the 
early phagocytic response of microglia cells to UCB may be under the control of p38 and 
ERK1/2 activation. In this case, the latter activation peak observed would engage the 
pro-inflammatory cascade that results in IL-1β and IL-6 enhanced secretion, as well as 
the induction of COX-2 and MMPs, a feature already observed for other immune cells 
(Gong et al., 2008; Hwang et al., 1997). 
Moving downstream on the intracellular signalling pathways is the original 
observation that, as in astrocytes (Fernandes et al. 2007; Fernandes et al. 2006), NF-κB 
activation is also present in microglia exposed to UCB. Interestingly, maximum activation 
of NF-κB takes place during and after the early MAPKs phosphorylation and again prior 
to the production of IL-1β, TNF-α and IL-6, postulating a possible involvement of NF-κB 
in both phagocytic and inflammatory responses elicited by UCB in microglia. The 
observations that NF-κB nuclear translocation in UCB-stimulated microglia is completely 
abrogated when microglia are pretreated with p38 and ERK1/2 inhibitors provided an 
unequivocal proof of MAPKs involvement in NF-κB engagement in UCB-challenged 
microglia which had already been previously established by other authors in different 
disease models (Wilms et al., 2003). 
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It isworthwhile to mention that cell viability and membrane integrity are 
compromised from 4 h onwards, indicating increased cell damage induced by UCB on 
microglial cells from this point onwards. In fact, UCB-induced apoptotic and necrotic 
microglial cell death have already been established (Gordo et al., 2006). Our results 
indicate that both the extrinsic and intrinsic apoptotic pathways are triggered culminating 
in the activation of effector caspase-3 and consequently causing cell death. However, 
cell death phenomena reach maximum peaks between 6 to 8 h but decreased for longer 
incubation periods. Together with the findings described above these data portray an 
interesting hypothesis for microglia response to UCB stimulus. So, it is conceivable that, 
either a shift on global microglia reaction occurs, or there are two distinct sub-
populations of microglial cells displaying complementary activation features, one directed 
at eliminating the damaged cells by phagocytosis, that died after engulfment of beads, 
and another engaging a more delayed inflammatory response. In fact, fragmentation of 
cytoplasm (cytorrhexis) which is suggested in our 24 h morphological observations, has 
been pointed to be indicative of widespread microglial degeneration in amyotrophic 
lateral sclerosis models (Fendrick et al., 2007). Degenerative changes in microglia such 
as beading and clusters of fragmented twigs have also been demonstrated in the aged 
brain (Hasegawa-Ishii et al., 2010). Which of the above mentioned hypotheses is the 
more valid demands further elucidation and will clarify the multifaceted profile of 
microglia activation under UCB stimulation. The complex network of UCB-induced 
events in microglia, as well as the proposed interactions between them, is depicted in 
Figure II.11. 
 
In conclusion, our experiments evidence that phagocytosis is differently 
modulated by UCB depending on the time of exposure, prevailing at an early time point, 
which is followed by the release of inflammatory cytokines, and activation of MMP-2 and 
-9, as well as of COX-2 activation. Thus, microglial phagocytosis and inflammatory 
response stand out as important events prompted by UCB. To what extent the activation 
of microglia by UCB has a beneficial or detrimental outcome is yet to be determined in 
future studies, where the influence of other nerve cells will be evaluated. Nevertheless, 
modulation of microglial activation seems to be a promising target in neonatal bilirubin 
encephalopathy. 
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Fig. II.11. Schematic representation of time-dependent microglial activation 
induced by UCB. Upon UCB stimulation of microglial cells, MAPK and NK-κB signalling 
pathways are engaged, culminating in the generation of a phagocytic response followed 
by an inflammatory profile. Both phenotypes might alternate due to a reciprocal 
regulatory effect or to the existence of two different sub-populations engaging both types 
of response, being the phagocytic sub-population firstly extinguished and replaced by a 
rather inflammatory sub-population. This inflammatory profile is characterized by the 
increased release of pro-inflammatory cytokines TNF-α, IL-1β and IL-6, the up-regulation 
of COX-2 and enhanced activities of MMP-2 and MMP-9. Regulatory interactions 
between the UCB-induced events are portrayed in the figure. 
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Abstract 
Microglia are the main players of the brain immune response acting as active 
sensors that rapidly respond to injurious insults by shifting into different activated states. 
Elevated levels of unconjugated bilirubin (UCB) induce cell death, immunostimulation 
and oxidative stress in both neurons and astrocytes. We recently reported that microglia 
phagocytosis phenotype precedes the release of pro-inflammatory cytokines upon UCB 
exposure. We investigated whether and how microglia microenvironment influences the 
response to UCB. Our findings, revealed that conditioned media derived from UCB-
treated astrocytes reduce microglial inflammatory reaction and cell death, suggesting an 
attempt to refrain microglial overactivation. Conditioned medium from UCB-challenged 
neurons, although down-regulating TNF-α and IL-1β promoted the release of IL-6 and 
nitric oxide, the activation of matrix metalloproteinase-9, and cell death, as compared to 
UCB-direct effects on microglia. Moreover, soluble factors released by UCB-treated 
neurons showed to intensify the phagocytic properties manifested by microglia under 
direct exposure to UCB. Results from neuron-microglia mixed cultures incubated with 
UCB evidenced that sensitized microglia was able to prevent neurite outgrowth 
impairment and cell death. In conclusion, our data indicate that stressed neurons signal 
microglial clearance functions, but also overstimulate its inflammatory potential ultimately 
leading to microglia demise. 
 
 
Keywords: Astrocyte- and neuron-conditioned media; Inflammatory reaction; Nerve cell 
death; Neurite outgrowth and branching; Neuron-microglia mixed cultures; Nitrosative 
stress; Phagocytosis; Unconjugated bilirubin. 
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1. Introduction 
Hyperbilirubinemia is a common disorder of the brain that occurs in the neonatal 
period (Dennery et al., 2001; Porter and Dennis, 2002) and has been associated with 
minor neurologic dysfunction (Soorani-Lunsing et al., 2001), motor and auditory 
impairment (Oh et al., 2003; Shapiro and Nakamura, 2001). In fact, recent findings have 
strongly correlated auditory neuropathy disorder and acute bilirubin-induced neurotoxicity 
(Saluja et al., 2010). Moreover, neonatal hyperbilirubinemia might be a vulnerability 
factor for mental disorders (Dalman and Cullberg, 1999) such as schizophrenia 
(Hayashida et al., 2009; Miyaoka et al., 2000). Interestingly, elevated levels of 
unconjugated bilirubin (UCB) have also been associated with sepsis (Zhai et al., 2009) 
and fever (Kaplan and Hammerman, 2005). Indeed, previous reports from our work 
group have already demonstrated the immunostimulant properties of UCB in neurons 
(Falcão et al., 2006) and, in a more marked fashion, in astrocytes (Falcão et al., 2005; 
Fernandes et al., 2006; Fernandes et al., 2004) and microglia (Gordo et al., 2006; Silva 
et al., 2010), thus reinforcing the immunostimulant effects  of UCB. 
Microglial cells have been acknowledged as the brain’s immune system 
constituting a link between the central nervous system (CNS) – a barrier protected organ 
– and the general immune system (Aloisi, 2001; Streit, 2002). Microglia can perform a 
plethora of diverse functions that range from immune surveillance (Nimmerjahn et al., 
2005) and phagocytic debris clearance (in both physiologic and pathologic conditions) 
(Cuadros and Navascues, 1998; Neumann et al., 2009; Streit, 2001), to the production of 
inflammatory mediators and reactive oxygen and nitrosative species (ROS and RNS, 
respectively) (Aloisi, 2001; Kim and de Vellis, 2005) which may contribute to nerve cell 
dysfunction and death (Gibbons and Dragunow, 2006). Our group has recently shown 
that microglia reacts to UCB by the acquisition of a phagocytic phenotype that shifts into 
a rather inflammatory profile (Silva et al., 2010). Accordingly, some authors have actually 
described microglia as active sensors that rapidly respond to microenvironmental 
changes with the engagement of different reactivity profiles (Hanisch and Kettenmann, 
2007).  
Indeed, cellular interactions may be relevant for microglial reactivity. Neurons 
have proven its role as key immune modulators in the brain as they can influence the 
release of inflammatory or neurotrophic mediators form microglia (Biber et al., 2007; Lai 
and Todd, 2008; Polazzi and Contestabile, 2006). Furthermore, damaged neurons can 
signal microglia to engage phagocytic clearance, thus limiting injury extension (Petersen 
and Dailey, 2004; Witting et al., 2000). Astrocytes can also attenuate microglial toxicity 
(Giulian et al., 1993; Rozenfeld et al., 2003) and down-regulate its inflammatory reaction 
(Eskes et al., 2003; Min et al., 2006) or, in opposite, further activate microglia through 
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increased ROS production (Yang et al., 1998). Finally, microglial reactivity is widely 
recognized as a cause of cell demise (Gibbons and Dragunow, 2006; Munch et al., 2003; 
Wang et al., 2005), that in some circumstances may also lead to a neuroprotective 
outcome (Minghetti et al., 2005; Zhang and Fedoroff, 1996). Considering that interplay 
between CNS cells may have such a strong and diverse influence on the cascade of 
microglial responses, this study was undertaken to ascertain if UCB-activated astrocytes 
or neurons could modulate the reactive response of microglia. Our findings indicate that 
soluble factors released by UCB-treated astrocytes dampen microglial inflammatory 
reaction upon UCB exposure. On the other hand, conditioned medium from neurons 
incubated with UCB, although exerting a similar down-regulation in microglial production 
of inflammatory cytokines, up-regulated matrix metalloproteinases (MMP) and nitric 
oxide (NO) secretion. Furthermore, neurons were able to augment microglial phagocytic 
abilities when facing UCB and ultimately increased UCB-induced microglial cell death. 
Microglia-neuron interplay in mixed cultures upon UCB stimulation revealed a 
neuroprotective role of microglia in preventing neurite impairment and necrotic-like cell 
death by UCB. We hypothesize that UCB-injured neurons might be signaling microglia to 
engage a phagocytic phenotype while hampering inflammatory reaction in an attempt to 
constrain lesion extent. 
 
2. Material and Methods 
 
2.1. Chemicals 
Neurobasal medium, B-27 Supplement (50x), Hanks’ balanced salt solution 
(HBSS), HBSS without Ca2+ and Mg2+, gentamicin (50 mg/mL), trypsin (0.5 g/L), Alexa 
Fluor 594 chicken anti-goat IgG and Trypsin/Ethylenediamine tetraacetic acid (EDTA) 
solution (0.25% trypsin, 1 mM EDTA in HBSS) were acquired from Invitrogen (Carlsbad, 
CA, USA). Dulbecco’s modified Eagle’s medium (DMEM), DMEM-Ham’s F12 medium, 
fetal bovine serum (FBS), sodium pyruvate, non-essential aminoacids (NEA) and L-
glutamine, were purchased from Biochrom AG (Berlin, Germany). Antibiotic antimycotic 
solution (20X), human serum albumin (HSA; Fraction V, fatty acid free), Hoechst 33258 
dye, biotinylated tomato lectin (Lycopersicon esculentum), avidin-fluorescein 
isothiocyanate (FITC), avidin-tetramethylrhodamine isothiocyanate (TRITC), fluorescent 
latex beads 1 μm (2.5%), propidium iodide (PI), N-1-naphthylethylenediamine, and 
Coomassie Brilliant Blue R-250 were purchased from Sigma Chemical Co. (St. Louis, 
MO, USA). UCB was also obtained from Sigma and purified according to the method of 
McDonagh and Assisi, (1972).  
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DuoSet® ELISA kits were from R&D Systems, Inc. (Minneapolis, MN, USA). Goat 
anti-ionized calcium-binding adaptor molecule 1 (Iba1) was from Abcam (Cambridge, 
UK) and mouse anti-microtubule associated protein (MAP)-2 antibody was from 
Chemicon (Temecula, CA, USA). FITC-labeled horse antibody anti-mouse was acquired 
from Vector (Burlingame, CA, USA). Lactate dehydrogenase (LDH) cytotoxicity detection 
kit was purchased from Roche Molecular Biochemicals (Manheim, Germany).  
All other chemicals were of analytical grade and were purchased from Merck 
(Darmstadt, Germany). 
 
2.2. Primary culture of microglia 
Animal care followed the recommendations of European Convention for the 
Protection of Vertebrate Animals Used for Experimental and other Scientific Purposes 
(Council Directive 86/609/EEC) and National Law 1005/92 (rules for protection of 
experimental animals). All animal procedures were approved by the Institutional Animal 
Care and Use Committee. Every effort was made to minimize the number of animals 
used and their suffering. 
Mixed glial cultures were prepared from 1 to 2 day-old Wistar rats as previously 
described (McCarthy and de Vellis, 1980), with minor modifications (Gordo et al., 2006). 
Cells (4 X 105 cells/cm2) were plated on uncoated 12 or 6-well tissue culture plates 
(Corning Costar Corp., Cambridge, MA, USA) in culture medium (DMEM-Ham’s F-12 
medium supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, NEA 1X, 10% 
FBS, and 1% antibiotic-antimycotic solution) and maintained at 37ºC in a humidified 
atmosphere of 5% CO2.  
Microglia were isolated as previously described by Saura et al., (2003). Briefly, 
after 21 days in vitro (DIV), microglia were obtained by mild trypsinization with a trypsin-
EDTA solution diluted 1:3 in DMEM-F12 for 20–45 min. The trypsinization resulted in 
detachment of an upper layer of cells containing all the astrocytes, whereas the microglia 
remained attached to the bottom of the well. The medium containing detached cells was 
removed and replaced with initial mixed glial-conditioned medium. Twenty-four hours 
after trypsinization, the attached cells were subjected to the different treatments.  
 
2.3. Primary culture of astrocytes 
Astrocytes were isolated from 2-day-old rats as previously described (Blondeau 
et al., 1993), with minor modifications (Silva et al., 1999). Cells were resuspended in 
DMEM containing 11 mM sodium bicarbonate, 71 mM glucose and 1% antibiotic 
antimycotic solution supplemented with 10% FBS, plated (2.0 X 105 cells/cm2) on 75 cm2 
culture flasks and cultured for 10 DIV.  
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2.4. Primary neuronal cell cultures 
Neurons were isolated from foetuses of 17–18-day pregnant Wistar rats, as 
described previously (Silva et al., 2002). Pregnant rats were anesthetized and 
decapitated. The foetuses were collected in HBSS and rapidly decapitated, the brain 
cortex was mechanically fragmented, and the fragments transferred to a 0.5 g/L trypsin 
in Ca2+ and Mg2+ free HBSS medium and incubated for 15 min at 37ºC. After 
trypsinization, cells were washed twice in calcium and magnesium free HBSS containing 
10% FBS, and resuspended in Neurobasal medium supplemented with 0.5 mM L-
glutamine, 25 µM L-glutamic acid, 2% B-27 Supplement, and 0.12 mg/ml gentamicin. 
Aliquots of 1 X 105 cells/cm2 were plated on poly-D-lysine coated 75 cm2 culture flasks 
and maintained at 37ºC in a humidified atmosphere of 5% CO2. Every 3 days, 0.5 ml of 
old medium was removed by aspiration and replaced by the same volume of fresh 
medium without L-glutamic acid. 
 
2.5. Neuron-microglia mixed cultures 
Primary cortical microglia were isolated from mixed glial cultures by mild 
trypsinization as described above. Remaining microglia was removed by trypsinization 
from the bottom of the plates and seeded on top of 2 DIV neurons at a density of 3.6 X 
104 cells/cm2. Mixed neuron-microglia cultures were kept for 24 h before treatment with 
UCB. 
 
2.6. Cell treatment 
Microglial cells were incubated in the absence (control) or in the presence of 50 
µM UCB plus 100 µM HSA, for 4 h or 24 h, at 37ºC. A UCB stock solution (10 mM) was 
prepared in 0.1 M NaOH immediately before use and the pH of the incubation medium 
was restored to 7.4 by addition of equal amounts of 0.1 M HCl. All the experiments with 
UCB were performed under light protection to avoid photodegradation. 
To study the role of soluble factors released by astrocytes or neurons upon UCB 
exposure, microglial cells were incubated for 4 or 24 h with conditioned medium from 
either 10 DIV astrocytes or 8 DIV neurons prior exposed to the same UCB and HSA 
levels for 12 h. Controls were performed in the absence of UCB. Neuron-microglia mixed 
cultures at 3 DIV were incubated in the absence (control) or in the presence of 50 µM 
UCB plus 100 µM HSA, for 24 h, at 37ºC. 
Neuron-microglia mixed cultures at 3 DIV were incubated in the absence (control) 
or in the presence of 50 µM UCB plus 100 µM HSA, for 24 h, at 37ºC. 
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2.7. Measurement of cytokine release 
Aliquots of the cell culture media were collected at the end of the incubations and, 
after removal of cellular debris by short centrifugation, placed in a 96-well microplate and 
assessed in triplicate for TNF-α, IL-1β and IL-6 with specific DuoSet® ELISA 
Development kits from R&D Systems, according to the manufacturer’s instructions. 
Results were expressed as fold change vs. control. 
 
2.8. Gelatin zymography 
Aliquots of culture supernatant were analyzed by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) zymography in 0.1% gelatine–10% 
acrylamide gels under non-reducing conditions. After electrophoresis, gels were washed 
for 1 h with 2.5% Triton X-100 (in 50 mM Tris pH7.4; 5 mM CaCl2; 1μM ZnCl2) to remove 
SDS and renature the MMP species in the gel. Then the gels were incubated in the 
developing buffer (50 mM Tris pH7.4; 5 mM CaCl2; 1μM ZnCl2) overnight to induce 
gelatine lysis. For enzyme activity analysis, the gels were stained with 0.5% Coomassie 
Brilliant Blue R-250 and destained in 30% ethanol/10% acetic acid/H2O. Gelatinase 
activity, detected as a white band on a blue background, was quantified by computerized 
image analysis and normalized for total cellular protein. 
 
2.9. Assessment of microglial phagocytic properties 
After treatment with UCB, cells were incubated with 0.0025% (w/w) 1 μm 
fluorescent latex beads for 75 min at 37ºC and fixed with freshly prepared 4% (w/v) 
paraformaldehyde in phosphate-buffered saline (PBS). Microglia were counterstained 
with a primary antibody raised against Iba-1 (goat, 1:500) followed by a secondary Alexa 
Fluor 594 chicken anti-goat antibody (1:200). Green- and red-fluorescence images of 
fifteen random microscopic fields (original magnification: 630X) were acquired per 
sample. The number of ingested beads per cell was counted in approximately 250 cells 
per sample.  
 
2.10. Quantification of nitrite levels 
Nitric oxide levels were estimated by measuring the concentrations of nitrites, 
which are the resulting NO metabolites. Briefly, supernatants free from cellular debris 
were mixed with Griess reagent in 96-well tissue culture plates for 10 min at room 
temperature in the dark. The absorbance at 540 nm was determined using a microplate 
reader (Bio-Rad Laboratories, Hercules, CA, USA). 
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2.11. Evaluation of cell death 
Necrotic-like cell death was estimated by evaluating the activity of LDH released 
by nonviable cells, as well as by monitoring the cellular uptake of the fluorescent dye PI 
[3,8-diamino-5-(3-(diethylmethylamino)propyl)-6-phenyl phenanthridinium diiodide].  
LDH was determined in the incubation medium using a cytotoxicity detection kit 
as described previously (Silva et al., 2002). The reaction was performed in a 96-well 
microplate and the absorbance measured at 490 nm. All readings were corrected for the 
possible interference of UCB absorption. The maximum amount of releasable LDH was 
obtained by lysing non-incubated cells with 2.0% Triton X-100 in DMEM for 5 min and 
the results were expressed as fold change vs. control. 
PI readily enters and stains non-viable cells, but cannot cross the membrane of 
viable cells. This dye binds to double-stranded DNA and emits red fluorescence (630 
nm; absorbance 493 nm). Unpermeabilized adherent cells cultured on coverslips were 
incubated with a 75 μM PI solution for 15 min in the absence of light. Subsequently, cells 
were fixed with freshly prepared 4% (w/v) paraformaldehyde in PBS and the nuclei 
stained with Hoechst 33258 dye. Red-fluorescence and U.V. images of ten random 
microscopic fields (original magnification: 400X) were acquired per sample and the 
percentage of PI positive cells was counted and expressed as fold vs. respective control.  
 
2.12. Neurite Extension and Ramification 
Neurite extension and ramification were assessed by the immunofluorescence 
detection of the cytoskeletal protein MAP-2, as described previously (Falcão et al., 
2007). Briefly, cells were fixed as described above and a standard indirect 
immunocytochemical technique was carried out using a mouse anti-MAP-2 antibody 
(1:100) as the primary antibody and a horse FITC-labeled anti-mouse antibody (1:227) 
as the secondary antibody.  
In neuron-microglia mixed cultures, microglia were counterstained with a primary 
antibody raised against Iba-1 (goat, 1:500) followed by a secondary Alexa Fluor 594 
chicken anti-goat antibody (1:200) and the nuclei stained with Hoechst 33258 dye. 
Fluorescence was visualized using a Leica DFC490 camera adapted to an 
AxioSkope® microscope. Green- and red-fluorescence images of ten random 
microscopic fields (original magnification: 400X) were acquired per sample. Evaluation of 
neurite extension and number of nodes from individual neurons, were traced manually 
using ImageJ software (National Institutes of Health). 
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2.13. Statistical Analysis 
Results of at least three different experiments, carried out in duplicate, were 
expressed as mean ± SEM. Differences between groups were determined by one-way 
ANOVA with Dunnett’s or Bonferroni’s multiple comparisons post tests, using Instat 3.05 
(GraphPad Software, San Diego, CA). Statistical significance was considered for a p 
value less than 0.05. 
 
3. Results 
 
3.1. Conditioned media from UCB-treated astrocytes and neurons modulate 
microglial secretion of cytokines, as compared to UCB-activated microglia 
Microglial cells are important sources of cytokines in the brain (Hanisch, 2002). In 
fact, a recent report from our group demonstrated that microglia, upon UCB stimulation, 
engages an inflammatory reaction which entails IL-1β IL-6 and TNF-α production and 
follows different temporal profiles of secretion (Silva et al., 2010). However, the influence 
of neighbouring cells must be considered when evaluating the response of microglia to 
toxic molecules like UCB. Indeed, several authors have described that neurons or 
astrocytes can modulate the inflammatory reaction undertaken by microglia (Giulian et 
al., 1993; Min et al., 2006; Mott et al., 2004; Polazzi and Contestabile, 2006). For that 
matter we compared cytokine secretion by microglia directly exposed to UCB or to 
astrocytes and neuron conditioned media (ACM and NCM, respectively) after incubation 
with UCB. Our results indicated that both UCB-treated ACM and NCM completely 
counteracted (p<0.01) the UCB-induced increase in IL-1β (1.5 fold, p<0.01), as depicted 
in Figure III.1A. Regarding TNF-α production (Figure III.1B), only NCM was able to 
significantly prevent (p<0.05) the elevation elicited by UCB (1.5 fold, p<0.05). Curiously, 
both ACM and NCM obtained after treatment with UCB led to an IL-6 overproduction by 
microglia (2.7 and 2.8-fold, respectively; p<0.01 vs. control) which proved to be 
significantly higher than the one triggered by the direct effect of UCB in microglia (p<0,01 
for both UCB-treated ACM and NCM), as can be seen in Figure III.1C. Therefore, these 
findings indicate that UCB-stimulated astrocytes and neurons dampen microglial 
inflammatory response triggered by UCB in isolated cells, since the release of pro-
inflammatory mediators such as IL-1β and TNF-α is down-regulated while the secretion 
of IL-6, which is considered to exert anti-inflammatory effects (Loddick et al., 1998), is 
greatly enhanced. 
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Fig. III.1. Conditioned media 
derived from astrocytes (ACM) 
and neurons (NCM) incubated 
with UCB modulate the 
secretion of IL-1β, TNF-α and IL-
6 by microglia directly exposed 
to UCB. Rat cortical microglial 
cells were treated for 24 h with 50 
µM UCB in the presence of 100 µM 
HSA, or with ACM or NCM from 
cells  exposed to the same UCB 
and HSA levels for 12 h. Controls 
were performed in the absence of 
UCB. IL-1β, TNF-α and IL-6 
concentrations in the media were 
determined by ELISA and 
expressed as mean ± SEM fold 
change vs. control from three 
independent experiments 
performed in triplicate. *p<0.05 and 
**p<0.01 vs. control; §p<0.05 and 
§§p<0.01 vs. UCB alone. 
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3.2. Conditioned media from UCB-treated astrocytes and neurons have 
opposing effects on microglial MMP-9 activity, as compared to UCB-activated 
microglia 
 UCB has been previously shown to enhance the activity of MMP-9 and -2, 
proteases that actively participate in inflammatory events. Moreover, the same study also 
evidenced the existence of regulatory interactions between cytokine secretion and MMP 
activation upon UCB exposure (Silva et al., 2010). Since conditioned media from UCB-
exposed astrocytes and neurons showed to modulate the secretion of inflammatory 
mediators, we wondered what effect could ACM and NCM exert on MMP activation. The 
results show that UCB-treated NCM and direct UCB stimulation have similar activation 
levels of MMP-2 (p<0.05 vs. control) but ACM from astrocytes exposed to UCB did not 
produce any significant effect (Figure III.2A). Curiously, our findings evidenced opposing 
effects of ACM and NCM upon UCB stimulation on MMP-9 activity by microglia directly 
exposed to UCB (Figure III.2B). While ACM abrogated (p<0.05) the increase in MMP-9 
activity elicited by UCB in microglia (1.1-fold, p<0.05), NCM further aggravated such 
effect (1.2-fold; p<0.01 vs. control and p<0.05 vs. UCB alone).  
 
3.3. Nitric oxide (NO) release by microglia is elicited by UCB and is higher by 
naïve microglia exposed to conditioned medium from UCB-treated neurons 
 Microglia and astrocytes generate an NO burst in response to injury, which may 
be cytotoxic (Cassina et al., 2002; Kawase et al., 1996) and trigger the clearance of 
damaged cells from the CNS (Bal-Price and Brown, 2001; Golde et al., 2002). Although 
UCB has been shown to elicit NO release in neurons (Brito et al., 2010), no evidence 
was ever confirmed regarding microglial cells exposed to UCB. Therefore, this study is 
the first to demonstrate that UCB can induce the generation of NO by microglia (1.3-fold; 
p<0.05 vs. control). Moreover, the results displayed in Figure III.3 indicate that the 
evoked NO production is even more enhanced when non-treated (naïve) microglia are 
exposed to conditioned medium derived from neurons incubated with UCB, NCM, (1.5-
fold; p<0.01 vs. control and p<0.05 vs. UCB alone). On the other hand, conditioned 
medium from astrocytes exposed to UCB, ACM, did not significantly alter the amount of 
NO release by UCB-stimulated microglia (1.3-fold, p<0.05 vs. control but N.S. vs. UCB 
alone). Data show that neighbouring neurons may further increase the nitrosative stress 
induced by UCB in microglia. 
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Fig. III.2. MMP-9 activation in microglia directly exposed to UCB is prevented by 
conditioned medium derived from UCB-treated astrocytes (ACM), but enhanced by 
conditioned medium derived from UCB-treated neurons (NCM). Culture 
supernatants from rat cortical microglial cells were harvested after 24 h incubation with 
50 µM UCB in the presence of 100 µM HSA or with ACM or NCM from cells exposed to 
the same UCB and HSA levels for 12 h. Controls were performed in the absence of 
UCB. Samples were subjected to zymography as described in Methods. (A) 
Representative gels of one experiment are reported. MMP-2 and MMP-9 were identified 
by their apparent molecular mass of 67 and 92 kDa, respectively. (B ,C) Intensity of the 
bands was quantified by scanning densitometry, standardized with respect to total 
protein content and expressed as mean ± SEM fold change compared with those 
obtained in control conditions. *p<0.05 and **p<0.01 vs. respective control; §p<0.05 vs. 
UCB alone. 
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Fig. III.3. NO release by UCB-activated microglia is intensified by conditioned 
medium derived from UCB-treated neurons (NCM), but not changed by 
conditioned medium derived from UCB-treated astrocytes (ACM). Rat cortical 
microglial cells were treated for 24 h with 50 µM UCB in the presence of 100 µM HSA or 
with ACM or NCM from cells exposed to the same UCB and HSA levels for 12 h. 
Controls were performed in the absence of UCB. NO production was estimated by the 
quantification of nitrite levels and expressed as mean ± SEM fold change from three 
independent experiments performed in duplicate. *p<0.05 and **p<0.01 vs. control and 
§p<0.05 vs. UCB alone. 
 
3.4. Loss of viability in UCB-stimulated microglia is less in naïve microglia 
exposed to conditioned medium from UCB-treated astrocytes (ACM), but higher if 
treated with medium from neurons incubated with UCB (NCM) 
  To evaluate whether the loss of microglia viability upon exposure to ACM and 
NCM was different from the one produced by the direct action of UCB on microglial cell 
death, we assessed the extracellular accumulation of LDH, a characteristic feature of cell 
membrane integrity loss. Our results evidenced that ACM does not produce any change 
over the results observed in the absence of UCB (Figure III.4) and was significantly less 
(p<0.01) than the release of LDH obtained in UCB-stimulated microglia (1.5 fold, 
p<0.01). In contrast, the values achieved with NCM-treated microglia were clearly higher 
(1.8 fold, p<0.01 vs. control and p<0.05 vs. UCB alone). This finding strengthens again 
the notion that neurons may further damage reactive microglia increasing UCB injury in 
brain parenchyma. 
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Fig. III.4. LDH leakage by UCB-activated microglia is completely abrogated by 
conditioned medium derived from UCB-treated astrocytes (ACM) but enhanced by 
conditioned medium derived from UCB-treated neurons (NCM). Culture 
supernatants from rat cortical microglial cells were harvested after 24 h incubation with 
50 µM UCB in the presence of 100 µM HSA or with ACM or NCM from cells exposed to 
the same UCB and HSA levels for 12 h. Controls were performed in the absence of 
UCB. Samples were used for determination of LDH activity. Results are mean ± SEM 
from three independent experiments performed in duplicate. **p<0.01 vs. control; 
§p<0.05 and §§p<0.01 vs. UCB alone. 
 
 
3.5. Microglial phagocytic properties enhanced by UCB further increase by 
medium collected from neurons exposed to UCB 
 Recently we have described that microglia reacts to UCB by the acquisition of an 
early phagocytic phenotype that afterwards shifted to a rather inflammatory state (Silva 
et al., 2010). Since icteric NCM was shown to decrease the production of pro-
inflammatory cytokines, but to promote microglia demise, we wondered how microglia 
would react if surrounded by neurons in an icteric parenchyma. Interestingly, as can be 
seen in Figure III.5, the uptake of fluorescent latex beads by microglia is stimulated in the 
presence of UCB, but even more by the icteric NCM (~40%, p<0.05). Therefore, UCB 
seems to induce the release of soluble factors from neurons that stimulate the 
phagocytic role of microglia. Whether deleterious consequences occur either by an 
increased time of exposure to UCB or by higher UCB levels, are to be seen in future 
studies. 
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Fig. III.5. Microglia phagocytic ability increases upon exposure to UCB, and this 
property is enhanced by icteric NCM derived from UCB-treated neurons. Rat 
cortical microglial cells were treated for 24 h with 50 µM UCB in the presence of 100 µM 
HSA or with ACM or NCM from cells exposed to the same UCB and HSA levels for 12 h. 
Controls were performed in the absence of UCB. Cells were incubated with 1 μm green 
fluorescent latex beads as described in Methods. (A) Microglial cells were counterstained 
with an antibody raised against Iba-1 (red) Representative results of one experiment are 
shown. Scale bar 20 μm. (B) Results are expressed as number of ingested beads per 
cell (± SEM) from three independent experiments. *p<0.05 and **p<0.01 vs. control; 
§p<0.05 and §§p<0.01 vs. UCB alone. 
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3.6. UCB-induced neuronal network impairment is prevented by microglia 
environment 
 
Considering that neurons showed to greatly influence microglial reactivity using a 
conditioned medium model and that the phagocytic profile seems to be promoted under 
these conditions, we decided to invert the picture and take a look at the effects of UCB-
reactive microglia on neurons. For that matter we used a neuron-microglia mixed culture 
system where cell-to-cell contact could take place. Since immature cortical neurons have 
previously been shown to be more vulnerable than the most differentiated ones to UCB-
induced cell death, glutamate release and TNF-α secretion (Falcão et al., 2006), we 
chose to explore the effect of microglia on 3 DIV neurons, a differentiation stage where 
UCB seems to produce a more injurious outcome. 
 
As previously reported by Falcão et al. (2007) 24 h exposure of immature cortical 
neurons to UCB decreases neuronal survival and causes an impairment of neurite 
development. The involvement of microglia in neurite outgrowth during brain 
development has been acknowledged (Cuadros and Navascues, 1998), as well as in 
pathologic events (Munch et al., 2003; Rozenfeld et al., 2003). Activated microglia has 
been accounted for as either neurotoxic (Zhang and Fedoroff, 1996) or neuroprotective 
in several models (Nakajima et al., 2007) due to its inflammatory and phagocytic nature. 
Nonetheless, the impact of microglia on neuronal plasticity in an icteric milieu had not 
been previously evaluated. Hence, we decided to verify if the UCB-elicited network 
impairment in neurons is modulated by the presence of microglia when mixed cultures of 
both cell types are used. As represented in Figure III.6, microglia when cultivated with 
neurons are able to protect the injury caused by UCB at the level of neurite extension 
(p<0.01) and ramification (p<0.05).  
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Fig. III.6. Reduction of neurite extension and ramification by UCB in immature 
neurons is counteracted by the presence of microglia. Cortical neurons and neuron-
microglia mixed cultures at 3 DIV were exposed for 24 h, to either no addition (control), 
or to 50 µM UCB as described in Methods. Neurite extension (A) and number of nodes 
(B) were identified by immunolabeling for MAP-2 (green), quantified by ImageJ and 
expressed as arbitrary units ± SEM. Microglial cells were counterstained with an 
antibody raised against Iba-1 (red). Representative results of one experiment are shown 
in (C). **p<0.01 vs. control; §p<0.05 and §§p<0.01 vs. UCB alone. Scale bar 40 µm. 
Therefore, defensive properties on the neuronal injury by UCB seem to be a key 
role of microglia when UCB gets into the brain. We hypothesize that the additional 
presence of risk factors such as sepsis or prematurity may change the protective role of 
microglia. We also questioned if the effects observed were really a protection or resulted 
from the increased microglia phagocytosis previously observed. Thus we next 
investigated the influence of microglia in neuron viability upon UCB exposure. 
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3.7. Neuronal cell death triggered by UCB is diminished in the presence of 
microglia 
 Interplay between neurons and microglia is widely recognized (Biber et al., 2007; 
Zhang and Fedoroff, 1996). In fact, several reports have demonstrated that activated 
microglia can decrease neuronal viability (Gibbons and Dragunow, 2006) or, by the other 
hand, exert a neuroprotective role (Figueiredo et al., 2008; Nakajima et al., 2007). 
Indeed, as demonstrated in Figure III.7, the propensity of microglia to decrease cellular 
necrosis is reinforced in the presence of UCB, with a completely abrogated UCB-induced 
death of immature neurons (p<0.01) in mixed cultures of neurons and microglia.  
 
 
Fig. III.7. Decreased neuronal survival by UCB disappears when microglia is 
nearby. Cortical neurons or neuron-microglia mixed cultures at 3 DIV were exposed for 
24 h, to either no addition (control), or 50 µM UCB and further incubated with 75 μM PI 
as described in Methods. Results are percentage of PI-positive cells and are expressed 
as mean ± SEM from three independent experiments performed in triplicate **p<0.01 vs. 
respective control and §§p<0.01 vs. UCB alone. 
 
These results reinforce the neuroprotective role that microglia may exert in 
preventing UCB neurological damage. However, given the acknowledged phagocytic 
nature of microglia and the fact that icteric NCM further enhances that property, we 
believe that this apparent protection results from the phagocytic clearance of UCB-
injured neurons, similarly to the events described in other disease models (Napoli and 
Neumann, 2009; Neumann et al., 2009; Tanaka et al., 2009). 
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4. Discussion 
Cell-to-cell interactions as well as the release of soluble mediators are essential 
regulators of many critical functions in brain health and disease. In this study we 
demonstrated, for the first time, that astrocytes and neurons stimulated by UCB can 
modulate microglial reactivity through different pathways. UCB-treated astrocytes lead to 
a decrease in the inflammatory response elicited by UCB in microglia and ultimately 
prevent UCB-induced cell demise. On the other hand, although UCB-exposed neurons 
release soluble factors with the capacity to down-regulate microglial production of pro-
inflammatory cytokines, neurons also lead to increased NO production and further 
aggravate UCB-induced MMP-9 activity in microglia. Interestingly, neurons exacerbate 
microglial early phagocytic phenotype while also increase microglia demise by UCB. Our 
study is the first to evaluate if injurious effects of UCB on neurons are modified in the 
presence of microglial cells, thus taking into consideration probable cellular interactions. 
Curiously, our findings show that microglial cells counteract the deleterious effects 
produced by UCB on neuronal cell death and neurite extension and ramification. 
Altogether, these observations allow us to hypothesize that UCB-evoked injury in 
neurons is signaling microglia to engage phagocytic clearance in an attempt to limit 
injury extension, rather than exacerbating inflammation. 
The contribution of microglial immune response to either damage or repair is a 
broadly discussed subject (Amor et al., 2010). Additionally, the influence of neighboring 
cells on microglial reactivity is renowned, substantiating the observed immunomodulatory 
effects produced by icteric ACM and NCM. In fact, when evaluating the role of microglia 
in organometallic compounds’ toxicity, astrocytes were shown to dampen TNF-α 
production and, additionally, were not able to induce morphogical changes (Eskes et al., 
2003). Furthermore, astrocytes can attenuate microglial activation in several disease 
models, thus preventing neurodegeneration (Giulian et al., 1993; Rozenfeld et al., 2003). 
It is also interesting to notice that, in our work model, UCB-treated astrocytes and 
neurons greatly enhanced IL-6 production by microglia. Similar effects were observed in 
studies regarding microglial reactivity to methylmercury where interaction between 
activated microglia and astrocytes was shown to increase local IL-6 release, which may 
cause astrocyte reactivity and ultimately culminate in neuroprotection (Eskes et al., 
2002).  
We have recently demonstrated that UCB-induced cytokine release by microglia, 
particularly IL-1β, originate MMP-9 and -2 activation (Silva et al., 2010). Thus, the 
observed decrease in microglial MMP-9 activity after exposure to icteric ACM could be 
explained by the regulatory interactions between cytokines and MMPs, since the 
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production of the formers is also hampered in this particular case. Collectively, our 
findings suggest an overall protective effect exerted by astrocytes on microglia, upon 
UCB stimulation. We theorize that microglia, when isolated, respond intensively to UCB 
stimulation, but previously activated astrocytes drive microglia to refrain its response. 
Other authors have postulated that this is a feasible mechanism to prevent excessive 
brain inflammation (Min et al., 2006).  
In this work we also describe the down-regulatory effect of icteric NCM upon 
UCB-stimulated microglial secretion of pro-inflammatory cytokines, particularly IL-1β and 
TNF-α. Accordingly, neurons reduce glial secretion of TNF-α after treatment with the 
bacterial endotoxin lipopolysaccharide (LPS) emphasizing their role as immune 
responsiveness regulators (Chang et al., 2001; Mott et al., 2004). Similarly, neurons 
constitutively release factors that maintain microglia in a quiescent state in the healthy 
brain (Biber et al., 2007), such as the protein CD200, a molecule shown to down-
regulate microglial inflammatory response (Broderick et al., 2002; Deckert et al., 2006). 
Nevertheless, under inflammatory or deleterious conditions, microglia’s behavior might 
be modified, as suggested by the study of Hasegawa et al. (2007) where the contact rate 
between activated microglia and hippocampal pyramidal cells’ dendrites is increased. 
Additionally, the severity of neuronal injury has been reported to determine the release of 
trophic or pro-inflammatory mediators form microglia (Lai and Todd, 2008). For example, 
interaction of microglia with apoptotic neurons leads to a progressive down-regulation of 
pro-inflammatory microglial functions (Minghetti et al., 2005). Considering that neurons 
reveal higher susceptibility to cell death than astrocytes, in the presence of high UCB 
levels (Brites et al., 2009; Silva et al., 2002), we postulate that this event leads to the 
release of factors by neurons which give the impression to influence microglial response 
to UCB in a more marked fashion than those produced by astrocytes. In fact, our results 
reveal that conditioned medium derived from UCB-stimulated neurons dampens 
microglial production of pro-inflammatory cytokines, yet increases MMP-9 activity and 
NO secretion, culminating in microglial death. These observations led to the assumption 
that UCB-injured neurons might be signaling microglia to shift its activity state rather than 
exerting a down- or up-regulation of its functions. Indeed, a previous report regarding 
microglial reactivity to UCB has already identified two different phenotypes (phagocytic 
and inflammatory) which occurred in an alternate fashion possibly indicating the 
existence of two different microglial subpopulations reacting towards UCB (Silva et al., 
2010). In the present study we observed that soluble factors released by UCB-damaged 
neurons are able to enhance the microglial phagocytic ability when compared to the one 
showed by UCB-stimulated microglia. These data reinforce the belief that neuron-
microglia interaction modifies the response phenotype of the latter cells, upon UCB 
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exposure. Consistently, other authors have reported that microglia recognize and 
phagocyte dying neurons (Petersen and Dailey, 2004; Witting et al., 2000) providing a 
clearance of potentially harmful debris.  
Although MMP-9 activation and increase in NO production are normally included 
in the inflammatory reaction engaged by microglia, in this case we may consider that 
these events can be related to the acquisition of a phagocytic profile. In fact, NO has 
been proven to regulate phagocytosis (Kopec and Carroll, 2000) and to trigger the 
clearance of damaged cells (Cassina et al., 2002; Kawase et al., 1996). Furthermore, 
MMPs can be involved in chemoattraction of microglial cells to injured sites since they 
participate in the cleavage of fractalkine from neuronal membranes following toxic insults 
(Chapman et al., 2000). MMPs also have the ability to degrade the basal lamina 
surrounding the blood-brain barrier allowing infiltration of immune cells (Michaluk and 
Kaczmarek, 2007; Rosenberg, 2002) consequently participating in phagocytic events 
(Buss et al., 2007). 
Nevertheless, the engagement of such a dramatic phenotype such as microglial 
phagocytosis may culminate in cell death. Our observations regarding the influence of 
UCB-reactive neurons on microglial response seem to corroborate this concept since cell 
death is further aggravated under these conditions. Other studies have also reported that 
NCM produces an overactivation of LPS-stimulated microglia culminating in apoptotic 
elimination as a safety mechanism (Polazzi and Contestabile, 2006).  
Besides studying the influence of soluble factors released by astrocytes or 
neurons stimulated by UCB on microglial response, we intended to advance one step 
further in the understanding of UCB-induced neurotoxicity and add neuron-microglia cell-
to-cell interactions to the puzzle. For this matter we used neuron-microglia mixed 
cultures to study the effects of UCB on network dynamics and cell death, since isolated 
immature neurons proved to be more affected by UCB than more differentiated cells in 
these particular features (Falcão et al., 2007). Unexpectedly, microglia proved to 
completely counteract UCB-elicited neurite impairment and loss of viability. Other 
authors have proven opposite results concerning the effects of microglia on neurite 
outgrowth and cell viability. For instance, Munch et al. (2003) demonstrated that 
microglial activation induces cell death and inhibits neurite outgrowth in neuroblastoma 
cells. Microglia is also involved in neuron loss in Alzheimer´s disease (Fuhrmann et al., 
2010) and may cause neuronal cell death and degeneration (Gibbons and Dragunow, 
2006; Rozenfeld et al., 2003). Taking into account all these confounding aspects, we 
hypothesize that this apparent microglial protection of UCB-induced neurotoxicity may 
indeed be regarded as a neuroprotective measure aiming at limiting injury extension by 
the phagocytic clearance of damaged neurons. Phagocytosis of amyloid deposits or 
Glial and neuronal pathological alterations by unconjugated bilirubin
 
 
101 
cellular debris by microglia was also proven to be important in Alzheimer´s disease 
(Simard et al., 2006) and multiple sclerosis (Takahashi et al., 2007). Thus, clearance of 
tissue debris performed by microglia following injury might constitute a regenerative 
measure (Napoli and Neumann, 2009; Neumann et al., 2009). 
In summary, our findings indicate that astrocytes activated by UCB release 
soluble factors that reduce microglial inflammatory reaction, probably in an attempt to 
refrain deleterious overactivation. On the other hand, UCB-stimulated neurons down-
regulate microglial production of inflammatory cytokines but further increase its 
phagocytic abilities and ultimately lead to microglial elimination. Furthermore, microglia 
counteract UCB-evoked impairment of neurite extension and ramification as well as 
neuronal cell death in a mixed culture model. Hence, we hypothesize that UCB-injured 
neurons might be signaling microglia to engage a phagocytic phenotype while hampering 
inflammatory reaction in an attempt to constrain lesion extent. In conclusion, this study 
introduces important knowledge to the understanding of the molecular basis of UCB-
induced neurotoxicity as it adds, for the first time, an important piece to the puzzle, e.g. 
cellular interactions between microglia and other nerve cells in a model mimicking acute 
neonatal jaundice.  
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Abstract 
Microglia has recently emerged as a crucial mediator of CNS inflammation since 
they are exquisitely sensitive to brain injury.  The role of microglia during neonatal 
jaundice is unrecognized, although we evidenced that microglia reacts to unconjugated 
bilirubin (UCB) by engaging a phagocytic phenotype followed by the secretion of 
cytokines and glutamate. In addition, UCB injury to neurons involve short- and long-term 
alterations in neurite outgrowth and synaptic density, namely in hippocampal neurons, 
and is mediated by oxidative and nitrosative stress, raising the possibility of having an 
impact on infant’s learning. 
This study investigated microglia neuroprotective or neurotoxic effects in a cell-to-
cell concerted action in response to UCB, namely in the production of glutamate and 
nitric oxide (NO), using organotypic cultured-hippocampal slices. Involvement of 
glutamate and NO in UCB-mediated toxicity to immature neurons was addressed using 
MK-801 (a NMDA glutamate-subtype receptor antagonist) and L-NAME (a non-specific 
NO synthase inhibitor). Therapeutic potential of glycoursodeoxycholic acid (GUDCA) and 
interleukin (IL)-10, with antioxidant and immunossupressive properties, in UCB-induced 
neurodegeneration was also evaluated. 
Microglia revealed to participate in glutamate homeostasis and to induce the 
release of this neurotransmitter and NO in UCB-treated hippocampal slices, which 
showed to be mediators in neuritic impairment, and cell death. Either GUDCA or IL-10 
counteracted these insidious effects on immature neurons, but only GUDCA showed 
preventive effects on cell death, synaptic changes and release of glutamate and NO in 
UCB-treated cortical neurons and hippocampal slices.  
Collectively our data reveal microglia, glutamate and NO as key players in UCB-
induced neurotoxicity and point to GUDCA as a promising therapy in infant’s 
hyperbilirubinemia. 
 
 
Keywords: Glutamate-mediated neurotoxicity; Glycoursodeoxycholic acid; Interleukin-10; 
Long-term disabilities; Microglia-neuron interactions; Neurite outgrowth impairment; Nitric 
oxide; Organotypic-cultured hippocampal slices; Unconjugated bilirubin. 
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1. Introduction 
Microglial cells are the first to respond to neural insults (Morioka et al., 1991) and 
its reactivity may be differentially modulated depending on microenvironmental signals 
(Zhang and Fedoroff, 1996). Activated microglia promote neuronal survival in ischemic 
lesion and facial nerve axotomy models (Moran and Graeber, 2004). Nevertheless, 
microglia can also release molecules, which may be harmful in acute brain insults and 
neurodegenerative diseases (Raivich et al., 1999).  
Hyperbilirubinemia, a very common neonatal condition, characterized by 
increased serum levels of unconjugated bilirubin (UCB) (Dennery et al., 2001), is 
associated with minor neurologic dysfunction (Soorani-Lunsing et al., 2001) and 
correlated with the emergence of long-term neurodevelopment disabilities (Dalman and 
Cullberg, 1999; Miyaoka et al., 2000). Several toxic effects have been accounted for 
UCB neurotoxicity such as cell death by both necrosis and apoptosis (Rodrigues et al., 
2002a; Silva et al., 2001) and neuronal oxidative injury (Brito et al., 2008b; Vaz et al., 
2010). UCB has also been shown to inhibit glutamate uptake prolonging its presence in 
the synaptic cleft (Silva et al., 1999; Silva et al., 2002) and to enhance its secretion in 
both astrocytes (Falcão et al., 2005; Fernandes et al., 2004) and microglia (Gordo et al., 
2006) enabling N-methyl-D-aspartic acid (NMDA)-mediated excitotoxicity (Brito et al., 
2010; Grojean et al., 2000; Grojean et al., 2001; McDonald et al., 1998). 
Microglia is one of the brain’s major sources of reactive oxygen species (ROS) 
and reactive nitrosative species (RNS). In fact, microglial activation upon UCB exposure 
has been demonstrated to engender inflammation (Silva et al., 2010), glutamate 
secretion (Gordo et al., 2006) and nitric oxide (NO) increased production (unpublished 
results).  
The involvement of glutamate in cell death (Barger and Basile, 2001; Barger et 
al., 2007; Hahn et al., 1988; Lee et al., 2000; Liang et al., 2008; Takeuchi et al., 2008) 
and neuritic outgrowth regulation (Hoffman et al., 1996; Lee et al., 2005; Mattson et al., 
1988; Monnerie et al., 2003) has been widely established. Intimately linked to 
excitotoxicity is the generation of destructive free radicals, especially RNS (Ha et al., 
2010). These species are accountable for synapse and neuron injury, can exacerbate 
excitotoxicity (Sunico et al., 2010) and are broadly implicated in neurodegenerative 
diseases (Bishop and Anderson, 2005). In a very recent paper it was evidenced that 
excitotoxicity plays a key role in UCB-induced oxidative damage to rat cortical mature 
neurons (Brito et al., 2010). 
Finally, UCB seems to produce neurodevelopmental deficits since it has 
deleterious effects in neurogenesis, neuritogenesis and synaptogenesis (Falcão et al., 
2007; Fernandes et al., 2009). Indeed, early exposure to UCB leads to impairment of 
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neuronal development by reducing dendrite extension and ramification, as well as 
dendritic spine formation and synapse establishment (Falcão et al., 2007). Moderate 
concentrations of UCB inhibit the induction of long term potentiation (LTP) in the 
hippocampus by short-term (Zhang et al., 2003) or prolonged exposure (Chang et al., 
2009), indicating that neonatal jaundice may have deleterious consequences in learning 
and memory. In fact, it was observed that the more the history of jaundice was severe 
the highest difficulty for learning was revealed (Weir and Millar, 1997). 
Glycoursodeoxycholic acid (GUDCA) was proven to reduce cell death induced by 
UCB in astrocytes (Fernandes et al., 2007) and neurons (Brito et al., 2008a; Vaz et al., 
2010), and to abrogate the UCB-induced oxidative damage in neurons (Brito et al., 
2008a; Vaz et al., 2010). Moreover, immunosuppressive properties of GUDCA and 
interleukin (IL)-10 were demonstrated on the release of pro-inflammatory cytokines by 
UCB-treated astrocytes (Fernandes et al., 2007). IL-10 has also been shown to reduce 
neuronal degeneration after central nervous system (CNS) injury (Bachis et al., 2001; 
Park et al., 2007). However, to the best of our knowledge, no evidence was established 
regarding the effect of GUDCA and IL-10 in the prevention of UCB-induced neurite 
impairment along neuronal maturation. 
Therefore, this study aimed at evaluating whether the production of glutamate 
and NO could be elicited by UCB in an ex-vivo model of hippocampal slice cultures and, 
more importantly, if this effect could be ascribed to microglial cells. This culture model 
maintains the cytoarchitecture of the tissue, allowing interaction of multiple cell types in 
the brain, namely neurons, astrocytes and microglia (Cho et al., 2007). Furthermore, we 
intended to clarify the role of glutamate and NO in UCB-induced neurotoxicity by using 
MK-801 (a NMDA glutamate-subtype receptor antagonist) and L-NAME (a non-specific 
NO synthase inhibitor), and to elucidate the protective effects of GUDCA and IL-10 in 
both isolated immature neurons and hippocampal slice cultures.  
Our studies clearly demonstrate a key role of NO and overactivation of NMDA 
receptors in UCB-induced impairment of neuritic outgrowth and cell death. Microglia 
revealed to directly participate in glutamate homeostasis and NO production. 
Additionally, we show, for the first time, that GUDCA and IL-10 prevent UCB-induced 
loss of cell viability and extracellular glutamate accumulation. Moreover, they completely 
abrogate the deleterious effects produced by UCB in neuronal network dynamics in a 
very sustained manner along cellular differentiation, indicating that both short- and long-
term UCB harmful consequences on CNS could be in this way counteracted. 
Furthermore, our findings report that UCB is able to down-regulate the expression of pre-
synaptic proteins, adding on the detrimental effects of UCB on synaptic plasticity, and 
that only GUDCA prove efficacy in preventing this injurious outcome. 
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2. Material and Methods 
 
2.1. Chemicals 
Neurobasal medium, B-27 Supplement (50x), Hanks’ balanced salt solution 
(HBSS), HBSS without Ca2+ and Mg2+, gentamicin (50 mg/mL), trypsin (0.5 g/L) and 
Alexa Fluor 594 chicken anti-goat IgG were acquired from Invitrogen (Carlsbad, CA, 
USA). Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS), and L-
glutamine, were purchased from Biochrom AG (Berlin, Germany). Antibiotic antimycotic 
solution (20X), human serum albumin (HSA; fraction V, fatty acid free), bovine serum 
albumin (BSA), Hoechst 33258 dye, mouse anti-β-actin antibody, propidium iodide (PI), 
N-1-naphthylethylenediamine, N-ω-nitro-L-arginine methyl ester (NAME), [(+)-5-methyl-
10,11-dihydro-5Hdibenzo[a,d]cyclohepten-5,10-imine maleate)] (MK-801) and DAPI 
were purchased from Sigma Chemical Co. (St. Louis, MO). UCB was also obtained from 
Sigma and purified according to the method of McDonagh and Assisi, (1972).  
Mouse anti-microtubule associated protein (MAP)-2, mouse anti- synaptosomal-
associated protein (SNAP)-25 and mouse anti-synaptophysin antibodies were from 
Chemicon (Temecula, CA) and fluorescein isothiocyanate (FITC)-labeled horse antibody 
anti-mouse was acquired from Vector (Burlingame, CA). GUDCA (minimum 96% pure) 
was obtained from Calbiochem, Darmstadt, Germany and recombinant rat IL-10 from 
R&D Systems, Minneapolis, MN. 
Nitrocellulose membrane and Hyperfilm ECL were from Amersham Biosciences 
(Piscataway, NJ, USA). Horseradish peroxidase-labeled goat anti-rabbit IgG and anti-
mouse IgG antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Cell 
lysis buffer and LumiGLO® were from Cell Signaling (Beverly, MA, USA). L-glutamic acid 
kit was purchased from Roche Molecular Biochemicals (Manheim, Germany).  
All other chemicals were of analytical grade and were purchased from Merck 
(Darmstadt, Germany). 
 
2.2. Organotypic-cultured hippocampal slices 
Animal care followed the recommendations of European Convention for the 
Protection of Vertebrate Animals Used for Experimental and other Scientific Purposes 
(Council Directive 86/609/EEC) and National Law 1005/92 (rules for protection of 
experimental animals). The Institutional Animal Care and Use Committee approved all 
animal procedures. Every effort was made to minimize the number of animals used and 
their suffering. 
Organotypic-cultured hippocampal slices were prepared from P8-P10 Wistar rat 
brains, according to the interface culture method (Stoppini et al., 1991), as previously 
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described (Markovic et al., 2005; Synowitz et al., 2006). Briefly, mice were killed by 
decapitation, their brains removed under sterile conditions and the two hippocampi 
isolated and cut in 400 µm coronal sections using a McIlwain tissue chopper. The 
hippocampal slices were then transferred onto the 0.4-μm polycarbonate membrane in 
the upper chamber of a Transwell tissue insert (Falcon model 3090, Becton Dickinson, 
Lincoln Park, NJ), which were placed into a six-well plate (Falcon model 3502, Becton 
Dickinson). Thereafter, slices were incubated in 1 mL culture medium per well containing 
DMEM supplemented with 10% heat-inactivated FBS (medium 1). After overnight 
equilibration of the organotypic-cultured hippocampal slices in medium 1, this was 
exchanged for cultivation medium (medium 2). Medium 2 (100 mL) contains 25 mL heat-
inactivated horse serum, 580 μL bicarbonate (7.5%), 2 mL of L-glutamine solution, 25 
mL HBSS, 10 μL of insulin (10 mg/mL), 1.2% glucose, 80 μL vitamin C (1 mg/mL), 1 mL 
antibiotic-antimycotic solution, and 500 μL of 1 mol/L Tris in DMEM. Medium was 
changed every day. 
 
2.3. Preparation of microglia-depleted organotypic-cultured hippocampal slices 
Microglia-depleted organotypic-cultured hippocampal slices were obtained by 24 
h treatment with liposomes filled with clodronate as described in (Markovic et al., 2005). 
Liposomes were obtained from GOT Therapeutics (Berlin, Germany) and from the 
Department of Molecular Cell Biology of the Free University of Amsterdam. For the 
preparation of clodronate-liposomes, 86 mg of phosphatidylcholine and 8 mg of 
cholesterol were combined with 10 ml of a clodronate (0.7 M; a gift of Roche Diagnostics 
GmbH, Mannheim, Germany) solution and sonicated gently. The resulting liposomes 
were washed to eliminate free drug. All liposomes were passed through a 12 mm filter 
immediately prior to use in order to eliminate large lipid aggregates (Van Rooijen and 
Sanders, 1994). 
 
2.4. Organotypic-cultured hippocampal slices treatment 
Slices were maintained in vitro for a minimum of 3 days prior to use, a period over 
which tissues recover from experimental trauma caused by the isolation procedure 
(Huuskonen et al., 2005).  
A stock solution of purified UCB was prepared in 0.1 N NaOH immediately before 
use and the pH of the incubation medium was restored to 7.4 by addition of equivalent 
amounts of 0.1 N HCl. All the experiments with UCB were performed under light 
protection to avoid photodegradation. Organotypic-cultured hippocampal slices were 
incubated in the absence (control) or in the presence of 50 µM UCB plus 100 µM HSA, 
Chapter IV 
 
 
112 
for 24 h, at 37ºC. When appropriate, slices were pre-incubated with 50 µM GUDCA (from 
a 5 mM stock solution) 1 h prior to UCB addition. 
 
2.5. Assessment of cell death in organotypic-cultured hippocampal slices 
Cell death in organotypic-cultured hippocampal slices was assessed by 
monitoring the cellular uptake of the fluorescent dye PI [3,8-diamino-5-(3-
(diethylmethylamino)propyl)-6-phenyl phenanthridinium diiodide]. PI readily enters and 
stains non-viable cells, but cannot cross the membrane of viable cells. This dye binds to 
double-stranded DNA and emits red fluorescence (630 nm; absorbance 493 nm). After 
UCB treatment, slices were exposed to 2 µg/mL PI for 2 h and fixed by immersion in 4% 
paraformaldehyde for 30 min, cryoprotected in 30% sucrose and stored at -20ºC until 
use. Slices were cut in 15 µm-thick sections and the nuclei were stained with DAPI 
(2ug/mL). Cellular uptake of PI was recorded by fluorescence microscopy using a 
rhodamine filter and a Leica DFC490 camera adapted to an AxioSkope® microscope. 
The percentage of PI-positive cells was quantified using ImageJ software (National 
Institutes of Health). 
 
2.6. Quantification of nitrite levels 
Nitric oxide levels were estimated by measuring the concentrations of nitrites 
(NO2-), which are the resulting NO metabolites. Briefly, supernatants free from cellular 
debris were mixed with Griess reagent [1 part 1% (w/v) sulfanilamide in 5% H3PO4, 1 
part 0.1% (w/v) N-1-naphthylethylenediamine (v/v)] in 96-well tissue culture plates for 10 
min at room temperature in the dark. The absorbance at 540 nm was determined using a 
microplate reader (Bio-Rad Laboratories, Hercules, CA, USA). 
 
2.7. Primary neuronal cell cultures 
Neurons were isolated from foetuses of 17–18-day pregnant Wistar rats, as 
described previously (Silva et al., 2002). Pregnant rats were anesthetized and 
decapitated. The foetuses were collected in HBSS and rapidly decapitated, the brain 
cortex was mechanically fragmented, and the fragments transferred to a 0.5 g/L trypsin 
in Ca2+ and Mg2+ free HBSS medium and incubated for 15 min at 37ºC. After 
trypsinization, cells were washed twice in calcium and magnesium free HBSS containing 
10% FBS, and resuspended in Neurobasal medium supplemented with 0.5 mM L-
glutamine, 25 µM L-glutamic acid, 2% B-27 Supplement, and 0.12 mg/ml gentamicin. 
Aliquots of 1 x 105 cells/cm2 were plated on poly-D-lysine coated 12-well tissue culture 
plates and maintained at 37ºC in a humidified atmosphere of 5% CO2. Every 3 days, 0.5 
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ml of old medium was removed by aspiration and replaced by the same volume of fresh 
medium without L-glutamic acid. 
 
2.8. Cell treatment 
A 100 mM stock solution of L-NAME, a competitive nitric oxide synthase (NOS) 
inhibitor, and a 1 mM stock solution of MK-801, a NMDA receptor antagonist, were 
prepared in phosphate-buffered saline (PBS), pH 7.4. A stock solution of purified UCB 
was prepared as described above. 
Neurons at 3 days in vitro (DIV) were incubated in the absence (control) or in the 
presence of 50 µM UCB plus 100 µM HSA, for 24 hr, at 37ºC. When appropriate, cells 
were pre-incubated with 50 µM GUDCA (from a 5 mM stock solution) or 10 ng/mL 
recombinant rat IL-10 (from a 50 µg/mL stock solution), 1 h prior to UCB addition. 
Parallel sets of experiments were performed where cells were incubated with UCB alone 
or in combination with 100 μM NAME or with 1 μM MK-801. 
At the end of the incubation period (considered as 4 DIV throughout the text) cell-
free medium was removed and attached cells were fixed for 30 min with freshly prepared 
4% paraformaldehyde in PBS, for immunocytochemical studies. In another set of 
experiments, incubation medium was removed and cells were additionally cultured until 
18 DIV, to study the long-term effects of UCB exposure.  
 
2.9. Neurite extension and ramification 
Neurite extension and ramification were assessed by the immunofluorescence 
detection of the cytoskeletal protein MAP-2, as described previously (Falcão et al., 
2007). Briefly, cells were fixed as described above and a standard indirect 
immunocytochemical technique was carried out using a mouse anti-MAP-2 antibody 
(1:100) as the primary antibody and a horse FITC-labeled anti-mouse antibody (1:227) 
as the secondary antibody.  
Fluorescence was visualized using a Leica DFC490 camera adapted to an 
AxioSkope® microscope. Green-fluorescence images of ten random microscopic fields 
(original magnification: 400X) were acquired per sample. Evaluation of neurite extension 
and number of nodes from individual neurons was achieved by manual tracing using 
ImageJ software (National Institutes of Health). 
 
2.10. Measurement of glutamate 
Glutamate content in incubation medium or in hippocampal slice homogenates 
was determined by an adaptation of the L-glutamic acid kit (Roche), using a 10-fold 
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volume reduction. The reaction was performed in a 96-well microplate and the 
absorbance measured at 490 nm. A calibration curve was used for each assay. All 
samples and standards were analyzed in duplicate and the mean value was used. 
 
2.11. Evaluation of cell death 
Necrotic-like cell death was assessed by monitoring the cellular uptake of the 
fluorescent dye PI. Unpermeabilized adherent cells cultured on coverslips were 
incubated with a 75 μM PI solution for 15 min in the absence of light. Subsequently, cells 
were fixed with freshly prepared 4% (w/v) paraformaldehyde in PBS and the nuclei 
stained with Hoechst 33258 dye.  
Red-fluorescence and U.V. images of ten random microscopic fields (original 
magnification: 400X) were acquired per sample and the percentage of PI positive cells 
was counted.  
 
2.12. Western blot assay 
Crude synaptosomes were obtained by differential centrifugation as described in 
Huttner et al. (1983). Total cell lysates were extracted from neurons using the Cell lysis 
buffer® and centrifuged at 800 X g to separate P1 (nuclear and debris) and supernatant 
(S1) fraction. S1 fraction was centrifuged at 9200 X g to separate P2 (membranous 
fraction) and S2 (cytosolic fraction). Western blot assay was carried out as usual in our 
lab (Fernandes et al., 2006). Briefly, crude synaptosomal fractions were separated on a 
12% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). 
Following electrophoretic transfer onto a nitrocellulose membrane and blocking with 5% 
milk solution, the blots were incubated with primary antibody overnight at 4ºC [anti-
SNAP-25 (1:1000), anti-synaptophysin (1:2000) in TBS, or anti-β-actin (1:10000) in 5% 
(w/v) bovine serum albumin] and with horseradish peroxidase-labelled secondary 
antibody [anti-mouse (1:5000) or anti-rabbit (1:5000)] for 1 h at room temperature. 
Protein bands were detected by LumiGLO® and visualized by autoradiography with 
Hyperfilm ECL. 
 
2.13. Statistical Analysis 
Results of at least three different experiments, carried out in duplicate, were 
expressed as mean ± SEM. Differences between groups were determined by one-way 
ANOVA with Dunnett’s or Bonferroni’s multiple comparisons post tests, using Instat 3.05 
(GraphPad Software, San Diego, CA). P <0.05 was accepted as statistically significant. 
 
Microglia, glutamate and nitric oxide as key players in hyperbilirubinemia
 
 
115 
3. Results 
 
3.1. Microglia modulate UCB-induced glutamate release and NO production in 
organotypic-cultured hippocampal slices 
 Activated microglia can produce a plethora of harmful products such as glutamate 
and NO in several disease models. Thus, we decided to evaluate glutamate and NO 
production in organotypic-cultured hippocampal slices upon UCB exposure and to 
determine if this production could be ascribed to microglia by the selective depletion of 
these cells.In homogenates prepared from hippocampal slices incubated with 50 μM 
UCB for 24 h, there was a significant increase in the amount of glutamate (3.8 fold, 
p<0.01, Figure IV.1A) when compared to slices not incubated with UCB. Interestingly, in 
microglia-depleted slices, the increase in glutamate induced by UCB was totally 
prevented (p<0.01), suggesting that glutamate accumulation was mainly due to resident 
microglia. The glutamate levels in the incubation media of UCB-treated slices (Fig. 
IV.1B) were also enhanced (1.4 fold, p<0.05, Figure IV.1B), as compared with non-
treated slices, and the increase was even more pronounced in microglia-depleted slices 
(p<0.01). These findings suggest that microglia affects glutamate homeostasis leading to 
the accumulation of the neurotransmitter upon UCB exposure. 
 
 
Fig. IV.1. Microglia modulate 
UCB-induced glutamate 
release in organotypic-
cultured hippocampal slices. 
Hippocampal slices non-
depleted or depleted in 
microglia, cultured for 3 days in 
vitro (DIV), were exposed for 24 
h, to either no addition (control), 
or 50 µM UCB. Tissue 
concentrations of glutamate (A) 
or glutamate levels in incubation 
media (B) were evaluated using 
a colorimetric assay and 
expressed as mean ± SEM fold 
change compared with non-
depleted in microglia, in the 
absence of UCB, from three 
independent experiments 
performed in duplicate. *p<0.05 
and **p<0.01 vs. non-depleted 
and depleted in microglia, in the 
absence of UCB; §p<0.05 and 
§§p<0.01 vs. UCB in non-
depleted in microglia. 
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Furthermore, incubation of hippocampal slices with UCB also led to increased NO 
release into the culture medium (1.4 fold, p<0.05), but not in microglia-depleted slice 
cultures (p<0.05 vs. non-depleted slices) as depicted in Figure IV.2.  
 
 
Fig. IV.2. Microglia modulate UCB-induced NO production in organotypic-cultured 
hippocampal slices. Hippocampal slices non-depleted or depleted in microglia, cultured 
for 3 days in vitro (DIV), were exposed for 24 h, to either no addition or 50 µM UCB. NO 
production was estimated by the quantification of nitrite levels and expressed as mean ± 
SEM from three independent experiments performed in duplicate. *p<0.05 vs. non-
depleted and depleted in microglia, in the absence of UCB; §p<0.05 vs. UCB in non-
depleted in microglia. 
 
Since glutamate and NO have already been implicated as mediators in UCB-
neurotoxicity (Brito et al., 2010; Grojean et al., 2000; McDonald et al., 1998; Vaz et al., 
2010), as well as in other diseases, these findings suggest that microglial reactivity may 
be an additional intervenient in brain injury by UCB. Next we decided to further clarify 
how this increased production of glutamate and NO could be involved in UCB-induced 
nerve cell injury. To answer this question we used primary cultures of cortical neurons in 
order to better elucidate the molecular mechanisms involved.  
 
3.2. NMDA receptors and NO are implicated in UCB-induced neurite impairment 
and in cell death 
 Cortical neurons cultured for 3 DIV were exposed, during 24 h, to either no 
addition (control), or 50 µM UCB, in the absence or presence of 1 µM MK-801 (a NMDA 
glutamate-subtype receptor antagonist) or 100 µM L-NAME (a non-specific NO synthase 
inhibitor). Following UCB exposure, we started by evaluating neuronal demise by using 
PI followed by the determination of neurite extension and ramification as we wanted to 
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assess if glutamate and NO were responsible partners in neuritic arborisation impairment 
by UCB. 
 As shown in Figure IV.3, either MK-801 or L-NAME added at the same time as 
UCB were able to totally prevent (p<0.01) the necrotic-like cell death that showed to 
duplicate by UCB over control values in immature neurons.  
 
Fig. IV.3. UCB-induced neuronal death is fully abrogated by MK-801 and L-NAME. 
Cortical neurons cultured for 3 days in vitro (DIV) were exposed for 24 h, to either no 
addition (control) or 50 µM UCB, in the absence or presence of 1 µM MK-801 or 100 µM 
L-NAME, and further incubated with 75 μM PI as described in Methods. (A) The 
percentage of PI-positive cells was calculated and expressed as mean ± SEM from three 
independent experiments performed in triplicate. (B) Representative results of one 
experiment are shown. Scale bar represents 40 µm. **p<0.01 vs. respective control; 
§§p<0.01 vs. UCB alone.  
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Moreover, the same was observed by either MK-801 or L-NAME in protecting the 
UCB-induced reduction in neurite extension and ramification provoked by UCB in both 4 
DIV (MK-801, p<0.01 and p<0.05, respectively; L-NAME, p<0.01 for both) and 18 DIV 
neurons (MK-801, p<0.05 for both; L-NAME, p<0.05 and p<0.01, respectively), as shown 
in Figure IV.4. These results provide proof of concept that glutamate and NO participate 
in UCB-induced neurodevelopment abnormalities implicated in UCB-enduring harmful 
consequences and that microglia, as major sources of these neurotoxic molecules upon 
UCB stimulation, participate in its harmful effects. Based on the antioxidant properties of 
GUDCA in neurons (Brito et al., 2008a; Vaz et al., 2010) and on the immunosuppressive 
properties of both GUDCA and IL-10 (Fernandes et al., 2007) we decided to investigate 
their potentialities in saving neuritic arborisation from UCB harmful effects.  
 
Fig. IV.4. UCB-elicited impairment in neuritic outgrowth at 4 and 18 days in vitro 
(DIV) is mediated by NO and overstimulated NMDA receptors. Cortical neurons 
cultured for 3 DIV were exposed for 24 h, to either no addition (control) or 50 µM UCB, in 
the absence or presence of 1 µM MK-801 or 100 µM L-NAME as described in Methods. 
Incubation medium was removed and neurons were allowed to culture until 18 DIV. 
Neurite extension (A) and number of nodes (B) were identified by immunolabeling for 
MAP-2, quantified by ImageJ and expressed as arbitrary units (mean ± SEM). 
Representative results of one experiment regarding 4 DIV neurons is shown in C. Scale 
bar represents 40 µm. *p<0.05 and **p<0.01 vs. respective control; §p<0.05 and §§p<0.01 
vs. UCB alone.  
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3.3. UCB-elicited accumulation of extracellular glutamate is reduced by both 
GUDCA and IL-10, but not abolished  
Taking into account the important role of glutamate NMDA receptors in UCB 
neurotoxicity portrayed by the above data, we then evaluated the effects of GUDCA and 
IL-10 upon UCB-induced glutamate release by cultured neurons. As shown in Figure 
IV.5, GUDCA significantly reduced (~30%, p<0.05) the efflux of glutamate by UCB-
treated immature neurons, an effect even more marked (~45%, p<0.01) when we used 
IL-10. Nevertheless, although these compounds significantly drop the extracellular 
accumulation of glutamate they were unable to prevent it.  
 
 
Fig. IV.5. UCB-induced extracellular 
accumulation of glutamate is 
prevented by both GUDCA and IL-10. 
Cortical neurons cultured for 3 days in 
vitro (DIV) were exposed for 24 h, to 
either no addition (control) or 50 µM 
UCB, in the absence or presence of 50 
µM GUDCA or 10 ng/mL IL-10. Results 
are mean ± SEM from three independent 
experiments performed in triplicate. 
**p<0.01 vs. respective control; §p<0.05 
and §§p<0.01 vs. UCB alone. 
 
 
 
3.4. GUDCA or IL-10 pre-treatment counteracts impairment of neurite outgrowth 
and ramification, as well as cell death in UCB-treated neurons 
Considering the effects of UCB in neurons, above described, and the protective 
effects displayed by GUDCA and IL-10 in these cells we next investigated whether these 
compounds reveal ability to abrogate UCB-induced necrotic-like cell death in immature 
neurons, as well as neuritic changes. Both molecules besides abolishing cell-death 
(p<0.01, Figure IV.6) showed efficacy in preventing short-term deficits in neurite 
extension (GUDCA, p<0.05; IL-10, p<0.01) as depicted in Figure IV.7.  
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Fig. IV.6. GUDCA or IL-10 pre-treatment counteracts cell death in UCB-treated 
immature neurons. Cortical neurons cultured for 3 days in vitro (DIV) were exposed for 
24 h, to either no addition (control) or 50 µM UCB, in the absence or presence of 50 µM 
GUDCA or 10 ng/mL IL-10, and further incubated with 75 μM PI as described in 
Methods. (A) The percentage of PI-positive cells was calculated and expressed as mean 
± SEM from three independent experiments performed in triplicate. (B) Representative 
results of one experiment are shown. Scale bar represents 40 µm. **p<0.01 vs. 
respective control; §§p<0.01 vs. UCB alone.  
 
The same was verified in the maintenance of neurite ramification, where 
significant protection was manifested by both GUDCA (p<0.05) and IL-10 (p<0.01) in 4 
DIV neurons. Interestingly, even after removing the UCB stimulus and additionally 
culturing neurons until 18 DIV, the protective effects of GUDCA and IL-10 on UCB-
induced long-term neuritic outgrowth impairment were still noticeable (p<0.05).  
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Fig. IV.7. GUDCA or IL-10 pre-treatment counteracts impairment of neurite 
outgrowth at 4 and 18 days in vitro (DIV) in UCB-treated immature neurons. Cortical 
neurons cultured for 3 DIV were exposed for 24 h, to either no addition (control) or 50 µM 
UCB, in the absence or presence of 50 µM GUDCA or 10 ng/mL IL-10 as described in 
Methods. Incubation medium was removed and neurons were allowed to culture until 18 
DIV. Neurite extension (A) and number of nodes (B) were identified by immunolabeling 
for MAP-2, quantified by ImageJ and expressed as arbitrary units ± SEM. Representative 
results of one experiment regarding 4 DIV neurons is shown in C. Scale bar represents 
40 µm. *p<0.05 and **p<0.01 vs. control; §p<0.05 and §§p<0.01 vs. UCB alone.  
 
3.5. UCB decreases the expression of pre-synaptic proteins and this event is 
abrogated by GUDCA, but not by IL-10 
Previous results have proven that UCB can adversely affect spine formation and 
synapse establishment (Fernandes et al., 2009). Moreover, UCB-induced impairment of 
synaptic plasticity has already been acknowledged (Chang et al., 2009). Therefore, we 
decided to examine if UCB can modify the expression of proteins such as synaptophysin 
and SNAP-25, which are involved in synaptogenesis and synaptic vesicle assembly. Our 
results showed that UCB led to a significant reduction in both protein levels (0.9 fold, 
p<0.05 and 0.8 fold, p<0.01, respectively). In line with the aforementioned benefits, 
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GUDCA prevented the UCB synaptotoxicity from occurring (p<0.05), while a slight and 
non-significant effect was produced by IL-10 pretreatment (Figure IV.8).  
 
 
 
 
Fig. IV.8. UCB down-regulation of 
synaptophysin and SNAP-25 protein 
expression in immature neurons is 
prevented by GUDCA. Cortical 
neurons cultured for 3 days in vitro 
(DIV) were exposed for 24 h, to either 
no addition (control) or 50 µM UCB, in 
the absence or presence of 50 µM 
GUDCA or 10 ng/mL IL-10. Crude 
synaptosomal fractions were analyzed 
by western blotting with antibodies 
specific for synaptophysin and SNAP-
25. The intensity of the bands was 
quantified by scanning densitometry, 
standardized with respect to β-actin 
protein expression. Graph bars 
represent the fold change values 
(mean ± SEM) from three independent 
experiments performed in duplicate for 
synaptophysin (A) and SNAP-25 (B). 
Representative results of one 
experiment regarding synaptophysin 
and another concerning SNAP-25 are 
shown in (C). **p<0.01 vs. respective 
control; §p<0.05 vs. UCB alone. 
 
 
 
 
 
Interestingly, GUDCA even revealed to up-regulate synaptophysin and SNAP-25 
expression. Thus, GUDCA evidence to be a more promising therapeutical approach in 
hyperbilirubinemia than IL-10 due to its broader benefits and induced increase in pre-
synaptic proteins that regulate synaptic vesicle docking, as well as membrane fusion and 
fission (Gray et al., 2010).  
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3.6. Hampering of UCB-induced NO and glutamate production, as well as cell 
death by GUDCA was reproduced in hippocampal slices 
Given the promising protective effects of GUDCA regarding UCB neurotoxicity, 
verified for purified cultures, we became interest in returning to the singular physiological 
conditions provided by the hippocampal slice model to verify if the observed effects were 
reproduced in this more complex model. We were particularly interested in studying the 
pathways previously shown as activated in microglial cells upon UCB exposure, namely 
glutamate and NO production. Therefore, we assessed extracellular accumulation of 
glutamate and NO release, as described in Figure IV.9, and found that GUDCA was able 
to counteract their production (p<0.01).  
 
 
 
 
Fig. IV.9. GUDCA hampers UCB-
induced NO and glutamate 
production in organotypic-
cultured hippocampal slices. 
Hippocampal slices cultured for 3 
days in vitro were exposed for 24 h, 
to either no addition (control) or 50 
µM UCB, in the absence or 
presence of 50 µM GUDCA. (A) 
Tissue concentrations of glutamate 
were evaluated using a colorimetric 
assay and expressed as mean ± 
SEM fold change compared with 
control conditions. (B) NO 
production was estimated by the 
quantification of nitrite levels and 
expressed as mean ± SEM from 
three independent experiments 
performed in duplicate. *p<0.05 and 
**p<0.01 vs. control; §§p<0.01 vs. 
UCB alone. 
 
 
 
 
 
Moreover, similar neuroprotective effects were demonstrated by the abrogation of 
PI uptake (p<0.01) in GUDCA-treated slices prior to UCB incubation (Figure IV.10), 
further highlighting the therapeutic potential of this particular bile acid. 
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Fig. IV.10. GUDCA hampers UCB-induced cell death in organotypic-cultured 
hippocampal slices. Hippocampal slices cultured for 3 days in vitro were exposed for 
24 h, to either no addition (control), or 50 µM UCB, in the absence or presence of 50 µM 
GUDCA, and further incubated with 2 μg/mL PI as described in Methods. (A) 
Representative results of one experiment are shown. Scale bar represents 40 µm. (B) 
Graph bars represent the fold change values (mean ± SEM) from three independent 
experiments performed in duplicate. **p<0.01 vs. respective control; §§p<0.01 vs. UCB 
alone. 
4. Discussion 
In this study we demonstrate, for the first time, that microglia modulate UCB-
induced neurotoxicity in organotypic-cultured hippocampal slices. This modulation 
involves glutamate and NO as key mediators in the injurious effects prompted by UCB. 
Furthermore, our study depicts the neuroprotective properties of GUDCA and IL-10, 
revealing that their potential to prevent neuronal damage observed in pure neuronal 
cultures is reproduced in the more complex system of organotypic cultures. In addition, 
their ability to abrogate the neurodevelopmental abnormalities caused by neonatal 
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hyperbilirubinemia reinforces their possible use as new therapeutic approaches in this, 
still, life-threatening condition. 
Previous reports have shown that UCB interacts with whole nerve cell and 
mitochondrial membranes disrupting its redox status (Rodrigues et al., 2002b; Rodrigues 
et al., 2002c) and that several oxidative biomarkers are elicited in neuronal (Vaz et al., 
2010) and astroglial cells (Brito et al., 2008b), as well as in synaptosomal membrane 
systems (Brito et al., 2004). Moreover, unpublished results from our group support the 
increase in NO production upon UCB exposure in neurons (personal communication Ana 
Rita Vaz, 2010) and microglia, where the production is further amplified by UCB-treated 
neuronal conditioned medium (unpublished results). Indeed, NO appears to be involved 
in numerous physiological and pathological processes (Bishop and Anderson, 2005). 
Several authors have evidenced that activated microglia releases NO following induction 
of nitric oxide synthase (Kawase et al., 1996) and that this radical mediates neural injury 
(Golde et al., 2002). On the other hand, the generation of an oxidative burst by microglia 
in response to injury may also constitute a measure to promote the clearance of 
damaged cells from the CNS (Kawase et al., 1996). The results displayed in this study 
support the role of glutamate and NO as important neurotoxic molecules. Moreover, as 
was shown in the ex vivo organotypic-cultured hippocampal slice model, their production 
upon UCB exposure may be attributed to microglial cells. Accordingly, blocking the 
action of both molecules abolished the toxic effects of UCB in our primary neuron culture 
model. 
However, the role of microglia in glutamate homeostasis upon UCB exposure 
seems to be more complex, as opposing effects were observed when evaluating 
glutamate content in tissue homogenates or incubation media from organotypic-cultured 
hippocampal slices. In fact, results from tissue samples point to microglia as the most 
important glutamate source, nevertheless, extracellular accumulation of glutamate in 
incubation media from microglia-depleted slices is enhanced, suggesting that microglia 
are actually promoting glutamate uptake. Indeed, activated microglia have been shown 
to up-regulate glutamate transporter-1 (GLT-1) in response to motoneuron injury in 
axotomized rat facial nucleus (Lopez-Redondo et al., 2000) and also as a defensive 
mechanism against herpes simplex virus infection (Persson et al., 2007). Additionally, 
inflammatory products such as tumor necrosis factor-α may similarly induce GLT-1 
expression in microglia (Persson et al., 2005) while glutamine synthetase, the enzyme 
responsible for converting glutamate into the less toxic glutamine, is also expressed in 
activated microglia (Chretien et al., 2002; Rimaniol et al., 2000). This inducible profile of 
microglia contrasts with the constitutive expression of glutamate transporters in 
astrocytes and can be regarded as a compensatory mechanism to limit the deleterious 
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consequences of microglial activation in the brain (Gras et al., 2006). Our hypothesis is 
that microglia initially exerts a neuroprotective action towards UCB by promoting 
glutamate clearance, either by themselves or by engaging astrocytes in this function, as 
previously observed (Tilleux et al., 2009). However, despite microglial efforts to limit 
glutamate concentration, the ultimate outcome is an increase in its extracellular levels, 
possibly due to the failure of the clearance mechanisms or to the increased production 
by either glial or neuronal cells upon prolonged exposure times. A growing body of 
evidence underscores glutamate’s key role in microglial neurotoxicity (Barger and Basile, 
2001; Liang et al., 2008). Furthermore, several reports link oxidative stress and 
glutamate-mediated excitotoxicity (Bal-Price and Brown, 2001; Barger et al., 2007; Brito 
et al., 2010; Golde et al., 2002), which is consistent with our results demonstrating that 
glutamate and NO participate in UCB-induced neuronal demise. In fact, earlier studies 
have already reported that UCB-induced neurotoxicity is mediated by glutamate 
receptors (Grojean et al., 2000; Grojean et al., 2001; Hanko et al., 2006; Hoffman et al., 
1996).  
Glutamate can cause alterations in dendritic outgrowth (Esquenazi et al., 2002; 
Mattson, 2008), even in immature neurons (Monnerie et al., 2003), as well as NO, that 
was shown to induce synapse loss (Sunico et al., 2010). Interestingly, our previous 
studies evidenced impairment of neurite extension and ramification in immature cortical 
neurons exposed to UCB that is sustained through cell maturation (Falcão et al., 2007). 
Changes in dendritic and axonal arborisation were also observed in UCB-treated 
immature hipppocampal neurons (Fernandes et al., 2009). Our novel results bridge 
those two findings, demonstrating a causal relation between UCB-induced impairment of 
neurite outgrowth, NMDA receptor overstimulation, and NO overproduction. This aspect 
gains additional relevance if we consider that glutamate efflux is enhanced in neurons 
and glial cells (Falcão et al., 2005; Fernandes et al., 2004) exposed to UCB, and its 
uptake inhibited in neurons (Silva et al., 1999; Silva et al., 2002). This finding is 
particularly important given the fact that neonatal hyperbilirubinemia has been 
associated to the development of mental disorders (Dalman and Cullberg, 1999) like 
schizophrenia (Hayashida et al., 2009; Miyaoka et al., 2000), and can impact on learning 
and memory (Zhang et al., 2003). UCB can adversely affect synapse establishment 
since it interferes with spine formation and reduces growth cone area (Fernandes et al., 
2009). Accordingly, UCB exposure leads to impairment of neurotransmitter release in 
synaptic vesicle membranes (Roseth et al., 1998), modification of long-term synaptic 
plasticity (Chang et al., 2009), and decreased synaptic activity in hippocampal slices 
(Hansen, 1994). These studies are consistent with our results regarding decreased pre-
synaptic protein expression upon UCB exposure. Actually, glutamate’s implication in 
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neuritogenesis and synaptogenesis has already been acknowledged (Mattson et al., 
1988).  
In this paper we report that UCB can lead to a diminished expression of the pre-
synaptic proteins synaptophysin and SNAP-25. Synaptophysin is a calcium binding 
protein expressed on pre-synaptic vesicles and SNAP-25 is anchored in the synaptic 
terminal plasma membrane. These proteins are essential for synaptic vesicle fusion to 
the pre-synaptic plasma membrane, thus participating in synapse establishment and 
neurotransmitter release (Wang and Tang, 2006). A decrease in synaptic protein 
expression is regarded as a biomarker of altered neuronal development. In fact, 
synaptophysin expression is altered in epilepsy (Xu et al., 2009) and changes in proteins 
relevant to synaptic transmission and axonal transport have been coupled to 
neuroinflammation in Parkinson's disease (PD) (Chung et al., 2009). Cytoskeleton 
abnormal assembly, loss of dendrites and axons and impairment of neurotransmission 
can cause disruption of synaptic connectivity and instigate neurodegenerative diseases 
like Alzheimer’s disease (Evans et al., 2008) or PD (Benitez-King et al., 2004), and 
psychiatric illnesses such as schizophrenia (Brennaman and Maness, 2008).  
GUDCA is the major product of ursodeoxycholic acid (UDCA) catabolism 
(Rudolph et al., 2002). UDCA and its conjugates have demonstrated neuroprotective 
effects by the stabilization of mitochondrial membranes (Solá et al., 2002), inhibition of 
mitochondrial swelling (Rodrigues et al., 2000b), cytochrome c release (Rodrigues et al., 
2000a) and, ultimately, by the decrease of apoptotic cell death (Silva et al., 2001). UDCA 
oral administration induces a rapid and sustained decrease in plasma UCB 
concentrations in Gunn rats, the animal model used to study bilirubin encephalopathy 
(Cuperus et al., 2009). Recent reports have indicated potential benefits for GUDCA at 
preventing UCB-induced protein oxidation, lipid peroxidation, impairment of glutathione 
homeostasis and neuron cell death (Brito et al., 2008a), or mitochondrial respiratory 
chain dysfunction by UCB and restoration of cellular antioxidant potential (Vaz et al., 
2010). Our group has also evidenced that both GUDCA and IL-10 can modulate 
astrocytic reactivity to UCB decreasing the elicited inflammatory properties and reducing 
cell death (Fernandes et al., 2007). The anti-inflammatory cytokine IL-10 has already 
been demonstrated to reduce glial activation (Ledeboer et al., 2000) and to exert 
neuroprotective effects (Bachis et al., 2001; Park et al., 2007). IL-10 is also able to down-
regulate microglial NO production, thus contributing to the recovery of neurite outgrowth 
(Rozenfeld et al., 2003). Our results show that UCB-induced deleterious effects on 
neuronal survival and neurite impairment are also prevented by GUDCA and IL-10. 
Protective properties of these compounds on the cellular efflux of glutamate, elicited by 
UCB, emphasize the protective effects observed since we have here demonstrated the 
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essential role of glutamate and NO in UCB-evoked alterations in network dynamics. To 
the best of our knowledge, only one other molecule, taurine, has evidenced protective 
effects against UCB-mediated neuronal damage (Zhang et al., 2010). It is also very 
important to acknowledge that neuroprotection by GUDCA in the purified neuronal 
culture, was kept in organotypic-cultured hippocampal slices, suggesting its usefulness 
in vivo.  
Given the fact that both GUDCA and IL-10 showed to prevent UCB-induced 
extracellular accumulation of glutamate, we expected that both molecules would exert 
protective effects on pre-synaptic protein expression. Surprisingly, only GUDCA proved 
to be effective at this level, which led us to the hypothesis that GUDCA might be acting 
on different mechanisms beyond glutamate-mediated neuronal damage. One possible 
explanation might be that GUDCA has recognized anti-oxidant properties (Brito et al., 
2008a; Vaz et al., 2010) and, in fact, oxidative stress is associated with synaptogenesis 
and neuritogenesis alterations (Sunico et al., 2010), while IL-10 is more notorious for its 
anti-inflammatory capacities (Ledeboer et al., 2000). Moreover, GUDCA and IL-10 have 
also shown to modulate astroglial reactivity to UCB following different mechanisms 
(Fernandes et al., 2007). 
In conclusion, the results obtained in this study portray an interesting and 
complex role for microglia in glutamate homeostasis upon UCB exposure. These cells 
induce glutamate clearance as a first attempt to limit the excitotoxic neuronal damage 
but, on the other hand, also contribute for the pool of released glutamate culminating in 
an extracellular accumulation of this molecule. Moreover, our study evidences microglial 
cells as a source of NO upon UCB exposure. Our work is the first to establish the 
involvement of glutamate and NO in UCB-induced impairment of neurite extension and 
ramification, thus substantiating target-driven approaches which may reveal important in 
the prevention of long-term neurodevelopment disabilities. Most important is the 
neuroprotective effects of GUDCA and IL-10 in hyperbilirubinemia as they are able to 
prevent the UCB-induced increase in glutamate secretion and, through this or other 
mechanisms, counteract the deleterious effects of UCB on neuronal network dynamics 
and cell death. GUDCA has an additional benefit in preventing down-regulation of pre-
synaptic protein expression, an event that may underlie UCB-evoked alterations in 
synaptic plasticity.  
In conclusion, our data reveal microglia, glutamate and NO as potential targets 
for more directed and effective early-therapeutic interventions, and GUDCA as a 
promising medicine in the management of neonatal hyperbilirubinemia. 
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1. Concluding remarks and perspectives 
The general goal of this thesis was to explore if and how migroglial cells 
participate in the neurodegeneration due to UCB encephalopathy. In fact, previous 
studies had already demonstrated that UCB promoted a marked inflammatory response 
in astrocytes with the release of pro-inflammatory cytokines and glutamate, and that this 
inflammatory reaction was prompted by the activation of several signalling pathways 
(Fernandes et al., 2007a; Fernandes et al., 2006; Fernandes et al., 2004). Moreover, this 
immunostimulant effect was proven to be more relevant in astrocytes than in neurons 
exposed to UCB, while for this last cell type cell death by both necrosis and apoptosis 
was the most likely expected outcome (Falcão et al., 2005; Falcão et al., 2006). 
Nevertheless, and despite the notorious contribution of microglia to several neonatal 
pathological conditions such as hypoxic- ischemic injury (McRae et al., 1995; Vexler and 
Yenari, 2009), little was known about the involvement of microglia in UCB-elicited 
toxicity. Early reports had demonstrated that UCB may alter the function of various cells 
of the immune system (both in vivo and in vitro) (Vetvicka et al., 1985; Vetvicka et al., 
1991). In addition, an increase in phagocytosis of both peripheral blood granulocytes and 
monocytes after UCB treatment was reported by Miler et al. (1985). Our group was the 
first to demonstrate that UCB also causes microglial activation characterized by 
morphological alterations, increased secretion of pro-inflammatory cytokines and 
glutamate as well as microglial cell death, after a short exposure period to UCB (Gordo 
et al., 2006). Indeed, when compared to other brain cells, microglia revealed to be the 
most responsive ones to UCB insult (Brites et al., 2009). However, a more detailed 
characterization of microglial reactivity profile to UCB was needed to further elucidate the 
molecular and cellular mechanisms of UCB-induced toxicity. 
 
Using an experimental model of isolated primary cultures of microglia we 
described the temporal profile of microglial reactivity towards UCB. We observed, for the 
first time, that UCB induces an increase in the phagocytic properties of microglia, 
followed by a shift into a rather inflammatory response with prolonged exposure time. So, 
we next characterized the inflammatory reaction elicited by UCB in those cells and found 
that MAPKs phosphorylation is an essential step for NF-κB nuclear translocation and that 
these events occur upstream of the release of inflammatory mediators such as TNF-α, 
IL-1β and IL-6, thus probably signalling this release. Moreover, additional inflammatory 
indicators were displayed by UCB-reactive microglial cells such as COX-2 up-regulation 
and MMP-2 and -9 increased activation. Furthermore, we provided evidence that UCB-
induced cytokine secretion, particularly IL-1β, may participate in MMPs activation 
suggesting that these events might be reciprocally regulated.  
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Interestingly, the alternation of the different activation stages of microglia along 
time in the presence of UCB, phagocytic and inflammatory, seem to indicate that 
microglia reacts towards UCB insult firstly with a phagocytic response, in an attempt to 
constrain the lesion extent and comprising a neuroprotective measure. Upon prolonged 
UCB exposure periods, either a shift on global microglia reaction occurs or two distinct 
sub-populations of microglial cells may co-exist, one directed at eliminating the damaged 
cells by phagocytosis, and another that engaged a more delayed inflammatory response. 
The fact that cell death by both apoptosis and necrosis arouses after the observed 
phagocytic response in microglia further corroborates the stated hypothesis. Accordingly, 
clearance of tissue debris performed by microglia following injury has been 
demonstrated in several disease models and might constitute a regenerative measure 
(Napoli and Neumann, 2009; Neumann et al., 2009). Our findings add on to the exciting 
concept that microglia displays functional plasticity (Graeber and Streit, 2009; Schwartz 
et al., 2006) and emphasize the role of these cells as active sensors of the brain that 
adapt their reactive phenotypes to the environmental circumstances (Hanisch and 
Kettenmann, 2007). 
 
Nevertheless, the brain is not compartmented and cellular interactions are 
essential regulators of many critical functions in the healthy and the diseased brain 
(Biber et al., 2007). Taking this into consideration, we found valuable to investigate how 
the interplay between microglia and other nerve cells could modulate the effects induced 
by UCB. In order to achieve this goal we used two different experimental models: 
conditioned media, to evaluate the effect of soluble factors, and mixed neuron-glia 
cultures, to assess proximity-dependent interactions. Our results showed that soluble 
factors released by astrocytes exposed to UCB dampen microglial production of 
inflammatory cytokines such as TNF-α and IL-1β, diminish MMP-9 activation and prevent 
cell death. Therefore, microglia, when isolated, respond intensively to UCB stimulation, 
but previously activated astrocytes seem to drive microglia to refrain its response. Other 
authors have postulated that this is a feasible mechanism to prevent excessive brain 
inflammation (Min et al., 2006). Interestingly, UCB-treated neuron conditioned medium 
produced a similar down-regulation on the production of inflammatory mediators by 
microglia but enhanced NO generation, MMP-9 activation and led to cell demise. In 
addition, we demonstrated that microglia’s phagocytic abilities were further enhanced 
when these cells were exposed to conditioned medium derived from UCB-exposed 
neurons, instead of direct UCB stimulation. Such finding suggests that UCB-injured 
neurons might be signalling microglia to engage a phagocytic phenotype in an attempt to 
constrain lesion extent but also enhanced its inflammatory potential ultimately leading to 
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microglia demise. This hypothesis was further strengthened by the results regarding 
UCB-deleterious effects on neurite network and neuronal cell death when neurons were 
cultivated in close proximity with microglial cells. In fact, these studies showed that the 
previously observed UCB-induced neurite outgrowth impairment and cell demise (Falcão 
et al., 2007) were abrogated in the presence of microglia. This apparent protection could 
be the result of the phagocytic clearance of UCB-damaged neurons, similarly to the 
events described in other disease models as revealed by the phagocytosis of cellular 
debris or amyloid deposits by microglia in MS (Takahashi et al., 2005) and AD (Simard et 
al., 2006), respectively. 
 
The results obtained pertaining neuron-glia dynamics upon UCB exposure 
prompted us to explore the role of microglia in UCB-induced neurotoxicity in a more 
complex model, the organotypic slice cultures. These studies were performed in the 
hippocampus, one of the brain areas affected in kernicterus (Shapiro, 2003; Shapiro, 
2005) that showed increased vulnerability to UCB’s toxic effects as proven by the 
impairment of long-term synaptic plasticity found by Chang et al. (2009) in this brain 
area. By the selective depletion of microglia from organotypic-cultured hippocampal 
slices we were able to determine that these cells are the major sources of NO upon UCB 
stimulation and that they significantly interfere with glutamate homeostasis. The inducible 
expression of glutamate transporters (Lopez-Redondo et al., 2000; Persson et al., 2005) 
as well as the presence of glutamine synthetase in microglia (Rimaniol et al., 2000) has 
been previously reported. Our results suggest an initial neuroprotective role for microglia 
as glutamate scavengers. However, despite microglial efforts to limit glutamate 
concentration, the ultimate outcome is an increase in its extracellular levels and tissue 
accumulation, possibly due to the failure of the clearance mechanisms or to increased 
production by either glial or neuronal cells upon prolonged exposure times to UCB.  
Interestingly, glutamate had already been stressed out as an important mediator 
of UCB-induced neurotoxicity (Johnston, 2005) since its astrocytic uptake is inhibited in 
astrocytes (Silva et al., 1999) prolonging its presence in the synaptic cleft and 
engendering NMDA overactivation and consequent excitotoxic death (Grojean et al., 
2000; Grojean et al., 2001; McDonald et al., 1998). Moreover, oxidative stress has also 
been demonstrated to be involved in UCB-induced injury (Brito et al., 2004; Brito et al., 
2008; Vaz et al., 2010). More recently the two events were shown to be associated 
during UCB cytotoxicity since overactivation of glutamate receptors seems to mediate 
oxidative damage in neurons (Brito et al., 2010). In addition, oxidative stress was also 
shown to mediate UCB-induced degeneration of excitatory synaptic terminals in the 
auditory brainstem (Haustein et al., 2010). Therefore, we decided to explore the role of 
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glutamate and NO in the impairment of neurite extension and ramification and in 
neuronal death in order to elucidate the molecular mechanisms triggering 
neurodevelopmental changes. Our studies clearly demonstrate the key role of NO and 
overactivation of NMDA receptors in UCB-induced impairment of neuritic outgrowth and 
neuronal demise, providing exciting new targets for the management of neonatal 
hyperbilirubinemia. Our results also indicated that UCB decreased the expression of pre-
synaptic proteins, which are essential for synapse establishment and neurotransmitter 
release, and are consistent with the findings showing that UCB can also adversely affect 
synapse establishment (Fernandes et al., 2009), and cause alterations of synaptic 
plasticity (Chang et al., 2009). Abnormal cytoskeleton assembly, loss of dendrites and 
axons and impairment of neurotransmission can cause disruption of synaptic 
connectivity and instigate neurodegenerative diseases and mental disorders like 
schizophrenia (Benitez-King et al., 2004; Brennaman and Maness, 2008). Thus, 
association between neonatal hyperbilirubinemia and proneness to mental disorders in 
later life seems to be a reasonable possibility. 
In this study we also evaluated the therapeutic potential of GUDCA and IL-10 and 
found that these molecules were able to counteract the above mentioned deleterious 
effects prompted by UCB, namely network dynamics impairment and neuronal cell 
death, probably by the reduction of glutamate extracellular accumulation. In addition, 
GUDCA proved to be more effective than IL-10 in preventing the down-regulation of pre-
synaptic proteins’ expression. Besides, GUDCA proved to also abrogate the injurious 
effect elicited by UCB not only in isolated neurons but also in the hippocampal slice 
culture model, thus reinforcing its potential as a therapeutic approach in the 
management of neonatal hyperbilirubinemia. 
 
Collectively, the data presented in this thesis (Fig. V.1) provide interesting 
findings regarding the implication of microglia in UCB-induced phenomena. Indeed, 
different reactive phenotypes are engaged by these cells depending on the duration and 
intensity of the toxic stimulus and on the modulation exerted by neighbouring cells, 
reinforcing their remarkable functional plasticity.  
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Fig.V.1. Schematic representation of microglia reactivity to unconjugated bilirubin. 
Isolated microglial cells present a dual phenotype, phagocytic and inflammatory, that 
switch along unconjugated bilirubin (UCB) exposure, with the release of several 
inflammatory mediators and activation of diverse upstream signalling pathways (A). In 
addition, astrocytes exposed to UCB dampen microglia activation while neurons signal a 
phagocytic phenotype in microglia and enhance its inflammatory potential leading to cell 
demise (B). Moreover, in UCB-stimulated neuron-microglia mixed cultures the neurotoxic 
effects of UCB are prevented, suggesting that stressed neurons promote a 
neuroprotective clearance function in microglia (C). Finally, microglia revealed to 
participate in glutamate homeostasis and to induce the release of nitric oxide (NO) in 
UCB-treated hippocampal slices (D), important molecules in UCB-induced neurotoxicity. 
Moreover, our results identify some of the therapeutic actions of interleukin (IL)-10 and 
glycoursodeoxycholic acid (GUDCA). 
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However, some questions are left unanswered and remaining to be clarified. 
Taking advantage of the singular physiological conditions provided by the hippocampal 
slice model, it would be interesting to evaluate exactly which glial cells participate more 
actively in the neurodegeneration process elicited by UCB. In addition, it would also be 
relevant to study the ability of UCB to promote cell proliferation and the identification of 
the most affected ones. In fact, one could speculate that microglia would top the list 
given its characteristic capacity to proliferate and migrate towards the injury site upon 
brain injury (Heppner et al., 1998; Ladeby et al., 2005). Indeed, the question whether 
microglia can migrate towards UCB in the icteric brain should also be addressed using 
this model. On the other hand, in vitro models for evaluation of microglial chemotactic 
properties could also reveal useful to estimate if UCB exposure can alter microglial ability 
to migrate towards known toxic chemoattractants. Finally, given the extraordinary 
therapeutic potential revealed by GUDCA and its previously observed ability to prevent 
astrocytic immunostimulation by UCB (Fernandes et al., 2007b), it would also be 
pertinent to further investigate the implication of microglia in the protective effects elicited 
by this molecule in slice cultures, performing additional studies in microglia-depleted 
slices. As in other brain diseases, the main question left unanswered regarding microglial 
reactivity in hyperbilirubinemia is to what extent silencing microglial activation might be 
beneficial or detrimental. Indeed, a growing body of evidence supports the notion that 
microglial cellular activities and inflammatory responses are mostly beneficial, becoming 
potentially destructive when the strict regulatory control upon microglia is disrupted, 
either by pathologic events or by dystrophy (Harry and Kraft, 2008).  
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